

## CURRICULUM VITAE

**Lisa M. Coussens, Ph.D., M.D. (h.c.), FAACR, FAIO**

Professor and Chair, Cell, Developmental & Cancer Biology Department

Hildegard Lamfrom Endowed Chair in Basic Science

Oregon Health & Science University  
Knight Cancer Research Bldg., Room 3030  
2720 S Moody Ave., #KC-CDCB  
Portland, OR 97201-5042

Voice: (503) 494-7811

Fax: (503) 494-4253

Email: [coussensl@ohsu.edu](mailto:coussensl@ohsu.edu)

Web: <https://www.ohsu.edu/cdcb/coussens>

### I. EDUCATION:

1976 - 1980	San Francisco State University	B.A.	Biology
1988 - 1993	University of California, Los Angeles	Ph.D.	Biological Chemistry

### II. PRINCIPAL POSITIONS HELD:

1981 - 1988	Research Associate	Molecular & Developmental Biology	Genentech, Inc., South San Francisco
1993 - 1997	Post-Doctoral Fellow	Cancer Biology	University of California, San Francisco
1997 - 1999	Assistant Research Biochemist	Hormone Research Inst.	Univ. of California, San Francisco
1999 - 2004	Assistant Professor, <i>(In Residence)</i>	Cancer Research Inst. & Dept. of Pathology	Univ. of California, San Francisco
2004 - 2006	Associate Professor, <i>(In Residence)</i>	Cancer Research Inst. & Dept. of Pathology	Univ. of California, San Francisco
2006 - 2007	Associate Professor, <i>(Ladder-rank; tenured)</i>	Dept. of Pathology & Cancer Research Inst.	Univ. of California, San Francisco
2007 - 2012	Professor <i>(Ladder-rank; tenured)</i>	Dept. of Pathology & Cancer Research Inst.	Univ. of California, San Francisco
2012 - 2015	Adjunct Professor	Dept. of Pathology	Univ. of California, San Francisco
2011 - present	Professor and Chair <i>(tenured)</i>	Cell, Developmental & Cancer Biology	Oregon Health & Science University
2011 - present	Hildegard Lamfrom Endowed Chair in Basic Research	School of Medicine	Oregon Health & Science University
2011 - 2022	Associate Director for Basic Research	Knight Cancer Institute	Oregon Health & Science University
2022 - 2025	Deputy Director for Basic & Translational Research	Knight Cancer Institute	Oregon Health & Science University
2025	Interim Director	Knight Cancer Institute	Oregon Health & Science University

### OTHER PROFESSIONAL APPOINTMENTS:

1989 - 1992	Lecturer	Biology Dept.	Whittier College, Whittier, CA
1992	Consultant	Dept. of Legal Affairs	Genentech, San Francisco CA
2000 - 2012	Co-Director	Mouse Pathology Core	Helen Diller Family Comp. Cancer Center, UCSF
2007 - 2009	Senior and Deputy Editor	<i>Tumor Microenvironment</i> Section	<i>CANCER RESEARCH (AACR)</i>
2009 - 2012	Co-Leader	Program in <i>Cancer Immunity &amp; Microenvironment</i>	Helen Diller Family Comprehensive Cancer Center, UCSF
2009 - 2012	Deputy Editor	<i>Breaking Advances</i>	<i>CANCER RESEARCH (AACR)</i>
2013 - present	Senior Editor	General	<i>Cancer Immunology Research</i>
2012 - 2018	Co-Leader	Program in Cancer Biology	Knight Cancer Institute, OHSU
2017 - 2020	Scientific consultant	Antibody development	Cell Signaling Technologies

2019 - 2020	Endowed Professor, TEFAF Oncology Chair	School for Oncology and Developmental Biology	Maastricht University Medical Center, The Netherlands
2020	Scientific consultant	Clinical strategy and design	AbbVie Inc
2020 - 2022	Scientific consultant	Translational R&D guidance	Shasqi, Inc.

### III. HONORS, AWARDS, FELLOWSHIPS, AND LECTURESHIPS

#### Honors, Awards and Fellowships

1985, '86, '88	Recognition Award	Genentech, Inc.,
2000 - 02	Hellman Family Award for Early Career Faculty	Univ. of Calif., San Francisco
2000 - 01	V Foundation Scholar	The V Foundation for Cancer Research
2000 - 03	Edward Mallinckrodt, Jr. Foundation Award for Medical Research	Edward Mallinckrodt, Jr. Foundation
2002	Gertrude B. Elion Cancer Research Award	AACR
2006 - 11	Era of Hope Scholar Award	Dept. of Defense, BCRP
2011 - 16	Era of Hope Scholar Expansion Award	Dept. of Defense, BCRP
2011 - 16	KOMEN Promise Award	Susan G Komen Foundation
2012	AACR-Charlotte Friend Lectureship	AACR Women in Cancer Research
2012	Mildred Scheel Memorial Lectureship (Inaugural)	German Cancer Aid and Deutsches Krebsforschungszentrum
2013	American Cancer Society/SSO Basic Science Lecture	Society for Surgical Oncology (SSO)
2015	13 <sup>th</sup> Rosalind E. Franklin Award	NIH, National Cancer Institute
2015 - 18	Top Industry Collaboration Award	Oregon Health & Science University
2017	Distinguished Women in Science Lecture	Barts Cancer Institute, Queen Mary University of London
2017	Doctor in Medicine ( <i>honoris causa</i> )	University of Buenos Aires, Argentina
2018	12 <sup>th</sup> AACR-Princess Takamatsu Memorial Lectureship	AACR
2018	Brinker Award for Scientific Distinction in Basic Science	Susan G. Komen Foundation
2018	Career Award	European Academy of Tumor Immunology
2019 - 20	TEFAF Oncology Chair	Maastricht University, The Netherlands
2018	AAAS Fellow (Lifetime)	American Association for the Advancement of Science (AAAS)
2019	Fellow of the AACR Academy (Lifetime; FAACR)	AACR
2019 - 25	Highly Cited Researcher (Clarivate)	Web of Science™ (ResearcherID: ABH-9834-2020)
2020 - 27	Komen Scholar (invited)	Susan G Komen Foundation
2021 - 24	President-Elect ('21-'22), President ('22-'23), Past-President ('23-'24). Elected	AACR
2022	Fellow of the Academy of Immuno-Oncology (FAIO)	Society Immunotherapy of Cancer (SITC)
2023	15 <sup>th</sup> Margaret L. Kripke Legend Award	Univ. of Texas, MD Anderson Cancer Center
2023	Member, National Academy of Sciences	National Academies of Science, Engineering, Medicine. USA
2024	2024 Heroine of Public Health	Johns Hopkins Bloomberg School of Public Health
2024	Member, National Academy of Medicine (inducted October 2025)	National Academies of Science, Engineering, Medicine. USA
2026	Women in Science Achievement Award	Metastasis Research Society (MRS)

**Named and Keynote Lectureships**

- 2002 **KEYNOTE ADDRESS**; *Dutch Cancer Society Annual Symposium*, Luntern, The Netherlands
- 2002 **KEYNOTE ADDRESS**; *Cancer: Genome, Signal & Environment, Takeda Genome Urology International*, Kyoto, Japan
- 2004 **KEYNOTE ADDRESS**; Vanderbilt University Digestive Disease Research Center Retreat, Vanderbilt University, Nashville, TN, USA
- 2006 **KEYNOTE ADDRESS**; *Vanderbilt-Ingram Cancer Center Annual Retreat*, Vanderbilt University, Nashville TN, USA
- 2006 **TUMOR BIOLOGY PLENARY LECTURE**; *Advances in Neuroblastoma Research*, Los Angeles, CA, USA
- 2007 **KEYNOTE ADDRESS**; *7<sup>th</sup> International Symposium on Hodgkin Lymphoma*, Cologne, GERMANY
- 2007 **CANDLELIGHT LECTURE**; *Inflammation and Cancer: From molecular links to bed side*; Inaugural meeting for the *Instituto Clinico Humanitas*, Milan ITALY
- 2008 **CANCER RESEARCH UK LECTURE**; National Cancer Research Institute Annual Conference, Birmingham UNITED KINGDOM
- 2008 **THE JOHN F. ANDERSON MEMORIAL LECTURE IN MEDICINE**; ‘*The Linkage between Inflammation and Cancer*’, University of Virginia, Charlottesville VA, USA
- 2008 **KEYNOTE ADDRESS**; Fox Chase Cancer Center 13<sup>th</sup> Annual Postdoctoral Fellow and Graduate Student Symposium, Philadelphia, PA USA
- 2008 **ANNUAL KEYNOTE ADDRESS**; Dept of Cancer Biology, Meharry Medical College, Nashville, TN USA
- 2009 **STATE-OF-THE-ART LECTURE**; International Cancer Conference, *CANCER 2009*, Dublin IRELAND
- 2009 **KEYNOTE ADDRESS**; European Association of Cancer Research, Special Conference on *Inflammation and Cancer*, Berlin GERMANY
- 2009 **PRESIDENT’S PLENARY LECTURE**; Italian Cancer Society Annual Meeting, Milano ITALY
- 2010 **DISTINGUISHED GUEST LECTURE**; Institute of Cancer, Barts & London School of Medicine. London UNITED KINGDOM
- 2010 **PLENARY LECTURE**; CHUV Research Day, University Hospital (CHUV) and the Faculty of Biology and Medicine, Lausanne, SWITZERLAND.
- 2010 **PLENARY LECTURE**; *Annual Meeting of the American Association for Cancer Research*, Washington DC USA
- 2010 **J. WALTER JUCKETT DISTINGUISHED LECTURE**; University of Vermont Cancer Center Clinical and Translational Research Symposium, *Inflammation & Cancer*, Burlington VT, USA
- 2010 **KEYNOTE ADDRESS**; Saban Research Institute *Annual Symposium, Honoring Yves DeClerck*, University of Southern California and Children’s Hospital Los Angeles, Los Angeles CA, USA
- 2010 **PLENARY LECTURE**; American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology, Concurrent Annual Meetings, Baltimore MD, USA
- 2011 **KEYNOTE ADDRESS**; 11<sup>th</sup> Annual Meeting of NANT Consortium Investigators. Biology and Therapy of High Risk Neuroblastoma, Redondo Beach CA, USA
- 2011 **PLENARY LECTURE**; San Antonio Breast Cancer Conference, San Antonio, Texas USA
- 2011 **BORNTREE DISTINGUISHED LECTURE**; Immunology and Infectious Disease Program, Dept of Veterinary and Biomedical Sciences, Pennsylvania State Univ. University Park, PA USA
- 2011 **HUCK DISTINGUISHED LECTURE**; The Huck Institute, University Park, Pennsylvania State Univ. University Park, PA USA
- 2011 **CHARLES I. SIEGAL MEMORIAL LECTURE**; Dana-Farber Cancer Institute and the Dana-Farber Cancer Institute, Boston MA, USA
- 2012 **PLENARY LECTURE**; “Tumor Heterogeneity: Challenges and Therapeutic Opportunities” *103<sup>rd</sup> Annual Meeting of the AACR*, Chicago, IL USA
- 2012 **MILDRED SCHEEL LECTURESHIP (INNAUGURAL)**; German Cancer Aid, and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, GERMANY
- 2013 **AMERICAN CANCER SOCIETY BASIC SCIENCE LECTURE**; Society of Surgical Oncology Annual Meeting, Washington D.C., USA
- 2013 **KEYNOTE ADDRESS**; 3<sup>rd</sup> Annual Women’s Cancer Research Center Retreat, University of Pittsburgh Cancer Institute, Pittsburgh PA USA
- 2013 **SOSNOVSKY DISTINGUISHED LECTURESHIP**; University of Wisconsin, Milwaukee, WI USA
- 2014 **ASHLEY DUNN ORATION: PLENARY LECTURE**; 26<sup>th</sup> Lorne Cancer Conference, Lorne, AUSTRALIA
- 2014 **Lola and John Grace DISTINGUISHED LECTURE in Cancer Research**; Institute Suisse de Recherche

- Experientale sur le Cancer (ISREC), Lausanne SWITZERLAND
- 2014 **KATHLEEN ROBISON HUNTSMAN DISTINGUISHED LECTURE**; Huntsman Cancer Center, Salt Lake City UT, USA
- 2014 **GRAND ROUNDS**; Moffit Cancer Center, Tampa FL, USA
- 2014 **KEYNOTE ADDRESS**; 2014 Breast Cancer Issues Conferences, Susan G. Komen, Oregon and Washington. Portland OR USA
- 2014 **KEYNOTE ADDRESS**; 2014 Betty Hise Foundation for Cancer Research Annual Convention. Clackamas, OR, USA
- 2014 **KEYNOTE ADDRESS**; Kearney Breast Center's 5<sup>th</sup> Anniversary, in honor of Breast Cancer Awareness Month, Pacific Health Southwest Medical Center Foundation, Vancouver, WA, USA
- 2015 **SENATOR GEORGE MITCHELL LECTURE**; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, N. Ireland
- 2015 **KEYNOTE ADDRESS**; Cell Symposia; *Cancer, Inflammation, and Immunity*, Sitges, SPAIN
- 2015 **13<sup>th</sup> Rosalind E. Franklin Award Lecture**; National Cancer Institute Intramural Program Retreat, Washington DC, USA
- 2015 **PLENARY LECTURE**; AACR 106<sup>th</sup> Annual Meeting, "*Oncology Meets Immunology: Not Just Another Hallmark*", Philadelphia, PA USA
- 2015 **KEYNOTE ADDRESS**; 6<sup>th</sup> Annual Meeting of the American Pancreatic Association, San Diego CA USA
- 2016 **KEYNOTE ADDRESS**; Towards Predictive Cancer Models, ICREA and VHIO Symposium, Barcelona SPAIN
- 2017 **KEYNOTE ADDRESS**; 1<sup>st</sup> Crick Cancer Meeting, Francis Crick Institute, London UNITED KINGDOM
- 2017 **KEYNOTE ADDRESS**; Keystone Symposia, "*Inflammation Driven Cancer: Mechanisms to Therapy/Microbiome in Health and Disease*", Keystone, Colorado USA
- 2017 **DISTINGUISHED WOMEN IN SCIENCE LECTURE**; Barts Cancer Institute, London UK.
- 2017 **SIDNEY H. SACHS LECTURE**; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH USA
- 2017 **MARGUERETTE VOGT LECTURE IN CANCER BIOLOGY**; The Salk Institute, La Jolla CA, USA.
- 2018 **CAREER AWARD LECTURE**; European Academy of Tumor Immunology (EATI), Centre de Recherche de Cordeliers, Paris, FRANCE.
- 2018 **KEYNOTE ADDRESS**; Joint Montagna Symposium & Annual PanAmerican Society for Pigment Cell Research Conference, "Melanoma to Vitiligo: The Melanocyte in Biology & Medicine". Glenenden Beach, Oregon USA
- 2019 **KEYNOTE ADDRESS**; TEFAF Oncology Symposia, Maastricht University, Maastricht, The Netherlands
- 2019 **KEYNOTE ADDRESS**; 'Stress and inflammation in Tumor Progression and Metastasis Conference', Weizmann Institute of Science, Rehovot, ISRAEL
- 2019 **KEYNOTE ADDRESS**; Immunology LA Symposium, Los Angeles CA USA
- 2019 **KEYNOTE ADDRESS**; 2<sup>nd</sup> Triannual Symposium Highlighting Parnassus Campus Cancer Research in the HDFCCC, Univ., of California, San Francisco, CA., USA
- 2019 **EDWARD J SARCIONE EXCELLENCE IN IMMUNOLOGY LECTURE**; Roswell Park Cancer Center, Buffalo NY. USA
- 2019 **FRANK AND SHIRLEY FITCH LECTURESHIP IN TUMOR IMMUNOLOGY**; Dept of Cancer Research, Ben May Cancer Center, University of Chicago, Chicago IL. USA
- 2021 **KEYNOTE LECTURE**; CRUK Grand Challenge Key Concepts, 'STORMing Cancer'. Virtual.
- 2021 **KEYNOTE ADDRESS**, 6<sup>th</sup> Meeting on the Biology of Cancer: Microenvironment & Metastasis, Cold Spring Harbor Laboratory Symposium, New York USA
- 2021 **KEYNOTE ADDRESS**, *Moving Breast Cancer Treatments Forward*, Jayne Koskinas Ted Giovanis Foundation for Health and Policy, Bethesda MS USA
- 2021 **KEYNOTE ADDRESS**, Society for Immunotherapy of Cancer (SITC) 36<sup>th</sup> Annual Meeting 2021, Washington DC, USA
- 2023 **PRESIDENTIAL ADDRESS**, 2023 AACR Annual Meeting, Orlando FL, USA
- 2023 **15<sup>TH</sup> MARGARET L. KRIPKE LEGEND AWARD LECTURE**, Univ. of Texas., MD Anderson Comprehensive Cancer Center, Houston TX, USA
- 2023 **KEYNOTE ADDRESS**, Internal Medicine Research Retreat, University of Texas, MD Anderson Comprehensive cancer Center 2023 Internal Medicine Research Retreat. Virtual

- 2023 **KEYNOTE ADDRESS**, Zena Werb Inaugural Memorial Symposium in Cancer Biology 2023. Univ. of Calif., San Francisco, Dept of Anatomy and Helen Diller Family Comprehensive Cancer Center.
- 2023 **KEYNOTE LECTURE**, Molecular and Medical Pharmacology Graduate Program Retreat, Univ. of Calif., Los Angeles. Huntington Beach CA, USA
- 2024 **KEYNOTE LECTURE**, *Tumor Microenvironment & Therapy*, Rogel Cancer Center Retreat, University of Michigan Medical School, Ann Arbor, MI USA
- 2024 **KEYNOTE LECTURE**, Aspen Cancer Ideas Lecture, Aspen Cancer Conference, Aspen, CO USA
- 2024 **KEYNOTE LECTURE**, *Inaugural Jeffrey W. Pollard Memorial Lecture*, Albert Einstein College of Medicine, NY, NY USA

#### IV. PROFESSIONAL ACTIVITIES

##### **External Scientific Advisory Boards and Councils (EAB/SAB/SAC) and Scientific Review Board (SRB)**

##### **Membership**

2007 - 2014	Member, EAB	(P30) Masonic Cancer Center, University of Minnesota, Minneapolis MN, USA
2007 - 2011	Member, EAB	(U54) <i>Aging, Tumor Microenvironment and Prostate Cancer</i> , PI: S. Plymate; Univ. of Washington, Seattle WA USA
2007 - 2011	Member, EAB	(U54), <i>Novel Methods for Detection Cell Interactions in the Tumor Microenvironment</i> ; P.I. J Condeelis. Albert Einstein College of Medicine of Yeshiva University, New York, NY USA
2009 - 2013	Member, EAB	(P01), <i>Neuroblastoma</i> ; P.I. R Seeger, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA USA
2009 - 2014	Member, EAB	(P01) <i>Motility and Invasion</i> , PI: J Condeelis; Albert Einstein College of Medicine, NY, NY USA
2011 - 2021	Member, SRB	STARR Cancer Consortium: 5 <sup>th</sup> , 8 <sup>th</sup> , 9 <sup>th</sup> , 10 <sup>th</sup> , 13 <sup>th</sup> grant competitions
2012 - 2019	Member, EAB	(P30) Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis IN, USA
2012 - present	Member, EAB	(P30) Koch Institute for Integrated Cancer Research, Massachusetts Inst. of Tech. Cambridge, MA USA
2013 - 2015	Member, EAB	Biodesign Institute at Arizona State University, Tempe, AZ USA
2013	Member, SRB	LabEx, Paris France
2013 - present	Member, SAC	Cancer Research Institute (CRI)
2013 - 2021	Member, SRB	The V Foundation for Cancer Research
2015 - present	Member, SAB	Genenta Sciences, Milan Italy
2016 - 2024	Member, EAB	NIH/NCI-Frederick National Laboratory Advisory Committee (FNLAC)
2016 - 2017	Member	GlaxoSmithKline (GSK), External Immunology Board (EIB)
2016 - 2017	Member	Jansen Research & Development, LLC; ImmunoOncology Board
2016 - 2021	Member, EAB	Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore MD. USA
2016 - 2020	Member, EAB	(P30) Salk Institute Cancer Center, La Jolla CA. USA
2016 - 2021	Member	Pharmacyclics, Inc: Advisory committee (NCT02436668)
2017	SAB, ad hoc	AstraZeneca Oncology External IO Science Panel, Waltham, MA. USA
2017 - present	Member, EAB	(P50) Breast Cancer SPORE, Dana Farber Cancer Center, Boston MA. USA
2016 - 2021	Member, EAB	Syndax Pharmaceutical, Inc. Boston MA. USA
2018 - 2023	Member, SAB	Carisma Therapeutics Inc. Philadelphia, PA. USA
2018 - 2022	Member, SAB	Verseau Therapeutics, Inc. Boston, MA. USA
2017 - 2019	Member, SRB	Cancer Research United Kingdom (CRUK); Early Detection (EDx) Research Committee. London, England
2019 - 2021	Member, SAB	Zymeworks, Inc. Vancouver, British Columbia, CANADA
2019 - 2024	Member, EAB	(P30) University of California, San Diego Moores Cancer Center, San Diego, CA. USA
2019 - present	Member, SAB	Cytomix Therapeutics, Inc., S. South Francisco, CA. USA
2019 - present	Member	Lustgarten Foundation, Therapeutics Working Group. NY, NY. USA
2019 - 2022	Ad hoc, EAB	(P30) Dana Farber/Harvard Cancer Center. Boston, MA. USA
2023 - 2025	Member, EAB	(P30) Dana Farber/Harvard Cancer Center. Boston, MA. USA

2020 - present	Member, SAB	Kineta Inc, Seattle, WA, USA
2020 – present	Member, SAB	HiberCell, Inc., New York, NY, USA
2021 – present	Member – Immuno SAB	Cell Signaling Technologies, Danvers, MA, USA
2021 – present	Member, EAB	(P30) The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA
2021 – present	Member, SAB	Alkermes, Inc., Waltham, MA, USA
2021 – present	Member, EAB	Prostate P01 (M. Shen, PI), Columbia University Medical Center, NY, NY, USA
2022 – present	Member, EAB	MD Anderson Cancer Center GI SPORE (P50; S. Kopetz and A Maitra, coPI), Houston, TX, USA
2022 – 2023	Member, SAB	PDX (RASKA) Pharmaceuticals, Inc., Portland OR, USA
2022 – present	Member, SAB	Pio Therapeutics Pty Ltd, Parkville VIC, AUSTRALIA
2022 – present	Member, SAB	NextCure, Beltsville MD, USA
2022 – present	Member, SAB	Guardian Bio, Boston MA USA
2023 - present	Member, SAB	Shasqi Inc., S San Francisco, CA USA
2023 – present	Member, EAB	(P30) Mayo Clinic Comprehensive Cancer Center, Rochester, MN USA
2024 – present	Member, EAB	(P30) Hollings Cancer Center, Medical Univ. of South Carolina, SC, USA
2024 - present	Member, SAB	Dispatch Biotherapeutics, San Francisco, CA USA

### **Editorial Board Activities:**

2003 - 2005	Associate Editor, <b><i>Cancer Research</i></b>
2005 – 2007	Editorial Board, <b><i>Carcinogenesis</i></b>
2004 – 2007	Senior Editor, <b><i>Cancer Research</i></b> ( <i>Cell, Tumor and Stem Cell Biology</i> Section)
2007 – 2009	Senior Editor, <b><i>Cancer Research</i></b> ( <i>Tumor Microenvironment</i> Section)
2007 – 2009	Deputy Editor, <b><i>Cancer Research</i></b>
2007	Guest Editor, PNAS Editorial Board
2008	Guest Editor (with Tyler Jacks), <i>Current Opinion in Genetics &amp; Development</i>
2008 – 2010	Editorial Board, <b><i>Cancer Microenvironment</i></b>
2009 – 2012	Deputy Editor for Breaking Advances, <b><i>Cancer Research</i></b>
2012 – present	Editorial Board, <b><i>Cancer Cell</i></b>
2012 – present	Senior Editor, <b><i>Cancer Immunology Research</i></b>
2013 – 2017	Editorial Board, <b><i>Cancer Immunology, Immunotherapy</i></b>
2013	Guest editor, Editorial Committee, <b><i>Annual Reviews of Pathology</i></b>
2016 – 2019	Board of Reviewing Editors, <b><i>Science</i></b>
2017 – present	Scientific Editor, <b><i>Cancer Discovery</i></b>

### **Local, National and International Meetings Organized:**

2005	Keystone Symposia, <i>Inflammation and Cancer</i> , Co-organizer with Dr. Ray DuBois (Vanderbilt Univ, TN), Breckenridge, CO, USA
2006	5 <sup>th</sup> Annual Timberline Symposium on Epithelial Cell Biology, ' <i>Intrinsic and Microenvironmental Regulation of Epithelial Cancer</i> ', Co-Organizer with Dr. Harold Moses (Vanderbilt University, TN, USA), Timberline, OR, USA
2006	Co-Organizer (with Dr. Lewis Lanier), UCSF HDFCCC Annual Symposium, ' <i>Inflammation &amp; Cancer: Bench to Bedside</i> '.
2007	Keystone Symposia, <i>Inflammation and Cancer</i> , Co-Organizer with Drs. Fran Balkwill (Cancer Research UK) and Glenn Dranoff (Beth Israel Cancer Center, Harvard, MA); Santa Fe, New Mexico, USA
2008	AACR Special Conference: <i>Inflammation and Cancer</i> , Co-organizer with Drs. Michael Karin (UCSD) and Larry Marnett (Vanderbilt Univ.). Oahu, Hawaii, USA.
2008	International Society for Biological Therapy of Cancer (ISBTc), <i>2008 Workshop on Inflammation in Cancer Development</i> , Co-Organizer with Drs. Michael Karin, (UCSD), Steven Dubinett (UCLA), and George Weiner (WU); San Diego CA USA
2010	Co-Organizer (with Dr. Lewis Lanier), UCSF HDFCCC Program in <i>Cancer Immunity and Microenvironment</i> Symposium
2011	AACR Special Conference: <i>Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy</i> , Co-Organizer with Drs. Yves DeClerck (USC, Children's Hospital) and Melody Swartz (EPFL). Miami,

- FL USA
- 2014 Keystone Symposia, *Immune Evolution in Cancer*, Co-Organizer with Drs. Suzanne Ostrand-Rosenberg (Univ. Maryland) and Olja Finn (Univ. of Pittsburgh). Whistler, British Columbia, CANADA
- 2014 3<sup>rd</sup> International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets, Mykonos, Greece. Co-organizer with Drs Amato Giacci (Stanford Univ) and Alexia Ileana-Zaromytidou (Nature Cell Biology).
- 2016 Keystone Symposia, *Cancer Pathophysiology: Integrating the Host and Tumor Environments*, Co-Organizer with Drs. Sheila Stewart (Washington Univ. St Louis), Sandra McAllister (Brigham Women's Hospital, Harvard Medical School). Breckenridge, CO USA
- 2017 Cell Symposium: *Cancer, Inflammation and Immunity*. Co-organizer with Drs. Catano Reis e Sousa (Crick Institute, UK), Laurie H Glimcher (Dana Farber Cancer Center). San Diego, CA USA.
- 2017-present 26<sup>th</sup>, 27<sup>th</sup>, 28<sup>th</sup>, 29<sup>th</sup> Annual Short Course on Experimental Models of Human Cancer, sponsored by The Jackson Laboratory, Co-organizer with Drs. Carol Bult (The Jackson Laboratory), Karolina Palucka (The Jackson Laboratory), and Charles Wray (The Jackson Laboratory). Bar Harbor, Maine, USA
- 2018 Keystone Symposium, *Cancer Immunotherapy: Combinations*. Co-organizer with Drs. Chris Boshoff (Pfizer Pharma) and Lieping Chen (Yale Medical), Montreal, Quebec. CANADA
- 2018 8<sup>th</sup> AACR Special Conference on Tumor Immunology and Immunotherapy. Co-organizer with Drs. Drew Pardoll (Johns Hopkins), Ira Mellman (Genentech) and James Allison (MDACC). Miami, FL, USA
- 2018 Forbeck Foundation Meeting: 'Tumor Microenvironment'. Co-organizer with Dr. Rakesh Jain (Harvard). Colorado, USA
- 2020 EACR-AACR-ASPIC Basic and Translational Research Conference, 'Tumor Microenvironment', AACR Co-Chair organizer with Drs. C Caldas (EACR), L Costa (ASPIC). Lisbon, PORTUGAL.
- 2020 Keystone Symposium, *Myeloid Cells and Innate Immunity in Solid Tumors*. Co-organizer with Drs. Judith Varner (UC San Diego) and Dmitry Gabrilovich (Wistar Institute), Virtual meeting due to COVID-19.
- 2020 AACR Translational Cancer Research for Basic Scientists Workshop. Course Co-Director with RB Corcoran (Mass. General Hospital), SB Horwitz (Albert Einstein College of Medicine), GR Oxnard (Dana-Farber Cancer Institute). Virtual meeting due to COVID-19.
- 2021 Founding co-organizer 'The Myeloid Network', a virtual international seminar series <<https://themyeloidnetwork.eng.ucsd.edu>>, with Drs. J Varner (UCSD), J Guerriero (BWH/Harvard), D Gabrilovich (AstraZeneca), J Joyce (UNIL).
- 2021 AACR Translational Cancer Research for Basic Scientists Workshop. Course Co-Director with RB Corcoran (Mass. General Hospital), GR Oxnard (Dana-Farber Cancer Institute). Virtual meeting due to COVID-19.
- 2022 AACR Special Conference on 'Carcinoma in situ', Co-Chair organizer with Drs. K. Polyak (DFCC/Harvard), L. Esserman (UCSF), Reis-Filho (MSKCC).
- 2022 AACR Translational Cancer Research for Basic Scientists Workshop. Course Co-Director with RB Corcoran (Mass. General Hospital), G Demetri (Dana-Farber Cancer Institute). Boston MA, USA.
- 2024 Precision Targeting of the Tumor Ecosystem Workshop, sponsored by The Mark Foundation for Cancer Research and Takeda. Co-organizer with Dr. Owen Sanson (CRUK Scotland Institute)

## V. RESEARCH PROGRAM AND ACCOMPLISHMENTS

**Research Program:** The Coussens' lab focuses on elucidating the roles of immune cells and their mediators as critical regulators of solid tumor (squamous cancer of the skin, mesothelioma, breast and pancreas cancer) development. During the early development of cancer, many physiological processes occur in the vicinity of 'young tumor cells' similar to processes occurring during embryonic development and healing of wounds in adult tissue, e.g., leukocyte recruitment and activation (inflammation), angiogenesis (development of new blood supply) and tissue remodeling. During tumor development however, instead of initiating a 'healing' response, activated leukocytes provide growth-promoting factors that aid tumor progression, in combination with factors that inhibit cytotoxic activities of CD8<sup>+</sup> T cells. We are interested in understanding the molecular mechanisms regulating leukocyte recruitment into neoplastic tissue, how the tumor microenvironment programs recruited and resident leukocytes, and how leukocytes in turn regulate subsequent aspects of tumorigenesis. To address these issues, we have taken several innovative approaches to investigate

mechanisms involved in: *i.* induction and maintenance of chronic inflammatory microenvironments in premalignant, malignant and metastatic tissues; *ii.* role of leukocytes in regulating tissue remodeling, angiogenesis, immune suppression, cancer development and response to cytotoxic/targeted/immune therapy; *iii.* development of novel non-invasive imaging reagents and discovery of tumor-derived and soluble biomarkers of tumor and immune response to therapy in tissues/tumors/blood; *iv.* Investigate preclinical therapeutic efficacy of “drugs” that inhibit protumorigenic activities of leukocytes in mouse models of cancer development and their translation to the clinic; and *v.* development of novel technology platforms for real-time monitoring of leukocyte presence and effector status at near single cell level in patients for evaluating response and resistance to therapy. The long-term goal of our research is to translate basic observations made in the mouse, toward rational design of novel therapeutics whose aim is to block and/or alter rate-limiting events critical for solid tumor growth, maintenance or recurrence in humans, and to leverage these findings for rationale delivery of drugs in the clinic and real time response/resistance monitoring. Currently, we are actively utilizing transgenic mouse models (non-melanoma squamous and breast cancer, pancreatic adenocarcinoma, and mesothelioma) to reveal functional roles of adaptive and innate leukocytes during tumor development, and to identify new targets for anti-cancer therapy. These experimental studies are conducted in parallel with evaluation of representative human cancer specimens to affirm that mechanisms revealed in the experimental setting represent fundamental parameters of multi-stage cancer development in humans.

**Research Accomplishments:** Dr. Coussens is internationally known for her original and fundamental discoveries on the molecular and cellular mechanisms of chronic inflammation that regulate solid tumor pathogenesis. Her research investigating functional significance of inflammation in cancer resulted in a paradigm shift by revealing that in vivo, activation of chronic inflammatory programs in early neoplasms is required for *promotion* to malignancy. She has elucidated immunologic, molecular and cellular underpinnings of pro-tumor immunity, and discovered previously unappreciated roles for B cells, CD4<sup>+</sup> T cells, and discrete myeloid subsets as critical regulators of solid tumor development.

She was first to mechanistically demonstrate in vivo that B cells foster squamous carcinogenesis by activating protumoral activity of myeloid cells infiltrating premalignant tissues (*deVisser et al., 2005; Schioppa et al., 2011*). Using a series of in vivo molecular genetic, biochemical and immunologic approaches, she revealed that humoral immunity and circulating immune complexes potentiate cutaneous carcinogenesis via induction of Th2-type inflammatory pathways in macrophages following activation of FcR $\gamma$ -mediated signaling that ultimately lead to CD8<sup>+</sup> T cell suppression (*Andreau et al., 2010; Affara et al., 2014*). Based on these studies, she examined B cell (CD20)-depleting antibodies in solid tumors and reported that B cell depletion enhanced therapeutic efficacy of chemotherapy by CD8<sup>+</sup> T cell-dependent mechanisms (*Affara et al., 2014*). By revealing similar “B cell signatures” in squamous, pancreas and head and neck (HNSCC) cancers, she identified a protumoral role for B cells in human pancreatic cancers (*Gunderson et al., 2016*). More recently, she extended her preclinical studies to reveal activation of complement cascades, complement protein C5a and its receptor expressed on diverse myeloid subtypes, fosters protumoral effector pathways leading to macrophage-based T cell suppression; inhibition of C5aR signaling blunts these and imparts antigen-specific CD8<sup>+</sup> T cell clonal expansion that is synergistic with chemotherapy (*Medler et al., 2018*). That B cells, humoral immunity and FcR $\gamma$  can enhance solid tumorigenesis remains a novel concept that has challenged existing paradigms in both the cancer biology and tumor immunology fields. Together, these studies identify novel myeloid-based pathways amenable for therapeutic targeting to quell pro-tumoral chronic inflammatory programs that can be leveraged for combinatorial strategies with cytotoxic, targeted and immune therapeutics to drive durable T cells responses to improve outcomes.

These preclinical findings and human correlations provided rationale for investigator-initiated proof-of-principle clinical studies evaluating Bruton’s Tyrosine Kinase (BTK) inhibitors in combination with gemcitabine and nab-paclitaxel in patients with locally advanced pancreatic adenocarcinomas (NCT02436668), and in combination with PD-1 immune checkpoint blockade in patients with advanced head & neck squamous carcinomas (NCT02454179); patients receiving BTK inhibitors evidence in situ and peripheral (blood) biomarker changes indicative of systemic immune reprogramming consistent with quelling of Th2 protumoral immunity (*Taylor et al 2022; Tempero et al, 2021; Sinha et al, 2023*).

Based on her early studies in squamous cancers, she investigated the hypothesis that protumoral macrophages in mammary carcinomas were similarly regulated by lymphocyte-derived paracrine factors. Using transgenic mouse models, she demonstrated that interleukins (IL)-4 and 13, derived from Th2-CD4<sup>+</sup> T



cells induce protumor activities of monocytes and macrophages, that in turn potentiate late-stage cancer progression and pulmonary metastasis (*DeNardo et al., 2009*). With the clinical potential of targeting macrophages via CSF1/CSF1R-blockade, she evaluated small molecule CSF1R antagonists and was first to report that clinical compounds targeting this macrophage survival pathway disrupt late-stage tumor progression and enhance chemo-sensitivity (*DeNardo et al., 2011; Strachan et al., 2013*) and radiation therapy sensitivity (*Shiao et al., 2015*) by CD8<sup>+</sup> T cell-dependent mechanisms. Together, these studies provided supporting data for an investigator-initiated phase Ib/II clinical trial evaluating a CSF1R inhibitor with chemotherapy in women with metastatic triple negative breast cancer (NCT01596751) funded by a Komen award (Coussens: coPI). Building on these clinical findings, further preclinical modeling revealed that CSF1R inhibition plus paclitaxel enhances the therapeutic index of antiPD-1-resistant mammary adenocarcinomas involving clonal expansion of resident memory CD8<sup>+</sup> T cells thus offering a strategy to enhance durable anti-tumor immunity. Accordingly, a clinical trial evaluating axatilimab (antiCSF1R), paclitaxel and retifanlimab (antiPD-1) has been initiated (NCT06320405).

Her preclinical studies have subsequently led to identification of a rare population of intratumoral TIM3<sup>+</sup> dendritic cells, whose maturation and production of IL-12 is repressed by macrophage-derived IL-10 in mammary tumors; these are critical for cross presentation and cytotoxic activity of intratumoral CD8<sup>+</sup> T cells, and importantly provide an immune-based signature for identifying patients likely to respond to immune therapy (*Ruffell et al., 2014; de Mingo Pulido et al., 2018*). These studies set the stage for her and collaborators to identify a macrophage-based RNA signature that identifies women with breast cancer, and a peripheral (blood-based) monocyte signature identifying women with endometrial cancer and breast cancer (*Casetta et al., 2019*). Her current research in this area is focused on understanding epigenetic regulation of macrophages and T cells in vivo, for identification of novel targets for therapy. Her pioneering research investigating the functional significance of myeloid biology in the pathogenesis of solid tumors has resulted in unleashing of a previously unappreciated area of tumor immunology that is now being embraced for its therapeutic relevance to combat cancer.

Together, a significant impact of her seminal research has been recognition that tissues vary with regards to “types” of immune programs exploited to potentiate and/or control early cancer. Her original findings underscore the tenet that complexity and tissue-specificity of host-tumor programs must be considered for therapy (*Coussens and Werb, 2001; deVisser et al., 2006; Tlsty and Coussens 2006; Hanahan and Coussens, 2012; Coussens et al., 2013; Ruffell et al., 2015; Medler et al., 2015; Palucka and Coussens, 2016*). Examples of this are illustrated by her studies described above, but also in her efforts to understand tissue-specific roles for stromal cell-derived proteases (24 publications) that fostered collaborative endeavors to develop in vivo imaging approaches for select proteolytic activities and/or immune cell infiltrates (13 publications). To evaluate leukocyte complexity in retrospective tumor specimens, we developed a 13-color polychromatic flow cytometry platform later disseminated as an SOP by the NCI-TMEN Network (*Ruffell et al., 2012; Del Alcazar et al., 2017*), and more recently, development of a 49-antibody panel for spectral flow cytometry for deep auditing human leukocyte composition and state (*Wright et al., 2026*). We elucidated myelomonocytic transcriptomic signatures predicting malignancy based on either tumor infiltrating macrophages or circulating monocytes (*Casetta et al., 2019*) and developed an ex vivo cell-based assay to identify drugs capable of neutralizing macrophage-mediated T cell suppression (*Kumar et al., 2024*). We developed a multiplex immunohistochemistry platform enabling single cell resolution simultaneous evaluation of 30 epitopes in one FFPE tissue section that preserves spatial geography. With this platform, we published a pancreatic adenocarcinoma (PDAC) atlas encompassing ~130 surgical resection specimens reporting immune contexture associated with clinical outcome. This atlas provided baseline data to evaluate impact of neoadjuvant CD40 immune therapy in PDAC. These powerful platforms are enabling retrospective/prospective evaluation of tumor specimens (>30 publications) and peripheral blood (>10 publications) at single cell levels for preclinical and clinical patient stratification and therapy response monitoring.

development of an inexpensive multiplex immunohistochemistry (mIHC) platform enabling quantitative and simultaneous evaluation of up to 30 epitopes in one FFPE tissue section, thus preserving regional geography so as to appreciate and monitor cellular heterogeneity in tumors in situ (*Tsujikawa et al., 2017; Banik et al., 2020*). With this platform, she and collaborators published an immune atlas for pancreatic adenocarcinoma (PDA) utilizing ~130 surgical resection specimens revealing previously unappreciated heterogeneity of immune contexture in this disease (*Liudahl et al., 2021*), and subsequently utilizing the PDA atlas as a baseline data set in which to evaluate impact of neoadjuvant immunotherapy (where baseline samples were not available; *Byrne et al., 2021*). These powerful platforms enable retrospective or prospective evaluation of

tissue/tumor specimens and peripheral blood at near single cell levels for preclinical and clinical patient stratification and therapy response monitoring (*Del Alcazar et al., 2016; Cooper et al., 2016; Gopalakrishnan et al., 2017; Li et al., 2018; Pennock et al., 2018; Means et al., 2019; Reddy et al., 2019; Blair et al., 2019; Hassan et al., 2019; Michaelis et al., 2019; Tsujikawa et al., 2020; Pennycuick et al., 2020; Vayrnen et al., 2021; Link et al., 2021; Byrne et al., 2021; Tempero et al., 2021; Labrie et al., 2021; Yoshimura et al., 2021; Taylor et al., 2022; Johnson et al., 2022; Kitko et al., 2022; Sinha et al., 2023; Blise et al., 2024*), as well as providing data sets for analytical tool development for spatial ecology and immune contexture synthesis (*Chang et al., 2017; Tsujikawa et al., 2019; Schapiro et al., 2022a,b; Blise et al., 2022, 2024; Mi et al., 2022; Brockman et al., 2023; Ehlers et al., 2025*)

## VI. PUBLICATIONS

**Peer-Reviewed Manuscripts** (Scopus: 73,961 citations, *h-index* 93; Google Scholar: 110,279 citations, *h-index* 108, *i10-index* 209)

1. Francke U, de Martinville B, **Coussens L**, Ullrich A. (1983) The human gene for the Beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. *Science* 222:1248-1251. PMID: [6648531](#)
2. Ullrich A, Gray A, Berman C, **Coussens LM**, Dull T. (1983) Sequence homology of human and mouse Beta-nerve growth factor subunit genes. *CSHSQ* 48:435-442. PMID: [6327169](#)
3. Breakefield X, Castiglione C, **Coussens L**, Axelrod F, Ullrich A. (1984) Structural gene for Beta-nerve growth factor is not defective in familial dysautonomia. *Proc. Natl. Acad. Sci. USA* 81:4213-4216. PMID: [6330750](#)
4. Ullrich A, **Coussens L**, Hayflick J, Dull T, Gray A, Tam A, Lee J, Yarden Y, Libermann T, Schlessinger J, Downward J, Bye J, Whittle N, Waterfield M, Seeburg P. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309:418-425. PMID: [6328312](#)
5. Ullrich A, Bell J, Chen E, Herrera R, Petruzzelli L, Dull T, Gray A, **Coussens L**, Liao Y-C, Tsubokawa M, Mason A, Seeburg P, Grunfield C, Rosen O, Ramachandran J. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature* 313:756-761. PMID: [2983222](#)
6. Lauffer L, Garcia P, Harkins R, **Coussens L**, Ullrich A, Walter P. (1985) Topology of the signal recognition particle receptor in the endoplasmic reticulum membrane. *Nature* 318:334-338. PMID: [2999608](#)
7. Schechter A, Hung M-C, Vaidanathan L, Weinberg R, Yang-Feng T, Francke U, Ullrich A, **Coussens L**. (1985) The *neu* gene: An *erbB*-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science* 229:976-978. PMID: [2992090](#)
8. **Coussens L**, Yang-Feng T, Liao T-C, Chen E, Gray A, McGrath J, Seeburg P, Libermann T, Schlessinger J, Francke U, Levinson A, Ullrich A. (1985) Tyrosine kinase receptor with extensive homology to the EGF receptor shares chromosomal location with *neu* oncogene. *Science* 230:1132-1139. PMID: [2999974](#)
9. **Coussens L**, Van Beveren C, Smith D, Chen E, Mitchell R, Isacke C, Verma I, Ullrich A. (1986) Structural alteration of viral homologue of receptor proto-oncogene *fms* at carboxyl terminus. *Nature* 320:277-280. PMID: [2421165](#)
10. Ullrich A, Riedel H, Yarden Y, **Coussens LM**, Gray A, Dull T, Schlessinger J, Waterfield MD, Parker PJ. (1986) Protein kinases in cellular signal transduction: Tyrosine kinase growth factor receptors and protein kinase C. *CSHSQ* 51:713-724. PMID: [3472757](#)
11. Chen E, **Coussens LM**, Liao Y-C, Smith D, Yang-Feng T, McGrath J, Van Beveren C, Verma IM, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. (1986) Structural features of growth factor receptors with oncogenic potential. *Biochem. Soc. Symp.* 52:65-82. PMID: [3579970](#)
12. Parker P, **Coussens L**, Totty N, Rhee L, Young S, Chen E, Stabel S, Waterfield M, Ullrich A. (1986) The complete primary structure of protein kinase C—the major phorbol ester receptor. *Science* 233:853-859. PMID: [3755547](#)
13. **Coussens L**, Parker P, Rhee L, Yang-Feng T, Chen E, Waterfield M, Francke U, Ullrich A. (1986) Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. *Science* 233:859-866. PMID: [3755548](#)
14. **Coussens L**, Rhee L, Parker P, Ullrich A. (1987) Alternative splicing increases the diversity of the human protein kinase C family. *DNA* 6:389-394. PMID: [3677994](#)
15. Yarden Y, Kuang W-J, Yang-Feng T, **Coussens L**, Munemitsu S, Dull T, Schlessinger J, Francke U, Ullrich A. (1987) Human proto-oncogene *c-kit*: A new cell surface receptor-tyrosine kinase for an unidentified ligand. *EMBO J.* 6:3341-3351. PMID: [2448137](#)
16. MacDonald R, Pfeffer S, **Coussens L**, Tepper M, Brocklebank C, Mole J, Anderson J, Chen E, Czech M,

- Ullrich A. (1988) A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. *Science* 239:1134-1137. [PMID: 2964083](#)
17. Formby B, Ullrich A, **Coussens L**, Walker L, Peterson C. (1988) Growth hormone stimulates insulin gene expression in cultured human fetal pancreatic islets. *J. Clin. Endo. Metab.* 66:1075-1079. [PMID: 3283160](#)
  18. Mosthaf L, Grako D, Dull T, **Coussens L**, Ullrich A, McClain D. (1990) Functionally distinct insulin receptors generated by tissue-specific alternative splicing. *EMBO J.* 9:2409-2413. [PMID: 2369896](#)
  19. **Coussens LM**, Yokoyama K, Chiu R. (1994) Transforming Growth Factor  $\beta$ 1-mediated induction of *junB* is selectively inhibited by expression of Ad.12-E1A. *J. Cell. Physio.* 160:435-444. [PMID: 8077281](#)
  20. **Coussens LM**, Hanahan D, Arbeit J. (1996) Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. *Am. J. Pathol.* 149:1899-1917. [PMID: 8952526](#)
  21. **Coussens LM**, Werb Z. (1996) Matrix metalloproteinases and the development of cancer. *Chemistry and Biology* 3:895-904. [PMCID: PMC8939708](#)
  22. Bergers G, Hanahan D, **Coussens LM**. (1998) Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. *Int. J. Dev. Biol.* 42:995-1002. [PMID: 9853830](#)
  23. **Coussens LM**, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. (1999) Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. *Genes & Development* 13:1382-1397. [PMID: 10364156](#)
    - Featured as journal cover image
  24. McKerrow JM, Bhargava V, Hansell E, Kuwahara T, Matley M, **Coussens LM**, Warren R. (2000) A functional proteomics screen of proteases in colorectal carcinomas. *Molecular Medicine* 6:450-460. [PMID: 10952024](#)
  25. Bergers G, **Coussens LM**. (2000) Extrinsic regulators of epithelial tumor progression: metalloproteinases. *Curr. Opin. Genetics & Development* 10:120-127. [PMID: 10679388](#)
  26. **Coussens LM**, Tinkle CL, Hanahan DH, Werb Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 103:481-490. [PMID: 11081634](#)
  27. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, **Coussens LM**. (2002) Epithelial carcinogenesis: Dynamic interplay between neoplastic cells and their microenvironment. *Differentiation* 70: 610-623. [PMID: 12492502](#)
  28. **Coussens LM**, Fingleton B, Matrisian LM. (2002) Matrix metalloproteinases and cancer: Trials and tribulations. *Science* 295:2387-2392. [PMID: 11923519](#)
  29. **Coussens LM**, Werb Z. (2002) Inflammation and cancer. *Nature* 420: 860-867. [PMID: 12490959](#)
  30. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, **Coussens LM**, Hanahan D. (2003) Immune enhancement of skin carcinogenesis by CD4<sup>+</sup> T cells. *J Exp. Med.* 197:1017-1028. [PMID: 12695493](#)
  31. van Kempen LCL, Rutter DJ, van Muijen GNP, **Coussens LM**. (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. *Euro J Cell Biol*, 82:539-548. [PMID: 14703010](#)
  32. Rhee JS, Diaz R, Korets L, Hogson G, **Coussens LM**. (2004) TIMP-1 alters susceptibility to carcinogenesis. *Cancer Research* 64:952-961. [PMID: 14871825](#)
  33. Chantrain CF, Shimada H, Groshen S, Ye W, Shalinsky DR, Werb Z, **Coussens LM**, DeClerck YA. (2004) Stromal matrix metalloproteinase-9 (MMP-9) regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. *Cancer Research* 64:1675-1686. [PMID: 14996727](#)
  34. Baluk P, Raymond WW, Ator E, **Coussens LM**, McDonald DM, Caughey GH. (2004) Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for micro vascular remodeling. *Am J Physiol Lung Cell Mol Physiol*, 287:307-317. [PMID: 15075248](#)
  35. de Visser KE, Korets LV, **Coussens LM**. (2004) Early neoplastic progression is complement-independent. *Neoplasia* 6: 768-776. [PMID: 15720803](#)
  36. Jodele S, Chantrain CF, Blavier L, Crooks GM, Shimada H, **Coussens LM**, DeClerck YA. (2005) The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9-dependent. *Cancer Research*, 65: 3200-3208. [PMID: 15833851](#)
  37. Robinson S, **Coussens LM**. (2005) Soluble mediators of inflammation during tumor development. *Adv Cancer Research* 93:159-187. [PMID: 15797447](#)
  38. Fingleton B, **Coussens LM**. (2005) Host-tumor interactions influencing cancer progression. *Drug Discovery Today: Disease Mechanisms*, 2:199-204
  39. de Visser KE, Korets LV, **Coussens LM**. (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. *Cancer Cell* 7:411-423. [PMID: 15894262](#)

*Featured in:*

- *Faculty of 1000 – Exceptional (Factor 6.0)*. Authoritative evaluation by R. Abraham, Wyeth Research. <http://f1000biology.com/guardpages/evaluation/1015124//>
- *Nature* 435:752-753 (2005). 'Inflammation by Remote Control'. A. Mantovani
- *Cancer Cell* 7: 403-405 (2005). 'The role of the immune system in early carcinogenesis: B-were the double-edged sword'. A. Houghton, H. Uchi, and J.D. Wolchok.
- *Nature Reviews Immunology* 5:517 (2005). 'B cells lead the way in tumour progression'. K. Minton
- *Nature Reviews Cancer* 5:501 (2005). 'B cells lead the way in tumour progression'. K. Minton
- 40. de Visser KE, **Coussens LM**. (2005) The interplay between innate and adaptive immunity regulates cancer development. *Cancer Immunology & Immunotherapy*, 54:1143-1152. PMID: 15889249
- 41. de Visser KE, Eichten A, **Coussens LM**. (2006) Paradoxical roles of the immune system during cancer development. *Nature Reviews Cancer*, 6:24-37. PMID: 16397525
- 42. Tlsty TD, **Coussens LM**. (2006) Tumor stroma and regulation of cancer development. *Ann Rev Pathol. Mech of Disease*, 1: 119-150. PMID: 18039110
- 43. van Kempen LCL, de Visser KE, **Coussens LM**. (2006) Inflammation, Proteases and Cancer. *Euro J Cancer*, 42: 728-734. PMID: 16524717
- 44. Yuan F, Verhelst HL, Blum G, **Coussens LM**, Bogyo M. (2006) A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/Cathepsin C. *J Am Chem Society*, 128: 5616-5617. PMID: 16637611
- 45. Junankar SR, Eichten A, Kramer A, de Visser KE **Coussens LM**. (2006) Analysis of immune cell infiltrates during squamous carcinoma development. *J Invest Dermatol*, 126:36-4. PMID: 17069009
- 46. Tan TT, **Coussens LM**. Humoral immunity, inflammation and cancer. (2007) *Curr Opin Immunology* 19(2), 209-216. PMID: 17276050
- 47. Johansson M, Tan T, de Visser KE, **Coussens LM**. (2007) Immune cells as anti-cancer therapeutic targets and tools. *J Cellular Biochemistry*, 101: 918-926. PMID: 17265430
- 48. Schwartz DR, Moin K, Yao B, Matrisian LM, **Coussens LM**, Bugge TH, Fingleton B, Acuff KB, Sinnamon M, Nassar H, Krawetz SA, Linebaug BE, Sloane, BF. (2007) Hu/Mu ProtIn oligonucleotide microarray: dual species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. *Mol Cancer Res*, 5:443-454. PMID: 17510311
- 49. Egeblad M, Shen HCJ, Behonick DJ, Wilmes L, Eichten A, Korets L, Kheradmand F, Werb Z, **Coussens LM**. (2007). Type I collagen is a modifier of matrix metalloproteinase 2 function in murine skeletal development. *Dev Dynamics*, 36:1683-1693. PMID: 17440987
- Featured as journal cover image
- 50. Eichten AE, Hyun WC, **Coussens LM**. (2007) Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. *Cancer Research*, 67:5211-5220. PMID: 17545601
- Featured as journal cover image
- 51. DeNardo D **Coussens LM**. (2007) Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. *Breast Cancer Res*, 9:212-222. PMID: 17705880
- 52. Kopitz C, Gerg M, Bandapalli O, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, Hann von Weyhern CW, Brucher BLD, Brand K, **Coussens LM**, Edwards DR, Kruger A. (2007) TIMP-1 promotes liver metastasis by induction of HGF-signaling. *Cancer Research*, 67:8615-8623. PMID: 17875701
- 53. DeNardo DG, Johansson M, **Coussens LM**. (2008) Immune cells as mediators of solid tumor metastasis. *Cancer Metastasis Rev*. 27:11-18. PMID: 18066650
- 54. Johansson M, DeNardo DG, **Coussens LM**. (2008) Polarized immune responses differentially regulate cancer development. *Immunol Rev*, 222:145-154. PMID: PMC2494984
- 55. Kenny H, Kaur S, **Coussens LM**, Lengyel E. (2008) Adhesion of OvCa cells to peritoneum is mediated by MMP-2 cleavage of fibronectin, *J Clin Invest*. 118(4):1367-1379. PMID: 18340378
- 56. Wolf K, Alexander S, Schacht V, **Coussens LM**, vom Andrian U, van Rheen J, Deryugina E, Friedl P. (2009) Collagen-based cell migration models in vitro and in vivo. *Seminars Cell Dev Biol*, 20(8): 931-941. PMID: 19682592
- 57. Yagui-Beltran A, **Coussens LM**, Jablons DM. (2009) Respiratory homeostasis and exploitation of the immune system for lung cancer vaccines. *US Oncology*. 5(1):40-47. PMID: 3285551
- 58. Watkins GA, Jones EF, Shell MS, VanBrocklin HV, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE,



- Dill KA, Contag CH, **Coussens LM**, Franc BL. (2009) Development of an optimized activatable MMP-14 targeted SPECT imaging probe. *Bioorganic & Medicinal Chemistry*, 17:653-659. [PMID: 19109023](#)
59. DeNardo DG, Baretto JB, Andreu P, Vasquez L, Kolhatkar N, **Coussens LM**. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell*, 16:91-102. [PMC: 19647220](#)
- Featured in:*
- *Faculty of 1000 – Exceptional (Factor 9.0)*. Authoritative evaluation by A. Mantovani, Univ. of Milan. <http://f1000biology.com/guardpages/evaluation/1163484//>
  - *Cancer Cell* 16:81-82 (2009). 'Metastasis-Promoting Immunity: When T cells turn to the dark side' by D. Pardoll
  - *Nature Reviews Cancer* 9:609 (2009). 'Influencing bad behaviour' by N. McArthy
  - *Nature Biotechnology* 27:828 (2009). 'Promoting metastasis' by L. DeFrancesco
  - *Nature Medicine* 15:1135 (2009). 'Not Immune' by C. Schubert
  - *Ranked as a "Top Cancer Papers" between 2008-2011, Nature Medicine*, 17:262-265; *Nature Medicine* 17: 278-279; *Nature Medicine*, 17:295
60. Sista AK, Knebel RJ, Tavri SA, Johansson M, DeNardo DG, Boddington SE, Kishore SA, Ansari C, Reinhart V, Coakley FV, **Coussens LM**, Daldrup-Link HE. (2009) Optical Imaging of the peri-tumoral inflammatory response in breast cancer. *J Transl Med*, 7(1): 94-100. [PMID: 19906309](#)
61. Andreu P\*, Johansson M\*, Affara NI\*, Tan TT, Junankar S, Korets L, Lam J, Tawfik D, Pucci F, De Palma M, DeNardo D, de Visser KE, **Coussens LM**. (2010) FcR $\gamma$  activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell*, 17(2):121-134. [PMID: 20138013](#)
- \*, equal contribution
- Featured in:*
- *Cancer Cell* 17(2) 111-112 (2010). 'La mala educacion of tumor-associated macrophages: Diverse pathways and new players', by A. Mantovani
  - *Nature Reviews Immunology* 10:158 (2010). 'Antibodies lend support to tumors', by, L. Byrd
  - *Faculty of 1000 – Exceptional (Factor 6.4)*. Authoritative evaluations by X. Ma (Weill Medical College of Cornell) and F. Kiefer (Max-Planck-Institute, Germany). <http://f1000biology.com/article/id/2467956>
  - *Ranked as a "Top Cancer Papers" between 2008-2011, Nature Medicine*, 17:262-265; *Nature Medicine* 17: 278-279;
  - *Nature Medicine* (2011), 17(3) 285-286. 'B Cells and Macrophages in Cancer: Yin and Yang', by A. Mantovani
62. Dannemark J, Lohmuller T, Mayerie J, Tacke M, Lerch MM, **Coussens LM**, Peters C, Reinheckel. (2010) Deficiency for cysteine protease cathepsin L promotes tumor progression in mouse epidermis mice. *Oncogene*, 29(11):1611-1621. [PMID: 20023699](#)
63. Sounni NE, Dehne K, van Kempen LCL, Egeblad M, Affara NI, Cuevas I, Wiesen J, Junankar S, Korets L, Lee J, Shen J, Morrison C, Overall CM, Krane SM, Werb Z, Boudreau N, **Coussens LM**. (2010) Stromal regulation of vessel stability by MMP14 and TGF $\beta$ . *Disease Model. Mech.* 3:317-332. [PMID: 20223936](#)
64. Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, Beltran A, Johansson M, **Coussens LM**, Clement G, Shi Y, Zhang F, Koizumi K, Shimizu K, Jablons DM, He B. (2010) EMX2 is epigenetically silenced and suppresses growth in human lung cancer. *Oncogene*, 29(44):5969-5975. [PMID: 20697358](#)
65. Doedens A, Stockman C, Rubenstein M, Liao D, DeNardo D, **Coussens LM**, Karin M, Goldrath A, Johnson R. (2010) Macrophage expression of HIF1 $\alpha$  suppresses T cell function and promotes tumor progression. *Cancer Res*, 70(90): 7465-7475. [PMID: 20841473](#)
66. Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, DeNardo D, **Coussens LM**, Brennan DJ, Gallagher WM, Park M, Pawson T, Hallett M, Muller WJ (2010) Receptor tyrosine kinase signaling in breast cancer cells inhibits the adaptive immune response to favor a pro-tumorigenic state. *Cancer Res*, 70(20): 7776-7787. [PMID: 20924104](#)
67. Ruffell B, DeNardo DG, Affara NI, **Coussens LM**. (2010) Lymphocytes in cancer development: Polarization towards pro-tumor immunity. *Cytokine Growth Factor Reviews*, 21:3-10. [PMID: 20005150](#)
68. DeNardo DG, Andreu P, **Coussens LM**. (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. *Cancer Metastasis Rev*, 29(2):309-316, [PMID: 20405169](#)
69. Shiao SE, **Coussens LM**. (2010) The tumor-immune microenvironment and response to radiation

- therapy. *J Mammary Gland Biol Neoplasia*, 15:411-421. PMID: 21161342
70. Masset A, Maillard C, Sounni NE, Jacobs N, Bruyere F, Delvenne P, Tacke M, Reinheckel T, Foidart JM, **Coussens LM**, Noel A. (2011) Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. *Int J Cancer*, 128:283-293. PMID: 20232379
  71. Erez N, **Coussens LM**. (2011) Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. *Int. J Cancer*. 128:2536-2544. PMID: 21387299
  72. **Coussens LM**, Pollard JW. (2011) Leukocytes in mammary development and cancer. *Cold Spring Harbor Perspectives in Biology*, 3(3) PMID: 21123394
  73. DeNardo DG, Brennan DJ, Rexhapaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, **Coussens LM**. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discovery*, 1(1): 54-67. PMID: 22039576
- Featured in:*
- *Nature* 472 303-304 (2011). 'Macrophages Limit Chemotherapy' by, M. De Palma and C.E. Lewis
  - *Nature Reviews Cancer*. 11:3056 (2011). 'Bad company', by N. McCarthy
  - *2011 Most-Cited Article in CANCER DISCOVERY*,  
[http://www.aacrjournals.org/site/SpecialPages/most\\_cited.xhtml](http://www.aacrjournals.org/site/SpecialPages/most_cited.xhtml)
74. Benavides F, Perez C, Blando J, Contreras O, Shen J, **Coussens LM**, Fischer SM, Kusewitt DF, Digiovanni J, Conti CJ (2011) Protective role of cathepsin L in mouse skin carcinogenesis. *Mol Carcinog*. 52: 352-361 PMID:21538579
  75. Barbone D, Ryan J, Kolhatkar N, Chacko A, Jablons DM, Sugarbaker DJ, Bueno R, Latei AG, **Coussens LM**, Fennel DA, Broaddus VC. (2011) The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. *Cell Death & Disease*; 2:e174. doi: 10.1038/cddis.2011.58. PMID: 21697949
  76. Schioppa T, Moore R, Thompson R, Rosser E, Kulbe H, Nedospasov S, Mauri C, **Coussens LM**, Balkwill F. (2011) B regulatory cells and the tumor-promoting actions of TNF-(alpha) during squamous carcinogenesis, *Proc. Natl Acad. Sci. USA*, 108(26):10662-10667. PMID: 21670304
  77. Daldrup-Link H, Golovko D, DeNardo DG, Ruffel D, Castenada R, Wendland M, Corot C, **Coussens LM**. (2011) MR imaging of tumor-associated macrophages with clinically-applicable iron oxide nanoparticles. *Clin Can Res*. 17(17): 5695-5704. PMID: 21791632
- Featured in:*
- Featured as journal cover image
  - Highlighted in *Cancer Research* 71: 6089, 2011
78. Shiao S, Ganesan AP, Rugo HS, **Coussens LM**. (2011) Immune microenvironments in solid tumors: New targets for therapy. *Genes and Development*, 25(24): 2559-2572. PMID: 22190457
  79. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, **Coussens LM**. (2012) Leukocyte composition of human breast cancer. *Proc. Natl Acad. Sci.*, 109(8):2796-2801. PMID: 21825174
  80. Ruffell B, Affara NI, **Coussens LM**. (2012) Differential macrophage programming in the tumor microenvironment. *Trends Immunol*. 33: 119-125. PMID: 22277903
  81. Daldrup-Link H. & **Coussens LM**. (2012) MR imaging of tumor-associated macrophages. *Oncol Immunology* 1(4), 507-509. PMID: 22754769
  82. Hanahan D, **Coussens LM**. (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment, *Cancer Cell*, 21: 309-322. PMID: 22439926
- Reprinted as: 'Cell Press Supplement – Hallmarks of Cancer', April 2013.  
<http://onlinedigeditions.com/publication?i=151915>.
83. **Coussens LM**, Zitvogel L, Palucka AK. (2013) Neutralizing tumor-promoting chronic inflammation: A magic bullet? *Science*, 339 (117): 286-291. PMID: 23329041
  84. Ganesan AP, Johanson M, Ruffell B, Beltran A, Lau J, Jablons DM, **Coussens LM**. (2013) Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cells responses to lung adenocarcinoma. *J Immunology*, 191(4):2009-2017. PMID: 23851682
  85. Gunderson AG, **Coussens LM** (2013) B cells and their mediators as targets for therapy in solid tumors. *Exp Cell Res*. 319, 1644-1649. PMID: 23499742
  86. Palucka K, **Coussens LM**, O'Shaughnessy (2013) Dendritic cells, inflammation and breast cancer. *Cancer J*. 19(6):511-516. PMID 24270350
  87. Ruffell B\*, Affara NI\*, Cottone L, Junankar, S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane

- BF, Bogoyo M, **Coussens LM**. (2013) Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. *Genes Dev.* 27(19): 2086-2098. PMID: 24065739
- \*, equal contribution
- Featured in:*
- Featured as journal cover image
  - Research Highlight 'In Brief'; 'Tumor Microenvironment: Tissue-Specific Functions'; Nature Reviews Cancer 13, 757 (2013). By: Sarah Seton-Rogers
88. Strachan DC, Ruffell B, Oei Y, Bissell M, **Coussens LM**, Pryer N, Daniel D. (2013) CSF1R inhibition impedes turnover of tumor-associated macrophages and increases infiltration by antitumor CD8+ T cells in murine mammary and cervical carcinomas. *Oncol Immunology*, 1;2(12):e26968. PMID: 24498562
89. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, **Coussens LM**, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM. (2014) A listeria vaccine and depletion of T-regulatory cells activate immunity against early-stage pancreatic intra-epithelial neoplasms and prolong survival of mice. *Gastroenterology*, 146(7): 1784-1794. PMID 24607504.
90. Affara NI\*, Ruffell B\*, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, **Coussens LM**. (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. *Cancer Cell*, 25(6): 809-821. PMID: 24909985.
- \*, equal contribution
- Featured in:*
- *Cancer Discovery* 17(2) 111-112 (2014). 'Protumor B cells are therapeutic targets in squamous cell carcinoma', DOI: 10.1158/2159-8290.CD-RW2014-132. June 19, 2014
  - *Immune Regulation News* 6.21 June 13, 2014. <http://www.immuneregulationnews.com/issue/volume-6-21-jun-13/>
91. Fornetti J, Martinson H, Betts CB, Lyons TR, Jindal S, Guo Q, **Coussens LM**, Borges VF, Schedin P. (2014) Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. *J Mammary Gland Biol Neoplasia* 19(2): 213-228. PMID: 24952477.
92. Medler TR, **Coussens LM**. (2014) Duality of the immune response in cancer: Lessons learned from skin. *J Invest Dermatol.* 134(e1):E23-28. PMID: 25302470.
93. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, Daniel D, Hwang SE, Rugo HS, **Coussens LM**. (2014) Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer Cell*, 26:623-637. PMID: 25446896.
- Featured in:*
- Preview. *Cancer Cell* 26:591-593 (2014). 'CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance', by L Zitvogel and G Kroemer.
  - *Cancer Discovery* 17(2) 111-112 (2014). 'Suppression of dendritic cells by IL10 limits chemotherapy responses', DOI: 10.1158/2159-8290.CD-RW2014-223. October 30, 2014.
94. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A<sup>13</sup>, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, **Coussens LM**, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F<sup>12</sup>, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. (2014) Classification of current anticancer immunotherapies. *OncoTarget*, 5(240):12472-12508. PMID: 25537519.
95. Shiao S, Ruffell B, DeNardo DG, Faddegon BA, Park CC, **Coussens LM**. (2015) TH2-polarized CD4+ T cells and macrophages limit efficacy of radiation therapy. *Can Immuno Res.* 3(5):518-525. PMID: 25716473.
96. Cuevas I, Layman H, **Coussens LM**, Boudreau N. (2015) Sustained endothelial expression of HoxA5 in vivo impairs pathological angiogenesis and tumor progression. *PLoS One.* 10(3):e0121720. PMID: 2582196.



97. Ruffell B, **Coussens LM**. (2015) Macrophages and therapeutic resistance in cancer. *Cancer Cell*. 27(4):462-472. [PMID:25828805](#).
  - Reprinted as: 'Cell Press Selections – Immuno-Oncology, The Cancer-Immunity Cycle, 2015. <http://digitaleditions.sheridan.com/publication/frame.php?i=278807&p=&pn=&ver=flex&submissionGuid=21b50452-1232-46df-b948-2aa05d3a9f13>
  - Reprinted as: 'Cancer Cell, Best of 2015'. August 2016. [http://ccell\\_bestof2015.elsevierdigitaledition.com/](http://ccell_bestof2015.elsevierdigitaledition.com/)
98. Cotechini T, Medler TR, **Coussens LM**. (2015) Myeloid cells as targets for therapy in solid tumors. *Cancer J*. 21(4), 343-350. [PMID: 26222088](#).
99. Medler TR, Cotechini T, **Coussens LM**. (2015) Immune response to cancer therapy: Mounting an effective antitumor response and mechanisms of resistance. *Trends in Cancer*. 1:66-75. [PMID: 26457331](#).
100. Davidson N, Armstrong S, **Coussens LM**, Cruz-Correa M, DeBerardinis R, Doroshov J, Hwu P, Kensler T, Morrow M, Mulligan C, Pao W, Platz E, Smith T, Willman C. AACR Cancer Progress Report 2016. *Clin Cancer Res*. Clin Cancer Res. 22(19 Supplement): S1-S137. [PMID:27697776](#).
101. Ruhland M, **Coussens LM**, Stewart S. (2016) Senescence and cancer: an evolving inflammatory paradox. *Biochimica et Biophysica Acta*. 1865:14-22. [PMID: 26453912](#).
102. Lund AW, Medler TR, Leachman SA, **Coussens LM**. (2016) Lymphatic vessels regulate the regional immune landscape: Implications for malignant and non-malignant cutaneous disease. *Cancer Discovery*, 6(1):22-35. [PMID: 26552413](#)
103. Gunderson AJ\*, Kaneda M\*, Tsujikawa T, Affara NI, Nguyen, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero M, Sheppard B, Irving B, Varner JA\*, **Coussens LM\***. (2016) Bruton's tyrosine kinase (BTK)-dependent immune cell crosstalk drives pancreas cancer. *Cancer Discovery*, 6(3): 270-285. [PMID: 26715645](#).  
 \*, equal 1<sup>st</sup> author, and senior author contributions  
 Featured in:
  - Research Highlight. Nature Reviews Cancer 16 (2), 67 (2016). "Pancreatic Cancer: Spotlight on B cells". By: Sarah Seton-Rogers
  - Views – In the Spotlight. Cancer Discovery, 6(3):230-232 (2016). "B cells Promote Pancreatic Tumorigenesis", By: Ali Roghanian, Christopher Fraser, Maruanna Kleyman, Jianzhu Chen.
  - Editor's Choice: *Cancer Immunology*. Sci. Signal. 9(422):ec77 (2016). "B cells fuel pancreatic cancer". By: Leslie K. Ferrarelli
104. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, **Coussens LM**, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. (2016) Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *Oncot Immunology*, 5(3):e1136044. [PMID: 27141370](#).
105. Palucka AK, **Coussens LM**. (2016) The basis of oncoimmunology. *Cell*, 164(6):1233-1247. [PMID: 26967289](#).
106. Daldrup-Link HE, Mohanty S, Ansari C, Lenkov O, Shaw A, Ito K, Hong SH, Hoffman M, Pisani L, Boudreau N, Gambhir SS, **Coussens LM**. (2016) Alk5-inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. *J Clin Invest Insight*. 1(6):e85608. [PMID: 27182558](#).
107. Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, **Coussens LM**, Daldrup-Link HE. (2016) Iron oxide nanoparticles inhibit tumor growth. *Nature Nanotechnol*, 11(11):986-994. [PMID: 27668795](#).
108. Liu Y, Wang Z, De La Torre R, Barling A, Tsujikawa T, Hornick N, Hanifin J, Simpson E, Wang Y, Swanzey E, Wortham A, Ding H, **Coussens LM**, Kulesz-Martin M. (2016) Trim32 deficiency enhances Th2 immunity and predisposes to features of atopic dermatitis. *J Invest Derm*. 137(2):359-366. [PMID:27720760](#).
109. Wilson RA, Espinoza-Diez C, Kanner N, Chattejee N, Ruhl R, Hipfinger C, Advani S, Li J, Khan O, Franovic A, Weis S, Kumar S, **Coussens LM**, Anderson D, Chen CC, Cheresh D, Anand S. (2016) MicroRNA regulation of endothelial TREX1 reprograms the tumor microenvironment. *Nature Comm.*, 7:13597. [PMID:27886180](#).
110. Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G,



- Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, **Coussens LM**. (2017) Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. *Cell Reports*, 19:203-217. [PMID:28380359](#)  
Featured as:  
• OHSU School of Medicine, *Paper of the Month*. May 2017
111. Ghist CE, Shaw AK, Wong MH, **Coussens LM**. (2017) Surgical: procedures and methodology for a preclinical murine model of de novo mammary cancer metastasis. *J. Vis. Exp.*, (125), e54852. doi: 10.3791/54852. [PMID:28784976](#)
  112. Del Alcazar CR, Huh SJ, Ekram M, Trinh A, Liu LL, Becca F, Zi X, Kwak M, Bergholtz, H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Kim EMH, McDonnell CH, Wagner J, Rowberry R, Freeman G, Dillon D, Sorlie T, **Coussens LM**, Garber JE, Fan R, Bobolis K, Allred DC, Park SY, Michor F, Polyak K. (2017) Immune escape in breast cancer during in situ to invasive carcinoma transition. *Cancer Discovery*, 7(10):1098-1115. [PMID: 28652380](#)
  113. Chang YH\*, Tsujikawa T\*, Margolin A, **Coussens LM**, Gray JW. (2017) Multiplexed immunohistochemistry image analysis using sparse coding. *Conf Proc IEEE Eng Med Biol Soc*. 2017:4046-4049. doi: 10.1109/EMBC.2017.8037744. [PMID:29060785](#)  
\*, equal contribution
  114. Gopalakrishnan V, Spencer C, Reuben A, Andrews M, Karpinets T, Prieto P, Vicente D, Nezi L, Hoffman K, Cogdill A, Zhao L, Hudgens C, Hutchinson D, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy S, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall E, Rezvani K, Alousi A, Chemaly R, Shelburne S, Vence L, Okhuysen P, Jensen V, Swennes A, McAllister F, Marcelo E, Sanchez R, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman J, Haydu L, Burton E, Gardner J, Sirmans E, Hu J, Lazar A, Tsujikawa T, Diab A, Tawbi H, Glitza I, Hwu WJ, Patel S, Woodman S, Amaria R, Davies M, Gershenwald J, Hwu P, Lee J, Zhang J, **Coussens LM**, Cooper Z, Tetzlaff M, Futreal A, Daniel-MacDougall C, Ajami N, Petrosino J, Sharma P, Allison J, Jenq R, Wargo J. (2018) Gut microbiota are associated with differential responses to PD-1 blockade in melanoma patients. *Science*, 359(359): 97-103. [PMID:29097493](#)
  115. de Mingo Pulido A, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, **Coussens LM**, Ruffell B. (2018) TIM-3 regulates CD103<sup>+</sup> dendritic cell function and response to chemotherapy in breast cancer. *Cancer Cell*, 33(1): 60-74. [PMID:29316433](#)
  116. Binnewies M, Roberts E, Kersten K, Chan V, Fearon DF, Merad M, **Coussens LM**, Gabrilovich D, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft K, Woodhouse E, Weinberg R, Krummel M. (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nature Med*. 24(5):541-550. [PMID: 29686425](#)
  117. Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin J, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe S, **Coussens LM**, Wherry EJ, Vonderheide RH, Stanger BZ. (2018) Tumor cell-intrinsic factors underlie immune heterogeneity and therapeutic response. *Immunity*, 49(1): 178-193. [PMID: 29958801](#)  
Featured in:  
• Preview: *Immunity* 49 (1):11-13 (2018). ‘A tumor cell-intrinsic yin-yang determining immune evasion’. By: Brendan Horton and Stefani Spranger
  118. Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson K, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shastri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer J, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, **Coussens LM**, Sheppard BC, Wong MH. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. *Science Adv.*, 4(9):eaat7828. [PMID:30214939](#)
  119. Pennock ND, Martinson HA, Guo Q, Betts CB, Jindal S, Tsujikawa T, **Coussens LM**, Borges VF, Schedin P. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of post-partum breast cancer. *J Immuno Ther Cancer*. 6(1):98. <https://doi.org/10.1186/s40425-018-0406-y>. [PMID:30285905](#)
  120. Medler TR, Murugan D, Horton W, Kumar S, Cotechini T, Forsyth AM, Leyshock P, Leitenberger JJ, Kulesz-Martin M, Margolin A, Werb Z, **Coussens LM**. (2018) Complement C5a fosters squamous

carcinogenesis and limits T cell response to chemotherapy, *Cancer Cell*, 34:561-578. [PMID:30300579](#)  
*Featured in:*

- Preview: *Cancer Cell* 34:531-533 (2018). 'Complement C51-mediated TAM-ing of antitumor immunity drives squamous carcinogenesis'. By: D.C. Mastellos, E.S. Reid, and J.D. Lambris.
  - Research Watch: *Cancer Discovery* DOI: 10.1158/2159-8290.CD-RW2018-181. 'Inhibiting C5a enhances chemotherapeutic efficacy'
  - Research Highlight: *Nature Reviews: Drug Discovery* 17(12):216 (2018). DOI:10.1038/nrd.2018.216 'Complementing tumor macrophage reprogramming' By: M. Teresa Villanueva.
  - Faculty of 1000 – Exceptional. Authoritative evaluation by MB Yaffe (Massachusetts Institute of Technology). [10.3410/f.734170602.793553517](#).
121. Saung MT, Muth S, Ding D, Thomas DL, Blair AB, Tsujikawa T, **Coussens LM**, Jaffee EM, Zheng L. (2018) Targeting myeloid-inflamed tumor with anti-CSF1R antibody expands CD137<sup>+</sup> effector T-cells in the murine model of pancreatic cancer. *J Immunother Cancer* 6(1): 118. doi: 10.1186/s40425-018-0435-6. [PMID:30424804](#)
  122. Keklikoglou I, Cianciaruso C, Guc E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassara A, Guichard A, Iruela-Arispe ML, Lewis CE, **Coussens LM**, Bardia A, Jain R, Pollard JW, De Palma M. (2018) Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. *Nature Cell Biology*, 21(2): 190-202. [PMID:30598531](#)
  123. Casetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong D, Cotechini T, Anur P, Lin E, Fidanza A, Yrigoyen ML, Millar MR, Urman A, Ai Z, Spellman P, Hwang ES, Dixon JM, Wiechmann L, **Coussens LM**, Smith HW, Pollard JW. (2019) Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers and therapeutic targets. *Cancer Cell*, 35(4): 588-602. [PMID: 30930117](#)  
*Featured in:*
    - Preview: *Cancer Cell* 35:538-539 (2019). 'Deciphering macrophage and monocyte code to stratify human breast cancer patients'. By: Vincenzo Bronte
    - Highlights from the Literature: *Cancer Immuno Res* June 2019. 'Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets'
    - Featured as journal cover image
    - Reprinted as 'Cancer Cell Best of 2019', Reprint compendium of 'Most Widely Read Papers of 2019'
  124. Tsujikawa T, Thibault G, Azimi V, Sivagnanam, Banik G, Means C, Kawashima R, Clayburgh DR, Gray JW, **Coussens LM**, Chang YH. (2019) Robust cell detection and segmentation for image cytometry reveal Th17 cell heterogeneity. *Cytometry*. 95(4): 389-398. [PMID:30714674](#)
  125. Means C, Clayburgh DR, Maloney L, Sauer D, Taylor M, Shindo M, **Coussens LM**, Tsujikawa T. (2019) Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. *Head & Neck*, 1-11. doi.org/10.1002/hed.25740. [PMID: 30896061](#)
  126. Reddy S, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens C, Tetzlaff M, Reuben J, Tsujikawa T, **Coussens LM**, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward W, Ueno N, Krishnamurthy S, Wargo J, Mittendorf E. (2019) Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. *Can Immuno Res*.7(6):1025-1035. [PMID: 31043414](#)
  127. Blair AB, Kim V, Muth S, Saung MT, Lokker N, Blouw B, Armstrong T, Jaffee E, Tsujikawa T, **Coussens LM**, He J, Burkhart R, Wolfgang C, Zheng L. (2019) Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer. *Clin Can Res*. 25(17):5351-5363. [PMID: 31186314](#)  
*Featured in:*
    - Journal cover image
    - News and Views: *Nature Reviews Clinical Oncology* 16:726-728 (2019). 'Immunotherapy trials in
  128. Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstron A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, **Coussens LM**, Brockstedt DG. (2019) Live-attenuated, *Listeria monocytogenes* expressing mesothelin (CRS-207) with chemotherapy for treatment of malignant pleural mesothelioma. *Clin Can Res*., 25 (19):5787-5798. [PMID: 31263030](#)  
*Featured in:*
    - Journal cover image
    - News and Views: *Nature Reviews Clinical Oncology* 16:726-728 (2019). 'Immunotherapy trials in

- mesothelioma – promising results, but don't stop here'. By: AK Nowak, PM Forde.
129. Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Rugo HS. (2019) Phase 1B study of the combination of pexidartinib (PLX3397), a colony stimulating factor receptor 1 (CSF-1R) inhibitor, and paclitaxel in patients with advanced solid tumors. *Ther Adv Med Onc.* 11:1758835919854238. PMID: 31258629
  130. Vitale I, Manic G, **Coussens LM**, Kroemer G, Galluzzi L. (2019) Macrophages and metabolism in the tumor microenvironment. *Cell Metabolism*, 30(1):36-50. PMID: 31269428
  131. Hundeyin M, Kurz E, Mishra A, Rossi JAK, Liudahl SM, Leis K, Mehrotra H, Kim M, Torres LE, Ogunsankin A, Link J, Sears RC, Sivagnanam S, Goecks J, Islam KMS, Dolgalev I, Savadkar S, Wang W, Aykut B, Leinwand J, Diskin B, Adam S, Israr M, Gelas M, Lish J, Farooq MS, Wadowski B, Wu J, Shah S, Adeegbe D, Pushalkar S, Vasudevaraja V, Saxena D, Wong KK, **Coussens LM**, Miller G. (2019) Innate  $\alpha\beta$ T cells mediate anti-tumor immunity by orchestrating immunogenic macrophage programming. *Can Disc.* 9(9):1288-1305. PMID: 31266770  
*Featured in:*
    - Spotlight: *Cancer Discovery* 9(9):1164-1166 (2019). 'Unconventional T cells in the pancreatic tumor microenvironment: Thinking outside the box'. By: S Banerjee, V Dudeja, A Saluja
  132. Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson BG, Pelz KR, Ramos DMA, Maurer HC, Olive KP, **Coussens LM**, Morgan TK, Marks DL. (2019) The TLR7/8 agonist R848 remodels tumor and host immune responses to promote survival in pancreatic cancer. *Nat. Comm.* 10(1):4682. PMID: 31615993
  133. Shirai T, Revenko A, Tibbitts J, Ngo A, Mitrugno A, Healy L, **Coussens LM**, McCarty OJT, Monia B, Gruber A. (2019) Antisense oligonucleotide targeting of thrombopoietin gene expression inhibits spontaneous breast cancer progression in mice. *Blood Advances*, 3(20):3080-3091. PMID: 31648335
  134. Galliverti G, Wullschlegel S, Tichet M, Murugan D, Zangger N, Horton W, Korman A, **Coussens LM**, Swartz MA, Hanahan D. (2020) Myeloid cells orchestrate systemic immunosuppression that impairs the efficacy of therapeutic vaccination and masks the effects of immunotherapy against HPV+ cancers. *Can Immuno Res.* 8(1):131-145. PMID: 31771984.
  135. Banik G, Betts CB, Liudahl S, Sivagnanam S, Kawashima R, Cotechini T, Larson W, Pai SI, Clayburgh DR, Goecks J, Tsujikawa T, **Coussens LM**. (2020) High-dimensional multiplexed immunohistochemistry characterization of immune contexture in human cancer. *Methods Enzymol.*, 635:1-20. PMID: 32122539
  136. Tsujikawa T, Crocenzi T, Durham JN, Sugar E, Wu A, Onners B, Nauroth JN, Anders RA, Fertig EJ, Lahreru DA, Reiss KA, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, **Coussens LM**, Jaffee EM, Le DT. (2020) Safety, survival, and immune response with GVAX pancreas prime and *Listeria Monocytogenes*-expressing mesothelin (CRS-207) boost vaccines with and without Nivolumab for metastatic pancreatic. *Clin Can Res.* 26(14):3578-3588. PMID: 32273276.
  137. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH; **Human Tumor Atlas Network** (2020) The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell.* 181(2):236-249. PMID: 32302568
  138. Pennycuik A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca A, Rosenthal R, Kalinke L, Chandrasekharan C, Pipinikas CP, Lee-Six H, Hynds RE, Gowers KHC, Henry JY, Millar FR, Hagos YB, Denais C, Falzon M, Moore D, Antoniou S, Durrenberger, PF, Furness A, Carroll B, Marceaux C, Asselin-Labat ML, Larson W, Betts C, **Coussens LM**, Thakrar RM, George J, Swanton C, Thirwell C, Campbell PJ, Marafioti T, Yuan Y, Quesada SA, McGranahan N, Janes S. (2020) Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer. *Cancer Discovery*, 10(10); 1489-1499. PMID: 32690541
  139. Maller O, Drain AP, Barrett AS, Borquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, **Coussens LM**, Nelson AC, Hansen KC, Weaver VM. (2021) Tumor-associated macrophages drive stromal cell-dependent collagen cross-linking and stiffening to promote breast cancer aggression. *Nature Materials.* 220(4): 548-559. PMID: 33257795



140. Väyrynen SA, Zhang J, Yuan C, Väyrynen JP, Costa AD, Williams H, Morales-Oyarvide V, Lau MC, Robinson DA, Dunne RF, Kozak MM, Wang W, Agostini-Vulaj D, Drage MG, Brais L, Reilly E, Rahma O, Clancy T, Wang J, Linehan DC, Aguirre AJ, Fuchs CS, **Coussens LM**, Chang DT, Koong AC, Hezel AF, Ogino S, Nowak JA, Wolpin BM. (2021). Spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. *Clin Can Res*, 27(4):1069-1081. PMID: 33262135
141. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Farcia-Carbonero R, Lonardi S, **Coussens LM**, Fong L, Tsao LC, Cole G, James D, Marcarulla T. (2021). Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: Phase 3 RESOLVE study. *Ann Oncol*. 32(5):600-608. PMID: 33539945
142. Liudahl SM\*, Betts CB\*, Sivagnanam S\*, Morales-Oyarvide V, da Silva A, Yuan C, Smuel Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Costa AD, Väyrynen SA, Clancy TE, Robinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RS, Park BS, Mori M, Nowak JA\*, Wolpin BM\*, **Coussens LM\***. (2021). Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. *Cancer Discovery*, 11(8):2014-2031. PMID: 33727309  
 \*, equal 1<sup>st</sup> author, and senior author contributions  
 Featured in:
  - 3<sup>rd</sup> OncoAlert, presented by A. Mitra (@CD\_AACR Academic Recap Video, 1 and 2)
  - Highlights from the Literature: *Cancer Immuno Res* October 2021.
143. Gatti G, Betts CB, Rocha D, Nicola M, Grupe V, Ditada C, Nunez NG, Roselli E, Araya P, Dutto J, Boffelli L, Fernandez E, **Coussens LM**, Maccioni M. (2021) High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. *Breast Cancer Res*, 23(1):40. PMID: 33766090 and 33888121 (correction)
144. Link JM, Liudahl SM, Betts CB, Sivagnanam S, Leis KR, McDonnell M, Pelz CR, Johnson B, Hamman KJ, Keith D, Sampson JE, Morgan TK, Lopez CD, **Coussens LM**, Sears RC. (2021) Tumor infiltrating leukocyte phenotypes distinguish outcomes in related patients with pancreatic adenocarcinoma. *JCO Precis Oncol*. 2021 Feb 5;5:PO.20.00287. doi: 10.1200/PO.20.00287. eCollection 2021. PMID: 34036232
145. Thomas PL, Groves SM, Zhang YK, Li J, Gonzalez-Ericsson P, Sivagnanam S, Betts CB, Chen HC, Liu Q, Lowe C, Chen H, Boyd KL, Koppapapu P, Yan Y, **Coussens LM**, Quaranta V, Tyson D, Iams W, Lovly CM. (2021) Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer. *J Thoracic Onc*. 16(7):1211-1223. PMID: 33839362
146. Byrne KT\*, Betts CB\*, Mick R\*, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Costa AD, Kaiser JC, Wherry EJ, Cheever MA, Wolpin BM, Furth EF, Jaffee EM, **Coussens LM**, Vonderheide RH. (2021) Neoadjuvant selicrelumab, an agonist CD40 antibody, changes the tumor microenvironment in patients with resectable pancreatic cancer. *Clin. Can Res*. 27: 4574-4586. PMID: 34112709  
 \*, equal 1<sup>st</sup> author contributions
147. Labrie M, Li A, Creason A, Betts CB, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chan YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, **Coussens LM**, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. (2021) Multi-omics analysis of serial PARP inhibitor-treated metastatic TNBC inform on rational combination therapies. *npj Precision Oncology*, 5(1):92; doi.org/10.1038/s41698-021000232-w. PMID: 34667258
148. Yoshimura K, Tsujikawa T, Mitsuda J, Ogi H, Saburi S, Ohmura G, Arai A, Shibata S, Thibault G, Chang YH, Clayburgh DR, Yasukawa S, Miyagawa-Hayashino A, Konishi E, Itoh K, **Coussens LM**, Hirano S. (2021) Spatial profiles of intratumoral PD-1<sup>+</sup> helper T cells predict prognosis in head and neck squamous cell carcinoma. *Frontiers in Immunology*. 28(12):769534. doi: 10.3389/fimmu.2021.769534. eCollection 2021. PMID: 34777389
149. Schapiro D, Sokolov A, Yapp C, Muhlich JL, Hess J, Lin JR, Chen YA, Nariya MK, Baker GJ, Ruukonen J, Maliga Z, Jacobson CA, Farhi SL, Abbondanza D, McKinley ET, Betts C, Regev A, Coffey RJ, **Coussens LM**, Santagata S, Sorger PK. (2022) MCMICRO: A scalable, modular image-processing pipeline for multiplexed tissue imaging. *Nature Methods*, 19(3): 311-315. PMID: 34824477
150. Taylor MH\*, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel A, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EE, **Coussens LM\***. (2022) Safety and

efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study. *Clin Can Res*, 28(5): 903-914. [PMID: 34862248](#)

\*, equal senior author contributions

*Featured in:*

- Journal cover image

151. Blise KE, Sivagnanam S, Banik GL, **Coussens LM**, Goecks J. (2022) Single-cell spatial proteomics analyses of head and neck squamous cell carcinoma reveal tumor heterogeneity and immune architectures associated with clinical outcome. *npj Precision Oncology*, 6(1):10. [PMID: 35217711](#)
  152. Johnson BE, Creason AL, Stommel JM, Keck JM, Parmar S, Betts CB, Blucher A, Bonafice C, Bucher E, Burlingame E, Camp T, Chin K, Eng J, Estabrook J, Feiler HS, Heskett MB, Hu Z, Kolodzie A, Kong BL, Labrie M, Lee J, Leyshock P, Mitri S, Patterson J, Riesterer JL, Sivagnanam S, Somers J, Sudar D, Thibault G, Weeder BR, Zheng C, Nan X, Thompson RF, Heiser LM, Spellman PT, Thomas G, Demir E, Chang YH, **Coussens LM**, Guimaraes AR, Corless C, Goecks J, Bergan R, Mitri Z, Mills GB, Gray JW. (2022) An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer, *Cell Reports Medicine*, 3(2): 100525. [PMID: 35243422](#)
  153. Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, Sudar D, Xie Y, Muhlich J, Arias-Camison R, Arena S, Taylor AJ, Nikolov M, Tyler M, Lin JR, Burlingame EA, **Human Tumor Atlas Network**, Chang YH, Farki SL, Thorsson V, Venkatamohan N, Drewes JL, Pe'er D, Gutman DA, Hermann MD, Gehlenborg N, Bankhead P, Roland JT, Herrndon JM, Snyder MP, Angelo M, Nolan G, Swedlow JR, Schultz N, Merrick DT, Mazzili SA, Cerami E, Rodig SJ, Santagata S, Sorger PK. (2022) MITI minimum information guidelines for highly multiplexed tissue images. *Nature Methods*, 19(3): 262-267. [PMID: 35277708](#)
  154. Crosby D, Bhatia S, Brindle K, **Coussens LM**, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P, Rebbeck T, Balasubramanian S. (2022) Early detection of cancer. *Science*, 18:375 (6586):eaay9004. [PMID: 35298272](#).
  156. Petroni G, Buque A, **Coussens LM**, Galluzzi L. (2022) Targeting oncogene and non-oncogene addiction to inflame the tumor microenvironment. *Nature Reviews Drug Discovery*, 21(6): 440-462. [PMID: 35292771](#).
  157. Daniel CJ, Pelz C, Wang X, Munks MW, Ko A, Murugan D, Byers SA, Juarez E, Taylor KL, Fan G, **Coussens LM**, Link JM, Sears RC. (2022) T-cell dysfunction upon expression of MYC with altered phosphorylation at threonine 58 and serine 62. *Molecular Cancer Research*, 20(7):1151-1165. [PMID: 35380701](#)
  158. Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin P, Ahn SW, Mills GB, **Coussens LM**, Jonas O, Gray JW. (2022) Systemic identification of synergistic combinations of targeted agents and immunotherapies in breast cancer using intratumor multiplex implantable microdevice assay. *Nature Biotechnology*, 40(12):1823-1833. [PMID: 35788566](#)
  159. Sundaram S, Kim EN, Jones GM, Sivagnanam S, Tripathi M, Miremad A, Di Pietro M, **Coussens LM**, Fitzgerald RC, Chang YH, Zhuang L. (2022) Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with sequential multiplex immunohistochemistry and sparse subspace clustering (SSC) approach. *Frontiers in Immunology - Cancer Immunity and Immunotherapy*, 13:874255. doi: 10.3389/fimmu.2022.874255. eCollection. [PMID: 35663986](#)
  160. Sepe JJ\*, Gardner RT\*, Blake MR, Brooks DM, Staffenson MA, Betts CB, Sivagnanam S, Larson W, Kumar S, Bayles RG, Jin H, Cohen MS, **Coussens LM**, Habecker BA. (2022) Therapeutics that promote sympathetic reinnervation modulate the inflammatory response after myocardial infarction. *JACC: Basic to Translational Science*, 7(9): 915-930. [PMID: 36317132](#)
- \*, equal 1<sup>st</sup> author contributions
161. Abrego J, Sanford-Crane H, Oon Chet, Xiao X, Betts CB, Sun D, Nagarajan S, Bhattacharyya S, Xia Z, **Coussens LM**, Tontonoz P, Sherman MH. (2022) A cancer cell-intrinsic GOT2-PPAR $\gamma$  axis suppresses antitumor immunity. *Cancer Discovery*, 12(10):2414-2433. [PMID: 35894778](#)
  162. Mi H, Sivagnanam S, Betts CB, Liudahl SM, Jaffee EM, **Coussens LM**, Popel AS. (2022) Quantitative spatial profiling of immune populations reveals prognostic significance in patients with pancreatic ductal adenocarcinoma. *Cancer Research*, 82(23):4359-4372. [PMID: 36112643](#). [Author correction: PMID: 39492679](#)

*Featured in:*

- Journal cover image

163. Kitko CL, Aroro M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, **Coussens LM**, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. (2022) Axatilimab for chronic graft-versus-host disease after failure of at least 2 prior systemic therapies: results of a phase 1/2 study. *J Clin Oncol*. 41(10):1864-1875. doi: 10.1200/JCO.22.00958. PMID: 36459673
164. Sinha M\*, Betts C\*, Zhang L, Chen B, Griffith MJ, Solman I, Liu E, Tamaki W, Stultz J, Cheung A, Sivagnanam S, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Vo J, Dragomanovich H, Sudduth-Klinger J, Vaccaro G, Lopez CD, Tempero M, **Coussens LM\***, Fong L\*. (2023) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in metastatic pancreatic ductal carcinoma patients. *J Immunother Cancer*, 11(1):e005425. doi: 10.1136/jitc-2022-005425. PMID: 36593070  
\*, equal contributions by co-first and co-senior authors
165. Brockman AA, Khurana R, Bartkowiak T, Thomas PL, Sivagnanam S, Betts CB, **Coussens LM**, Lovly CM, Irish JM, Ihrle RA. (2023) Alignment, segmentation, and neighborhood analysis of cyclic immunohistochemistry data using CASSATT. *Cytometry Part B: Clinical Cytometry*, 104(5):335-406. doi: 10.1002/cyto.b.22114. PMID: 36748312  
Featured in:
  - Journal cover image
166. Steele MM, Jaiswal A, Delclaux I, Dryg ID, Murugan D, Femel J, Son S, du Bois H, Hill C, Leachman SA, Chang YH, **Coussens LM**, Anandasabapathy N, Lund AW. (2023) T cell egress via lymphatic vessels limits the intratumoral T cell repertoire in melanoma. *Nature Immunology*, 24(4): 664-675 PMID: 36849745; PMID: 36932125 (author correction)
167. Gurun B, Horton W, Murugan D, Zhu B, Leyshock P, Qu P, Kumar S, Byrne KT, Vonderheide RH, Margolin AA, Mori M, Spellman PT, **Coussens LM**, Speed TP. (2023) An open protocol for modeling T cell clonotype repertoires in TCR $\beta$  CDR3 sequences. *BMC Genomics*. 24(1):349. doi: 10.1186/s12864-023-09424-z. PMID: 373665517
168. Kim EN, Chen PZ, Bressan D, Tripathi M, Miremadi A, di Pietro M, **Coussens LM**, Hannon GJ, Fitzgerald RC, Zhuang L, Chang YH. (2023) Dual-modality imaging of immunofluorescence and imaging mass cytometry for whole slide imaging with accurate single-cell segmentation. *Cell Rep Methods* 3: 100595. doi: 10.1016/j.crmeth.2023.100595. PMID: 37741277
169. Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, Kim EN, Pelz C, Munks M, Betts C, Kwon S, Bucher E, Li X, Waugh T, Tatarova Z, Blumberg D, Ko A, Kirchenberger N, Pietenpol JA, Sanders ME, Langer E, Dai M, Mills G, Chin K, Chang YH, **Coussens LM**, Gray JW, Heiser LM, Sears RC. (2023) MYC deregulation and PTEN loss model tumor and stromal heterogeneity of aggressive triple-negative breast cancer. *Nature Commun*. 14(1): 5665. doi 10.1038/s4146023-408416. PMID: 37704631  
• bioRxiv. 2023 Mar 25:2023.03.23.533712. doi: 10.1101/2023.03.23.533712. PMID: 36993424
170. Ren T, Chen C, Danilov AV, Guan X, Du S, Wu X, Sherman MH, Spellman PT, **Coussens LM**, Adey AC, Mills GB, Wu LY, Xia Z. (2023) Supervised learning of high confidence phenotypic subpopulations from single cell data. *Nat Mach Intell*. 5, 528–541. <https://doi.org/10.1038/s42256-023-00656-y>
171. Blise KE, Sivagnanam S, Betts CB, Betre K, Kirchberger N, Tate B, Furth EE, Dias Costa A, Nowak JA, Wolpin BM, Vonderheide RH, Goecks J\*, **Coussens LM\***, Byrne KT\*. (2024) Machine learning links T cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer. *Can Immuno Res.*, 12(5): 544-558. PMID: 38381401
  - bioRxiv 2023 doi: <https://doi.org/10.1101/2023.10.20.563335>; PMID: 37961410
  - \* equal contributions by senior authors
  - Journal cover image
  - 2025 Outstanding journal article award authored or co-authored by an OHSU School of Medicine graduate student
172. Phillips E, Alharithi Y, Kadam L, **Coussens LM**, Kumar S, Maloyan A (2024) Metabolic abnormalities in the bone marrow cells of young offspring born to obese mothers. *Int J Obesity*, 48(11): 1542-1551. doi: 10.1038/s41366-024-01563-x. PMID:38937647
  - bioRxiv [Preprint]. 2023 Dec 1:2023.11.29.569274. doi: 10.1101/2023.11.29.569274. PMID: 38077037
173. Shepard RM, Ghebremedhin A, Pratumchai I, Robinson S, Betts C, Dayao DA, Hu J, Sasik R, Fisch KM, Zak J, Chen H, Paradise M, Rivera J, Amjad M, Uchiyama S, Seo H, Campos AD, Dayao DA,



- Tzipori S, Piedra-Mora C, Das S, Hasteh F, Russo H, Sun X, Xu L, Alexander LC, Duran JM, Odish M, Pretorius V, Kirchenberger NC, Chin SM, Von Schalsha T, Cheresch D, Morrey JD, Alargova R, O'Connell B, Martinot TA, Patel SP, Nizet V, Martinot AJ, **Coussens LM**, Teijaro JR, Varner JA. (2024) PI3K $\gamma$  inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections. *Sci. Trans. Med.* 16(754):eadi6887. doi: 10.1126/scitranslmed.adi6887. Epub 2024 Jul 3. PMID: 38959328
174. Kumar S\*, Tailor D\*, Dheeraj A, Li W, Stefan K, Lee JM, Nelson D, Keefe BF, Schedin P, Kummar S, **Coussens LM\***, Malhotra SV\*. (2024) High throughput approach to identify therapeutic targets abating macrophage-mediated T cell suppression and sensitization to PD-L1 therapy. *Cell Reports Medicine*, 5(9):101698. doi: 10.1016/j.xcrm.2024.101698. PMID: 39181134; correction PMID: 39492679
    - \* equal contributions by first authors and senior authors
  175. Mi H, Sivagnanam S, Ho WJ, Zhang S, Bergman D, Deshpande A, Baras AS, Jaffee EM, **Coussens LM**, Fertig EJ, Popel AS. (2024) Computational methods and biomarker discovery strategies for spatial proteomics: a review in immune-oncology. *Brief Bioinform* 25(5):bbae421. PMID 39179248
  176. Barette M, Danilova L, Durham JN, Betts CB, Cope L, Sidiropoulos DN, Tandurella JA, Charmsaz S, Gross N, Hernandez A, Ho WJ, Thoburn C, Walker R, Leatherman J, Mitchell S, Christmas B, Saeed A, Gaykalova DA, Yegnasubramanian S, Fertig EJ, **Coussens LM**, Yarchoan M, Jaffee E, Azad NS. (2024) Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. *Nature Comm.*, 15(1): 9801. PMID: 39532835.
  177. Link JM, Pelz C, Worth PJ, Owen S, Keith D, Eng J, Sivagnanam S, Langer EM, Grossblatt-Wait A, Creason AL, Egger J, Holly H, Chin K, Kirchenberger N, Betre K, Bucher E, Kilburn D, Hi Z, English E, MacPherson K, Tsuda M, Goecks J, Demir E, Kardosh A, Lopez CD, Sheppard BC, Guimaraes A, Brinkerhoff B, Morgan TK, Mills G, **Coussens LM**, Brody JR, Sears RC. (2025) Ongoing replication stress response and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. *Nature Cancer*, 6(1):123-144. doi: 10.1038/s43018-024-00881-3. PMID: 39789181
  178. Ehlers FAI, Blise KE, Betts CB, Sivagnanam S, Kooreman LFS, Hwang ES, Bos GMJ, Wieten L, **Coussens LM**. (2025) NK cells occupy unique spatial neighborhoods in HER2<sup>-</sup> and HER2<sup>+</sup> breast cancers. *Breast Can Res.* 27(1):14 doi: 10.1186/s13058-025-01964-4. PMID: 39856748
  179. Yang X, Zhao F, Ren T, Chen C, Byrne KT, Heiser LM, Danilov AV, Sears RC, Nelson PS, **Coussens LM**, Mills GB, Xia Z. (2025) OmicsTweezer: A distribution-independent cell deconvolution model for multi-omics data. *Cell Genomics*. 5(9):100950. doi: 10.1016/j.xgen.2025.100950. PMID:40675159
  180. Johnson JAI, Bergman DR, Stein-O'Brien, Rocha HL, Zhou D, Cramer E, Dance Y, Booth M, Nicholas Z, Lopez-Visal T, Deshpande A, Heiland R, Kurtoglu F, Bucher E, Shokaeian F, Dunworth M, Forjaz A, Getz M, Godet I, Kurtoglu F, Lyman M, Metzcar J, Mitchell J, Raddatz A, Solorzano J, Sundus A, Wang Y, DeNardo D, Ewald E, Gilkes D, Kogohara LT, Kieman AL, Thompson ED, Wirtx D, Wood LD, Zheng L, , Jaffee EM, Gray JW, **Coussens LM**, Chang YH, Heiser LM, Stein O'Brian GL, Fertig EJ, Macklin P. (2025) Digitize your biology! Modeling multicellular systems through interpretable cell behavior. *CELL*, 188(17):4711-4733.e37. doi: 10.1016/j.cell.2025.06.048. PMID:40713951
    - bioRxiv doi: 10.1101/2023.09.17.557982; PMID: 37745323
  181. Berens EB, Khou S, Huang E, Hoffman A, Johnson B, Kirchberger N, Sivagnanam S, Calistri NI, Derrick D, Liby TA, McLean IC, Alanizi AA, Ozmen F, Ozmen TY, Mills GB, Hwang ES, Schedin PJ, Gonzalez H, Werb Z, Heiser LM, **Coussens LM**. (2026) Neoplastic immune mimicry potentiates breast tumor progression. *Cancer Research*, 86(3):587-603. PMID: 41129726
    - bioRxiv [Preprint]. 2025 Apr 13:2025.02.07.632847. doi: 10.1101/2025.02.07.632847. PMID: 40291674
  182. Wright AP, Lindaman M, Huang E, **Coussens LM**, Poissonnier A. (2026) A high parameter spectral cytometry workflow for immune subset characterization and functional assessment of cryopreserved human blood with 49-biomarkers. *STAR Protocols*, Jan 31;7(1):104333. doi: 10.1016/j.xpro.2025.104333. Online ahead of print. PMID: 41621072
  183. Wei S\*, Lee J\*, Deng Y\*, Lan H\*, Yang Z\*, Labrie M\*, Betts CB\*, Duan H, Tate B, Pucilowska J, Frederick D, Lawless A, Sharova T, Yang Y, Hu W, Beasley GM, Schuchter LM, Wang X, Xu W, Yong G, Vandenberg MEG, Torigian DA, Sivagnanam S, Du K, Sugarman E, McGettigan S, Zheng C, Al-Rohil N, Selim MA, Kuang D, Sugarman E, McGettigan, Zheng C, Al-Rohil R, Selim MA, Datto MB, Datto MB, Lopez GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O'Rourke DM, Brem S, Lopez GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O'Rourke DM, Brem S, O'Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Mou

Y, Flaherty KT, **Coussens LM**, Boland G, Herlyn M, Mills G, Liu L, Zhang G. A longitudinal, multi-omic atlas reveals the emergence of spatially organized immunosuppressive ecosystem in resistant melanoma. *Cell Reports Medicine*, in press.

### Online Protocols:

1. Shamilene Sivagnanam, Courtney Betts, **Lisa Coussens** 2023. Multiplex IHC Image Processing V0.2. protocols.io. <https://dx.doi.org/10.17504/protocols.io.n92ldmmzn15b/v2>

### Manuscripts Submitted or In Revision:

- ❖ Creason A, Watson C, Gu G, Persson D, Sargent L, Chen YA, Lin JR, Sivagnanam S, Wunnemann F, Nirmal AJ, Chin K, Feiler HS, Holly H, **Coussens LM**, Schapiro D, Gruning B, Sorger PK, Sokolov A, Goecks J. A web-based software resource for interactive analysis of multiplex tissue imaging datasets. *Revision submitted*.  
➤ bioRxiv doi: <https://doi.org/10.1101/2023.09.27.557464>
- ❖ Maltez VI, Arora C, Sor R, Lian Q, Blise KE, Sivagnanam S, **Coussens LM**, Vonderheide RH, Germain RN, Byrne KT. Agonistic anti-CD40 converts Tregs into highly activated type 1 effectors within the tumor microenvironment. *Submitted*.
- ❖ Mitri ZI, Creason AL, Stommel JM, Bottomly D, Ozman TY, Rames MJ, Ozman F, Lim JY, Sivagnanam S, Betre K, Lee J, Labrie M, SMMART Clinical Trials Program, **Coussens LM**, Corless CL, McWeeney SK, Mills GB. Adaptive responses to PARP inhibition predict response to Olaparib and durvalumab: multi-omic analysis of serial biopsies in the AMTEC trial. *Submitted*.
- ❖ Ruiz RK, Khou S, Cornelison J, Kowalewski K, Lazzara M, Poissonnier A, Bullock T, **Coussens LM**, Kelly KA. Plectin as a novel immunomodulator in pancreas cancer. *Submitted*.
- ❖ Guo Y, Finan JM, Bartlett AQ, Sivagnanam S, Blise KE, Kirchberger N, Betre K, Hawthorne K, Chen C, Grossberg A, Xia Z, **Coussens LM**, Sears RC, Brody JR, Eil R. mRNA stability factor HuR promotes immune evasion in pancreatic ductal adenocarcinoma. *Submitted*.  
➤ bioRxiv 2025 doi: <https://doi.org/10.1101/2025.02.07.632847>. PMID: 40291674
- ❖ Mitchell J, Stapleton O, Krishnan K, Nagara Sj, Lvovs D, Cherry C, Poissonnier A, Horton W, Adey A, Rao V, Huff A, Zimmerman J, Kagohara LT, Zaidi N, **Coussens LM**, Jaffee EM, Elisseff J, Fertig EJ. Differential cell signaling testing for cell-cell communication inference from single-cell data by dominoSignal. *Submitted*.  
➤ bioRxiv [Preprint]. 2025 May 3:2025.05.02.651747. doi: 10.1101/2025.05.02.651747. PMID: 40654902
- ❖ Ren T, Zhao F, Chen C, Zhou L, Wu LY, Mills GB, **Coussens LM**, Xia Z. scSurvival: single cell survival analysis of clinical cancer cohort data at cellular resolution. *Submitted*
- ❖ English IA\*, Worth PJ\*, MacPherson-Hawthorne KA, Vergara M, Pelz K, Kiemen AL, Shah V, KE, Pelz C, Tsuda M, Heskett MB, Farrell AS, Allen-Petersen BL, Jimenez P, Joly MM, Thoma MC, Eng J, Daniel CJ, Wang X, Cunningham M, Salgado G, JL, Betts C, Sivagnanam S, Morgan TK, Wood LD, **Coussens LM**, Brody J, Langer EM, Sears RC. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model. *Submitted*.  
➤ bioRxiv [Preprint]. 2025 Jul 18:2025.07.14.664767. doi: 10.1101/2025.07.14.664767. PMID:40791545
- ❖ Takahashi H\*, Zak J\*, Mognol G, Sivagnanam S, Kircherberger N, Hu J, Guo T, Shepard RM, Ghebremedhin A, Chilin-Fuentes D, Fisch K, Sasik R, Rosenthal SB, Wang E, Chen H, Harris W, Paradise M, Amjad M, Hubbard C, O'Connell B, Cohen EEW, **Coussens LM**, Varner JA. T cell exclusion from tumors depends on myeloid PI3K $\gamma$ . *Submitted*.
- ❖ Fife V, Bromley CP, Grainger D, Lee I, Roberts M, Chaturvedi A, Zhou C, Morris K, Gassio AF, Atkinson S, Sivagnanam S, Betre K, Millrine D, Kilgour E, McGranahan N, Jamal-Hanjani M, Swanton C, **Coussens LM**, Crosbie PAJ, Dive C, Zelenay S. A cyclooxygenase 2 (COX-2) associated pro-tumorigenic inflammatory signature predicts outcome after surgery in early-stage lung cancer. *Submitted*.
- ❖ Chen C, Gribbin KP, Li X, Ozmen TY, Ozmen F, Sivagnanam S, Kim J, Yang X, Zhang Y, Keith D, Sherman M, Dia MS, **Coussens LM**, Lopez CD, Sears RC, Mills GB, Byrne KT, Xia Z. Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy. *Submitted*



- bioRxiv [Preprint]. 2025 Oct 22:2025.10.21.683745. doi: 10.1101/2025.10.21.683745. [PMID: 41278823](#)
- ❖ Poissonnier A\*, Rugo HS\*, Horton W, Kim T, DeLuca A, Egeland E, Cotechini T, Sivagnanam S, Mori M, Yi Y, Park B, Beelen N, Murugan D, Kirchberger N, Samson S, Kummar S, Mayer IA, Blackwell K, Hwang ES, **Coussens LM**. CSF1R inhibition plus chemotherapy relieves systemic immune suppression in metastatic triple negative breast cancer and enhances anti-PD-1 response by eliciting resident memory T cells in transgenic mammary tumors. *Submitted*.
  - ❖ Moschos SJ, Mooradian MJ, Johnson ML, Opyrchal M, Janne PA, Romero O, Brouwer S, Sankoh S, Ordentlich P, Meyers ML, Betts CB, Sivagnanam S, Kircherberger N, Poissonnier A, **Coussens LM**, Agarwala SS, Sullivan RJ. Entinostat added to pembrolizumab induces durable response in patients with metastatic melanoma previously treated with anti-PD-(L)1 therapy; A single-arm phase II study. *Submitted*
  - ❖ Wu L, Nguyen MA, Yang Z, Potluri S, Sivagnanam S, Kirchberger N, Joshi A, Ahn KJ, Tumulty JS, Cabrera EC, Romberg N, Tan K, **Coussens LM**, Camara PG. ImmunoPheno: A computational framework for data-driven design and analysis of immunophenotyping experiments. *Submitted*
  - ❖ Tsuda M, Keith D, Daniel CJ, Pelz C, Blise KE, Ozmen TY, Ozmen F, Hawthorne K, Eng JR, Li X, Wang X, Zimny H, Sivagnanam S, Betre K, Kirchberger N, Chong B, Lee J, Matter A, Smith A, Agritelley ES, Waugh T, Sannecy A, Alarcon K, Youm I, Protzek S, Egger J, English IA, Yang M, Shah VM, Link JM, Creason AL, Worth PJ, Goodyear SM, Chin K, Muschler JL, Suciuc CG, Corless CL, Cao S, Soucek L, Kardosh A, **Coussens LM**, Brody JR, Lopez CD, Mills GB, Sears RC. A window trial in metastatic pancreatic adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway. bioRxiv [Preprint]. 2025 Dec 15:2025.12.12.693851. doi: 10.64898/2025.12.12.693851. [PMID: 41446172](#)

### Manuscript previews, Editorials, Commentaries, Symposium Reviews

1. **Coussens LM**, Werb Z. (2001) Inflammatory cells and cancer: Think Different! *J. Exp. Med.* 193:F23-F26. [PMID: 11257144](#)
2. Rhee JS, **Coussens LM**. (2002) RECKing MMP functions: Implications for cancer development. *Trends in Cell Biology*, 12: 209-211. [PMID: 12062160](#)
3. van Kempen LCL, **Coussens LM**. (2002) MMP9 potentiates pulmonary metastasis formation. *Cancer Cell*, 2: 251-252. [PMID: 12398887](#)
4. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian L, Sloane BF, Noel A, Hendrix MJ, **Coussens LM**, Padarathsingh M. (2004) Proteases, Extracellular Matrix and Cancer: A workshop of the PathB study section. *Am J Pathol*, 164:1131-1139. [PMID: 15075248](#)
5. Balkwill F, **Coussens LM**. (2004) Inflammation and cancer – the missing link? *Nature* 431:405-406. [PMID: 15385993](#)
6. De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, **Coussens LM**, Cohen MB. (2006) Tumor Progression and Metastasis from Genetic to Microenvironmental Determinants: A Workshop of the Tumor Progression and Metastasis NIH Study Section in Honor of Dr. Martin L. Padarathsingh, May 31, 2006, *Cancer Biol Ther.* 5:1588-1599. [PMID: 17224636](#)
7. **Coussens LM**. Inflammation, Proteolysis and Cancer Development. *In: Cancer Microenvironments. Extended Abstracts for the 37<sup>th</sup> International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 2006.* (H Esumi, HL Moses, S Hirohashi, K Miyazono, ED). Princess Takamatsu Research Fund. Tokyo Japan, pp. 33-35.
8. Affara NI, **Coussens LM**. (2007) IKK $\alpha$  at the crossroads of inflammation and metastasis. *Cell*, 129: 25-26. [PMID: 17418780](#)
9. **Coussens LM**, Jacks T. (2008) Genetic and cellular mechanisms of oncogenesis. Editorial Overview. *Curr Opin Genet Dev*, 18:1-2. [PMID: 18440220](#)
10. DeNardo DG, Johansson M, **Coussens LM**. (2008) Inflaming gastrointestinal oncogenic programming. *Cancer Cell*, 14: 7-9. [PMID: 18598939](#)
11. Demaria S, Pikarsky E, Karin M, **Coussens LM**, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. (2010) Cancer and inflammation: promise for biologic therapy. *J Immunother.* 33(4):335-351. [PMID: 20386472](#)
12. Ruffell B, **Coussens LM** (2011) Histamine restricts cancer: Nothing to sneeze at. *Nat Med* 17, 43-44. [PMID:21217680](#)

13. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, **Coussens LM**, DeClerck YA. (2012) Conference Report: Tumor microenvironment complexity: Emerging roles in cancer therapy. *Cancer Research*, 72(10):2473-2480. [PMCID: PMC3653596](#)
14. Ruffell B, **Coussens LM** (2013) Some DCs are "B"etter. *Immunity* 38(4): 626-628. [PMID: 23601679](#)
15. Chan CJ, **Coussens LM** (2013) Poker face no more: cancer recurrence reveals its hand. *Nature Medicine*, 19(12):1569-1570. [PMID: 24309652](#)
16. Anand S, **Coussens LM** (2014) Manipulating micro RNAs to reverse macrophage polarization in glioma. *J Natl Can Inst.*, 106 (8): dju230. doi: 10.1093/jnci/dju230. [PMID: 25136034](#)
17. Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, **Coussens LM**, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis L, Vaccaro GM, Wong MH, Mayo SC. (2017) Colorectal cancer liver metastasis: Evolving paradigms and future directions. *Cell Mol Gastroenterol Hepatol*, 3(2):163-173. [PMID:28175683](#)
18. Zloza A, Palucka KA, **Coussens LM**, Gotwals PL, Headley M, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW. (2017) Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 Annual Meeting for the Society for Immunotherapy of Cancer. *J Immunotherapy Cancer*, 5(1), 77. [PMID:28923102](#)
19. Liudahl SM, **Coussens LM** (2018) B cells as biomarkers: predicting immune checkpoint therapy adverse events. *J Clin Invest*. 128(2):577-579. [PMID: 29309049](#)
20. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, **Coussens LM**, De Carvalho D, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz L, Simon R, Þórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nistico P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Charen AS, Sweis RF, Valpione S, Butterfield LH, Disis ML, Fox BA, Thurin M, Cesano A, Marincola FM, and on behalf of the Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. (2019) A comprehensive view on cancer immune responsiveness: A synopsis from the SITC workshop. *J Immunotherapy Ca*. 7(1):131-154. [PMID: 31113486](#)
21. Datta M, **Coussens LM**, Nishikawa H, Hodi FS, Jain RK. (2019) Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. *Am Soc Clin Oncol Educ Book*. 39:165-174. [PMID: 31099649](#)
22. Egeblad M, **Coussens LM**, Weaver V. (2020) Zena Werb 1945 – 2020. *Nature Cancer*, 1: 753-754.
23. Pucci F, **Coussens LM**. (2021) Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs. *Cancer Cell*, 39(10):1300-1302. [PMID: 34637745](#)
24. AACR Cancer Progress Report 2022 Steering Committee (2022) Cancer in 2022. *Cancer Discovery*, 12(12): 2733-2738. DOI: 10.1158/2159-8290.CD-22-1134. [PMID: 36458429](#).
25. Anczukow O, Airhart S, Chuang JH, **Coussens LM**, Kuchel GA, Korstanje R, Li S, Lucido AL, McAllister SS, Politi K, Polyak K, Ratliff T, Ren G, Trowbridge JJ, Ucar D, Palucka K. (2023) Challenges and opportunities for modelling aging and cancer. *Cancer Cell*, 41(4) 641-645. [PMID: 37001528](#)
26. **Coussens LM**, De Palma M, SA Mariani, Cassetta L, Jeff Pollard (1950-2023). (2023) *Nat Rev Cancer*, 23(8): 507. doi: 10.1038/s41568-023-00600-7. [PMID: 37353680](#)

### Book Chapters

1. Breakefield XO, Orloff G, Castiglione CM, Axelrod FB, **Coussens LM**, Ullrich A. (1983) Genetic linkage analysis in familial dysautonomia using a DNA probe for Beta-nerve growth factor. In: *Biochemical and Clinical Aspects of Neuropeptides: Synthesis Processing and Gene Structure* (Koch, G., Richter, D., Eds.) Academic Press, San Francisco, pp. 113-128.
2. Breakfield XO, Castiglione CM, **Coussens LM**, Axelrod FB, Ullrich A. (1983) Linkage Analysis in Familial Dysautonomia Using Variations in DNA Sequence in the  $\beta$ -Nerve Growth Factor Gene Region: A Beginning. In: *Cellular and Molecular Biology of Neuronal Development*, pp.309-328. DOI: 10.1007/978-1-4613-2717-2\_20
3. Breakefield XO, Castiglione CM, **Coussens LM**, Axelrod FB, Ullrich A. (1984) Linkage analysis in familial dysautonomia using polymorphisms in DNA sequence: A beginning. In: *Cellular and Molecular Biology of Neuronal Development* (Black, I.B., Ed.) Plenum Press, New York, pp. 309-328.
4. Ullrich A, **Coussens LM**, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA,

- Schlessinger J, Downward J, Whittle N, Waterfield MD, Seeburg PH (1985) Structure of human epidermal growth factor receptor and expression of normal and variant mRNAs in epidermoid carcinoma cells. In: *Cancer Cells 3: Growth Factors and Transformation*, Cold Spring Harbor Laboratory, New York, pp. 1-9.
5. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, **Coussens LM**, Liao Y-C, Tsubokawa M, Grunfield C, Rosen OM, Ramachandran J. (1986) Structure of the human insulin receptor precursor. In: *Mechanisms of Insulin Action* (Belfrage, P., Donner, J., and Stralfors, P., Eds) Elsevier Science Publishers (Biomedical Division), New York, pp. 1-11.
  6. Riedel H, Yarden Y, **Coussens LM**, Lee J, Dull TJ, Gray A, Schlessinger J, Ullrich A. (1986) Structural and functional analysis of cell surface receptors with tyrosine kinase activity. In: *Cell Cycle and Oncogenes* (Tanner, W., and Gallwitz, D., Eds.) Springer Verlag, Heidelberg, pp. 157-171.
  7. Werb Z, Vu TH, Rinkenberger JL, **Coussens LM**. (1999) Matrix-degrading proteases and angiogenesis during development and tumor formation. In: *Proteases and Protease Inhibitors in Cancer*. (L. Matrisian, N. Brunner, and K. Dano, Eds). APMIS 107:11-18. [PMID: 10190275](#)
  8. Sternlicht MD, **Coussens LM**, Vu T, Werb Z. (2000) Biology and regulation of the matrix metalloproteinases. In: *Matrix Metalloproteinase Inhibitors in Cancer Therapy*. (NJ Clendeninn and K Apperlt, Eds). Humana Press, Totowa NJ, USA, pp. 1-38.
  9. **Coussens LM**, Shapiro SD, Soloway PD, Werb Z. (2001) Models for gain-of-function and loss-of-function of MMPs: Transgenic and gene targeted mice. In: *Methods in Molecular Biology: Matrix Metalloproteinases*. (I. Clark, Ed.). Humana Press, Totowa, NJ, USA. pp. 149-179. [PMID: 11217297](#)
  10. de Visser KE, **Coussens LM**. (2004) Inflammation and matrix metalloproteinases: Implications for cancer development. In: *Cancer and Inflammation*. (Morgan D, Forssman U, and Nakada M, Eds) Birkhauser Publishing, Basel, Switzerland. pp. 71-97.
  11. Diaz RJ, Eichten AE, de Visser KE, **Coussens LM**. (2005) Matrix metalloproteinases: Mediators of Tumor-Host Cell Interactions. In: *Cancer Growth and Progression*, Vol. 15. 2<sup>nd</sup> Edition (Hans E. Kaiser, Series Ed), *Integration/Interaction of Oncologic Growth*, (Gary Meadows, Ed), Springer, The Netherlands. pp. 81-126.
  12. Eichten A, Shen HCJ, **Coussens LM**. (2005) Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. In: *Current Protocols in Cytometry*, Unit 12.5, John Wiley & Sons, Inc., Canada. pp 12.5.1-12.5.11. [PMID: 18770816](#)
  13. de Visser KE, **Coussens LM**. (2006) The inflammatory tumor microenvironment and its impact on cancer development. In: *Infection and Inflammation: Impacts on Oncogenesis* (T Dittmar, KS Zaenker, A Schmidt, Ed) Karger Pub. Basel Switzerland, vol 13, pp 118-137 [PMID: 16627962](#)
  14. Eichten AE, de Visser KE, and **Coussens LM**. (2008) Macrophages in tumor development and metastasis. In: *Cancer Growth and Progression*, 2<sup>nd</sup> Edition (Hans E. Kaiser and Aejaz Nasir, Eds), *Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response*. (Ronald H. Goldfarb, Ed), Springer, The Netherlands. Vol 11, pp115-137.
  15. De Palma M, **Coussens LM**. (2008) Immune cells and inflammatory mediators as regulators of tumor-associated angiogenesis. In: *Angiogenesis: an Integrative Approach from Science to Medicine* (W.D. Figg, J Folkman, Eds.) Springer Science, New York, NY USA, pp 225-238.
  16. Affara NI, **Coussens LM**. (2008) Proteolytic pathways: Intersecting cascades in cancer development. In: *The Cancer Degradome-Proteases and Cancer Biology*, 1<sup>st</sup> Edition (Dylan Edwards, Gunilla Hoyer-Hansen, Francesco Blasi, Bonnie F. Sloane, Eds), Springer Science and Business Media, pp 157-182.
  17. Affara NI, Andreu P, **Coussens LM**. (2009) Delineating protease function during cancer development. In: *Methods in Molecular Biology, Proteases and Cancer*. (Thomas Bugge and Toni Antalis, Eds.) Humana Press, 539:1-32. [PMID: 19377975](#)
  18. de Visser KE, **Coussens LM**. (2011) Utilizing mouse models of human cancer for assessing immune modulation of cancer development. In: *Mouse Models for Cancer Research*. (Jeffrey Green and Thomas Ried, Eds.). Springer Science, Chapter 21, 443-463.
  19. Kumar S, **Coussens LM**. (2014) Cancer Microenvironments as Therapeutic Targets. In: *Pathobiology of Human Disease*. (Linda M. McManus, Richard N. Mitchell, Eds) Elsevier, San Diego USA; 2014. pp. 412-422.
  20. Kumar S, Chan CJ, **Coussens LM**. (2016) Inflammation and Cancer. In: *Inflammation and Cancer*. In: *Encyclopedia of Immunobiology*, Vol. 4, pp.406–415. (Ratcliffe, M.J.H. Editor in Chief), Oxford: Academic Press.
  21. Liudahl SM, **Coussens LM** (2018) To help or to harm: Dynamic roles of CD4<sup>+</sup> T helper cells in solid tumor



- microenvironments. In: Immunology – Immunotoxicology, Immunopathology, and Immunotherapy. Vol 1. (M.A. Hayat, Eds). Elsevier/Academic, United Kingdom; 2018. Chapter 8. pp 98-117.
22. Gray E, Liudahl S, Sivagnanam S, Betts C, Link J, Keith D, Sheppard B, Sears R, Thibault G, Gray JW, **Coussens LM**, Chang YH. (2020) Activation vs. Organization: Prognostic Implications of T and B Cell Features of the PDAC Microenvironment. In: Bebis G., Alekseyev M., Cho H., Gevertz J, Rodriguez Martinez M. (eds) Mathematical and Computational Oncology. ISMCO 2020. Lecture Notes in Computer Science, vol 12508. Springer, Cham. [https://doi.org/10.1007/978-3-030-64511-3\\_5](https://doi.org/10.1007/978-3-030-64511-3_5)
  23. Kumar S, Poissonnier A, Betts CB, Murugan D, Valen Egeland E, Ehlers F, Woods J, Beleen N, **Coussens LM**. (2021) Tumor-infiltrating myeloid cells in cancer progression and therapy response. In: Cancer Immunotherapy Principles and Practice (Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, Eds), Springer Publishing Company. Second Edition; Chapter 34, pp 444-461.

### Book Editor

1. Advances in Experimental Medicine and Biology: Tumor Microenvironment, Study Protocols. Eds: Constantinos Koumenis, **Lisa M Coussens**, Amato Giacci, Ester Hammond. Springer International Publishing. ISSN 0065-2598 and 2214-8019 (electronic). ISBN 978-3-319-26664-0.

### Published Abstracts

1. Laig-Webster M., **Coussens LM**, Caughey GH. (1998) A general method for genotyping mast cell-deficient KIT<sup>W</sup>/KIT<sup>Wv</sup> mice by allele-specific polymerase chain reaction. *FASEB J*, 12:A895
2. McDonald DM, Thurston G, Murphy TJ, **Coussens L**, Baluk P. (1998) Wild-type FVB/N mice are unusually susceptible to *Mycoplasma pulmonis* respiratory tract infection. *FASEB J* 12(5) 4559 Part 2.
3. Baluk P, **Coussens LM**, Werb Z, Raymond WW, Caughey GH, McDonald DM. (1999) Gelatinase B is not essential for microvascular remodeling in airway inflammation. *Am. J. Resp. Crit. Care Med.* 159:A353
4. van Kempen L, Rhee JS, Reuter J, Krane S, **Coussens LM**. (2001) To digest or not digest: Collagen Type I remodeling during squamous carcinogenesis. *Mol. Biol. Cell.* 12:269a.
5. van Kempen L, Rhee JS, Reuter J, Krane S, **Coussens LM**. (2002) To digest or not digest: Collagen Type I remodeling during squamous carcinogenesis. *Proceedings American Association for Cancer Research*, 43:535.
6. Chantrain C, Shimada H, **Coussens L**, Shalinsky D, Brekken J, De Clerck YA. (2002) Role of matrix metalloproteinase-2 and -9 in neuroblastoma angiogenesis and metastasis. *Proceedings American Association for Cancer Research*, 43:539.
7. Machamer JE, van Kempen LCL, **Coussens LM**. (2002) Endothelial cell migration through collagen is independent of collagenolysis. The International Symposium on Laboratory Automation and Robotics 2002, Boston, MA. Published online: <http://198.199.168.17:8080/islar/proceedings.nsf/>
8. van Kempen LCL, Lee J, Krane S, **Coussens LM**. (2002) Type I collagen remodeling functionally regulates vascular permeability and epithelial carcinogenesis. *Mol. Biol. Cell.* 13: 4a
9. Diaz RJ, van Kempen L, Dehne K, Schmuth M, Krane S, Albertson D, **Coussens LM**. (2004) Type I collagen remodeling regulates keratinocyte malignant potential. *Proceedings American Association for Cancer Research*, 45:792
10. de Visser KE, **Coussens LM**. (2004) The interplay between adaptive and innate immunity promotes cancer development. *Proceedings American Association for Cancer Research*, 45:403.
11. Eichten A, **Coussens LM**. (2004) Microenvironmental regulation of lymphatic metastasis development. *Proceedings American Association for Cancer Research*, 45:335.
12. **Coussens LM**. (2004) ECM architecture regulates tissue homeostasis and disease pathogenesis. *FASEB J*, 18:A21-A21.
13. **Coussens LM**. (2004) Inflammation and cancer. *Toxicologic Pathology*, 32:732.
14. Rugo HS, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Wesolowski R. (2014) Phase Ib study of PLX3397, a CSF1R inhibitor, and paclitaxel in patients with advanced solid tumors. (Clinical trial information: [NCT# NCT01525602](https://clinicaltrials.gov/ct2/show/study/NCT01525602)). Eur Soc Med Onc 2014. Abstract #8457.
15. Sharma N, Wesolowski R, Reebel L, Rodal MB, Peck A, West B, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Rugo HS. (2014) A phase Ib study to assess the safety of PLX3397, a CSF1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. (Clinical trial information: [NCT# NCT01525602](https://clinicaltrials.gov/ct2/show/study/NCT01525602)). Abstr TPS3127. 2014 ASCO Annual Meeting Chicago, IL USA. Clin Oncol 32(15):TPS3127.
16. Shiao SL, DeNardo DG, Faddegon BA, Underhill DM, Park CC, **Coussens LM**. (2015) Abstract A28:

- Impact of macrophage function on the efficacy of radiation therapy. 75 (1 Suppl): Abstract nr A28. doi:10.1158/1538-7445.CHTME14-A28.
17. Hassan R, Antonia SJ, Alley EW, Kindler HL, Jahan T, Grous JJ, Honarmand S, McDougall K, Whiting CC, Nair N, Lemmens E, Tsujikawa T, Kumar S, **Coussens LM**, Murphy AL, Thomas A, Brockstedt DG. (2015) RS-207, a mesothelin-targeted immunotherapy, in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM) (Clinical trial information: NCT# NCT01675765). 18<sup>th</sup> ECCO - 40<sup>th</sup> ESMO European Cancer Congress, 25 Sep - 29 Sep 2015, Vienna, Austria.
  18. Link JM, Allen-Peterson B, Gunderson A, Jorgens D, Dorrell C, Hooper J Streeter P, Grompe M, **Coussens LM**, Gray J, Hardaker H, Lopez CD, Sears RC, Sheppard BC. (2015) Developing a molecular and cellular atlas of pancreatic disease. AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Cancer Res 2015;75(13 Suppl):Abstract nr B118.
  19. Tsujikawa T, Borkar RN, Azimi V, Rassi EE, Clayburgh DR, Kumar S, Gunderson AJ, Kulesz-Martin M, Flint PW, **Coussens LM**. (2015) Multiplex immunohistochemistry for immune profiling of HPV-associated head and neck cancer. J ImmunoTherapy of Cancer. 3(2):p419.
  20. Tempero M, **Coussens LM**, Fong L, Manges R, Singh P, Li Y, Cole G, James DF, Tabernero J. (2016) A randomized, multicenter, double-blind, placebo-controlled study of the Bruton Tyrosine Kinase inhibitor, ibrutinib, vs. placebo in combination with nab-paclitaxel and gemcitabine in the first line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). (Clinical trial information: (NCT# NCT02436668). Abstract TPS483. 2016 Gastrointestinal Cancers Symposium (January 21-23, 2016), San Francisco CA USA. J Clin Oncol 34(4):TPS483
  21. Tempero MA, **Coussens LM**, Fong L, Manges R, Singh P, Li Y, Cole GW, James DF, Tabernero J. (2016) A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton Tyrosine Kinase inhibitor, with nab-paclitaxel and gemcitabine in the first line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). (Clinical trial information: NCT# NCT02436668). Abstract 164533. 2016 ASCO Annual Meeting (June 3-7, 2016) Chicago, IL USA. J Clin Oncol 34(15):TPS2601.
  22. Hassan R, Alley EW, Kindler HL, Antonia SJ, Jahan TM, Honarmand S, McDougall K, Whiting CC, Nair N, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, **Coussens LM**, Murphy AL, Thomas A, Brockstedt DG. (2016) CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM) (Clinical trial information: NCT# NCT01675765). Abstract 170532. 2016 ASCO Annual Meeting (June 3-7, 2016). Chicago, IL USA. J Clin Oncol 34 (15): 8558.
  23. Wesolowska R, Sharma N, West B, **Coussens LM**, Marimuthu A, Pelayo M, Le MH, Hsu H, Karlin DA, Rugo HS. (2016) A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset. (Clinical trial information: NCT# NCT01525602). Poster 293. 47<sup>th</sup> Annual meeting on Women's Cancer, Society of Gynecologic Oncology. Gynecologic Onc 141:121.
  24. Tempero M, Oh D, Macarulla T, Reni M, Van Cutsem E, Hendifar A, Waldschmidt D, Starling N, Bachet J, Chang H, Maurel J, Lonardi S, **Coussens LM**, Fong L, Tsao L, Cole G Jr, James D, Tabernero J. (2019) Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. PMID: 32085015.
  25. Sinha M, Griffith M, Betts C, Choe G, Sivagnanam S, Cheung A, Tamaki W, Liu E, Sudduth-Klinger J, Vaccaro G, Lopez C, Fong L, **Coussens L**, Tempero M. (2019) Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma. Ann Oncol. 2019 Jul;30 Suppl 4:iv40. doi: 10.1093/annonc/mdz155.145. Epub 2019 Dec 4. PMID: 32085149.
  26. Thomas PL, Betts C, Gonzalez G, Coussens LM, Lovly CM. 2020. Defining immune contexture in small cell lung cancer: Implications for immunotherapy. Can Res. DOI: 10.1158/1538-7445.AM2020-3862
  27. Tatarova Z, Blumberg DC, Mills GB, **Coussens LM**, Jonas O, Gray JW (2023) Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer. Cancer Research 83 (7\_Supplement), 4916-4916.
  28. Fife V, Roberts M, Bromley CP, Morgan D, Atkinson S, Zhou C, Chaturvedi A, Bagley S, Ashton G, **Coussens LM**, Crosbie PA, Dive C, Kilgour E, Zelenay S. (2023) A COX2-based pro-tumorigenic inflammatory signature predicts poor outcome in early-stage non-small cell lung cancer. Cancer Research 83 (7\_Supplement), 5572-5572

29. Kumar S, McCane M, Drees J, Bose N, Coussens LM. (2023) Combination therapy using PERK and PD-1/PD-L1 inhibitors reprograms tumor-associated macrophages and reduces tumor burden. *Cancer Research* 83 (7\_Supplement), 3247-3247
30. Wei S, Lee J, Labrie M, Betts C, Liu L, **Coussens LM**, Herlyn M, Boland G, Mills G, Zhang G. (2023) Spatiotemporal analysis of metastatic melanoma reveals mechanisms of resistance to immune checkpoint blockade. *Cancer Research* 83 (7\_Supplement), 2276-2276.
31. Sivagnanam S, Betts CM, Kirchberger N, Betre K, **Coussens LM** (2023). Strategies and resources for applying a quantitative multiplex IHC imaging workflow to characterize immune contexture in solid tumors. *Cancer Research* 83 (7\_Supplement), 4293-4293
32. Poissonnier A, Valen Egeland E, Erbe R, Horton W, Howells-Ferreira A, Sivagnanam S, Kirchberger N, Murugan D, Fields A, Ordentlich P, Adey AC, Fertig EJ, **Coussens LM** (2023). Relieving immune suppressive pathways in breast cancer to improve outcomes. *Cancer Research* 83 (7\_Supplement), 4164-4164.
33. Kumar S, Tailor D, Dheeraj A, Li W, Lee JM, Stefan K, Nelson D, Kummar S, **Coussens LM**, Malhotra SV. (2023) High throughput screening of combination therapies to improve response to checkpoint inhibitors in solid tumors using a myelomonocytic and T cell co-culture assay. . *Cancer Research* 83 (7\_Supplement), 3473-3473.
34. Creason AL, Egger J, Watson C, Sivagnanam S, Lin JR, Chin K, Sorger PK, **Coussens LM**, Mitri ZI, Gray JW, Mills GB, Goecks J. (2023). Longitudinal, multimodal profiling of metastatic ER+ breast cancer on CDK4/6 inhibitor therapy. *Cancer Research* 83 (7\_Supplement), 6618-6618.

## Patents

1. Coussens LM and Werb Z. *Novel Indications for Transforming Growth Factor-Beta Regulators*. U.S. Patent Publication #2008-0206219-A1. International filing date: August 9, 2004. Application Filing Number: 60/493,643; Docket Number: 23540-09361/PCT; International Publication Number WO 2005/013915 A2; International Application Number: PCT/US2004/025902
2. DeNardo D, Brennan D, **Coussens LM**. *Phenotyping Tumor-Infiltrating Leukocytes*. US patent publication No.: US 2014/0100188 A1, April 10, 2014; EP application: 10802804.4, AU application: 2010276324.
3. Tsujikawa T, Kumar S, **Coussens LM**. *Multiplex Immunohistochemistry Image Cytometry*. US Provisional application 62/257,926. November 20, 2015. US Patent Publication Number: 20170160171 (June, 2017)
4. Chang YH, Tsujikawa T, **Coussens LM**, Gray JW, *Automated Image Analysis Tool for Multiplexed Immunohistochemistry/immunofluorescence* (Application number: 62481842)
5. Malhotra S, **Coussens LM**, Tailor D, Kumar S., Dheeraj A. *Combination Therapy for Treatment of Solid Tumors*. 343 U.S. Provisional patent application:344 Provisional filed on 04/10/2023. Provisional Pat. Application. No. 63/495,246.

## VII. RESEARCH AWARDS AND GRANTS:

### CURRENT

<b>No Number</b> (PI: Coussens)	04/01/22 – 03/31/26
<b>Source:</b> National Foundation for Cancer Research	\$400,000 total directs
<b>Title:</b> <i>Multi-omics analysis of immune therapy responses in mammary carcinoma</i> .	
The goal of this project is to develop analytical tools for multi-omic auditing of breast cancer responses to immune therapies	
<b>Role:</b> PI	
<b>No Number</b> (PI: Coussens)	01/01/22 – 12/31/25
<b>Source:</b> Brenden-Colson Center for Pancreatic Health	\$100,000 directs/year
<b>Title:</b> <i>Immune cells in pancreatic disease</i>	
The goal of this project is to identify and define roles for leukocytes in states of pancreatic disease	
<b>Role:</b> PI	
<b>P30 CA069533</b> (PI: Coussens)	07/01/22 – 06/30/27
<b>Source:</b> NIH/NCI	\$23,180,495 total directs/indirects
<b>Title:</b> <i>OHSU Knight Comprehensive Cancer Institute</i>	

Support the administration, programs, Clinical Protocol & Data Management, Protocol Review & Monitoring System, and shared resources of the Knight Cancer Institute at OHSU.

**Role:** Associate Director for Basic Science

**SAC210100** (PI: Coussens) 08/01/21 – 08/01/25

**Source:** Susan G. Komen Breast Cancer Foundation \$600,000 total directs/indirects

**Title:** *Immune-mediated protumoral pathways in breast cancer*

Investigate impact of CSF1R-blockade plus chemotherapy on sensitivity to immune checkpoint therapy by relieving tumor-induced T cell dysfunction and enabling activation of long-term T cell memory to combat ongoing and subsequent tumor growth.

**Role:** PI

**T32 CA254888** (multiPI: Coussens/Zuckerman) 02/01/21 – 06/30/26 (NCE)

**Source:** NIH/NCI \$2,048,233 total directs

**Title:** *Integrated training in quantitative and experimental cancer systems biology*

Training of graduate and postdoctoral fellows in quantitative and experimental systems biology

**Role:** multiPI

## PREVIOUS

**USPHS 5 T32 CA09056** (PI: Fox, F, UCLA) 07/01/89 – 06/30/92

**Source:** NIH/UCLA \$9,300 directs/yr1

**Title:** *Regulation of junB Gene Expression by TGF-Beta* \$25,800 directs/yr 1-3

Competitive Pre-Doctoral award to study transcription factor *junB*.

**Univ. of Calif., Dissertation Year Fellowship** (PI: Coussens, LM, UCLA) 10/1/92 – 09/31/93

**Source:** University of California, Office of the President \$13,350 directs/yr

**Title:** *Effects of E1A on TGF-Beta-inducible junB Expression*

Competitive Pre-Doctoral award to study transcription factor *junB*.

**USPHS 5 T32 CA09043** (PI: Bishop, KM, UCSF) 10/01/93-06/31/96

**Source:** NIH/UCSF \$25,000 directs/yr

**Title:** *Molecular Analysis of Tumor Viruses* \$75,000 directs/yr 1-3

Post-Doctoral fellowship to study mouse model of epithelial carcinogenesis.

**American Social Health Association/Pfizer Post-Doctoral Research Fellowship in** 10/01/96 – 9/30/98

**Sexually Transmitted Diseases** (PI: Coussens, LM, UCSF)

**Source:** Private Foundation \$27,500 directs/ yr 1

**Title:** *Metalloproteinases and Malignant Progression of Squamous Epithelium in K14-HPV16 Transgenic Mice* \$56,250 directs/yr 1-2

**Role:** Principal Investigator

Competitive Post-Doctoral fellowship to study proteases and tumor development

**P01 CA072006** (PI: Shuman M, UCSF) 06/10/97 – 06/30/03

**Source:** NIH/NCI \$803,021 directs/yr 1

**Title:** *Proteases in Cancer Biology and Drug Development* \$4,280,649 directs/yr 1-5

Project 3 – Proteases in Models of Tumor Initiation/Progression \$165,438 directs/yr 1

**Role:** Co-Investigator, Project 3 \$940,281 directs/yr 1-5

The major goal of this project was to study the role of proteases in cancer biology. \$72,595 directs/yr 1

Core C – Transgenic Animal Models \$470,620 directs/yr 1-5

**Role:** Director (year 4 and 5)

The major goal of this Core is to develop and provide protease null and transgenic mice to program projects.

**UCSF IRG-97-150-01** (PI: Coussens LM, UCSF) 07/01/99-06/30/00

**Source:** American Cancer Society \$20,000 directs/yr

**Title:** *Proteases and Genomics in a Mouse Model of Epithelial Cancer* \$20,000 directs/yr 1

**Role:** Principal Investigator

Pilot project tested role of proteinases as effectors of genomic instability.

**UCSF Cell Cycle and Dysregulation Program** (PI: Coussens LM, UCSF) 02/01/00-01/31/01

**Source:** UCSF Comprehensive Cancer Center, Intramural \$14,000 directs/yr 1

**Title:** *Epithelial Neoplastic Progression and Degradation of Type I Collagen* \$14,000 directs/yr 1

**Role:** Principal Investigator

Pilot project assessed functional significance of type I collagen metabolism during epithelial carcinogenesis.

**Research Evaluation & Allocation Committee** (PI: Coussens LM, UCSF) 07/01/00-06/30/01

**Source:** UCSF Academic Senate \$30,000 directs/yr 1

**Title:** *Role of Gelatinase B in Maintenance of Genomic Instability* \$30,000 directs/yr 1

<b>Role:</b> Principal Investigator	
Pilot project tested the role of MMP9 as an indirect regulator of genomic instability.	
<b>UCSF IRG AC-04-02</b> (PI: Coussens LM, UCSF)	10/01/00-09/30/01
<b>Source:</b> American Cancer Society	\$20,000 directs/yr 1
<b>Title:</b> <i>Regulation of Intracellular Signaling Pathways by Gelatinase B/MMP-9</i>	\$20,000 directs/yr 1
<b>Role:</b> Principal Investigator	
Pilot project to study signal transduction pathways regulated by MMP-9.	
<b>The V Foundation for Cancer Research</b> (PI: Coussens LM, UCSF)	06/02/00-05/31/02
<b>Source:</b> Private Foundation	\$50,000 directs/yr 1
<b>Title:</b> <i>Gelatinase B and Epithelial Cancer Development</i>	\$100,000 directs/yr 1-2
<b>Role:</b> Principal Investigator	
Pilot project to study role of MMP9 during epithelial carcinogenesis.	
<b>Gertrude B. Elion Cancer Research Award</b> (PI: Coussens LM, UCSF)	07/01/01 – 06/30/02
<b>Source:</b> American Association of Cancer Research	\$50,000 directs/yr 1
<b>Title:</b> <i>Functional Role of MMP-2 During Epithelial Carcinogenesis</i>	\$50,000 directs/yr 1
<b>Role:</b> Principal Investigator	
Pilot project to study role of MMP-2 during epithelial carcinogenesis.	
<b>Univ. of Calif., Cancer Research Coordinating Committee</b> (PI: Coussens LM, UCSF)	07/01/01 – 06/30/02
<b>Source:</b> University of California	\$48,874 directs/yr 1
<b>Title:</b> <i>Gelatinase A/MMP-2 and Epithelial Cancer Development</i>	\$48,874 directs/ yr 1
<b>Role:</b> Principal Investigator	
Pilot project to study role of MMP-2 as a potentiator of tumor development.	
<b>Hellman Family Award for Early Career Faculty</b> (PI: Coussens LM, UCSF)	11/01/00-09/30/02
<b>Source:</b> UCSF Intramural	\$49,000 directs/ yr 1
<b>Title:</b> <i>Paracrine Regulation of Epithelial Carcinogenesis by MMP-9</i>	\$89,000 directs/yr 1-2
<b>Role:</b> Principal Investigator	
Pilot project to identify matrix molecules regulated by MMP-9.	
<b>Edward Mallinckrodt, Jr. Foundation</b> (PI: Coussens LM, UCSF)	10/01/00-09/30/03
<b>Source:</b> Private Foundation	\$61,000 directs/yr 1
<b>Title:</b> <i>Regulation of epithelial cancer by gelatinase B/MMP-9</i>	\$194,000 directs/yr 1-3
<b>Role:</b> Principal Investigator	
Pilot project to determine how MMP-9 regulates proliferation, VEGF bioavailability and angiogenesis during epithelial carcinogenesis.	
<b>P50 CA58207</b> (PI: Gray, J: UCSF)	03/01/03-02/28/05
<b>Source:</b> NIH/NCI	\$50,000 directs/yr 1
Bay Area Breast Cancer Translational Research Program (SPORE)	\$100,000 directs/yr 1-2
<b>Title:</b> <i>Type I Collagen Remodeling and Mammary Carcinogenesis</i>	
<b>Role:</b> Principal Investigator (Developmental Project)	
The overall goal of this pilot project was to explore the role of collagen metabolism during mammary carcinogenesis.	
<b>DE-FG02-05ER6401</b> (PI: Franc, B; UCSF)	03/01/05 – 01/16/06
<b>Source:</b> DOE Medical Applications Grant	\$225,100 directs yr 1
<b>Title:</b> <i>Therapeutic Radionuclide Tumor-targeting Strategy for Breast Cancer</i>	\$1,125,500 total directs
<b>Role:</b> Co-Investigator	
The specific aim of this project were to develop a radionuclide delivery molecule (RDM) that specifically targets cancer cells that express matrix-metalloproteinase-14 (MMP-14) on their surface and demonstrate delivery of radiolabeled RDM to MMP-14 expressing cells <i>in vitro</i> and <i>in vivo</i> .	
<b>R01 DK067678</b> (PI: Cher, M: Wayne State University)	07/01/03-06/30/06
<b>Source:</b> NIH/NIDDK	\$14,675 directs/yr 1
<b>Title:</b> <i>Proteases in Prostate Cancer Bone Metastasis</i>	\$122,794 directs/yr 1-4
<b>Role:</b> Subcontract Principal Investigator	
The major goal of this subcontract is to assist with the planned experiments by providing mice (protease deficient) of defined genotype for proposed studies to analyze proteases during prostate metastasis to bone <i>in vivo</i> .	
<b>Opportunity Award, Sandler Family</b> (PI: Coussens, LM; UCSF)	02/15/05 -02/14/07
<b>Source:</b> UCSF Intramural	\$95,000 directs yr 1
<b>Title:</b> <i>B Lymphocytes as Targets for Cancer Prevention</i>	\$191,000 total directs
<b>Role:</b> Principal Investigator	
The major goal of this project was to investigate the efficacy of targeting B cells for chemoprevention	
<b>DAMD17-02-1-0693</b> (PI: Sloane, B; Wayne State University)	08/01/02-07/31/06
<b>Source:</b> Department of Defense	\$5,746,832 directs/yr 1-4
<b>Breast Cancer Center of Excellence</b>	\$49,576 directs/yr 1



<b>Title:</b> <i>Validation of Proteases as Therapeutic Targets in Breast Cancer Functional Imaging of Protease Expression, Activity and Inhibition</i>	
<b>Role:</b> Subcontract Principal Investigator	\$198,307 directs/yr 1-4
The goal of this program was to validate proteases as therapeutic targets in breast cancer by functional imaging of protease expression, activity and inhibition.	
<b>R01 CA94168</b> (PI: Coussens, LM; UCSF)	04/01/02-06/31/07
<b>Source:</b> NIH/NCI	\$222,500 directs/yr 1
<b>Title:</b> <i>Regulation of Epithelial Cancer by MMP-9/gelatinase B</i>	\$1,112,500 directs/yr 1
<b>Role:</b> Principal Investigator	
The goal of this project was to identify molecules that mediate proliferative and cellular pathways activated by MMP9.	
<b>U54 RR020843</b> (PI: Smith, J; Burnham Institute)	09/30/04-07/31/09
<b>Source:</b> NIH/National Center for Research Resources	\$1,916,878 directs/yr 1-5
<b>Title:</b> Center on Proteolytic Pathways	
<b>Role:</b> Principal Investigator (Driving Biological Problem #1)	\$67,306 directs/yr
DBP#1 <i>Proteolytic Pathways in Acute Vascular Response</i>	
<b>P01 CA72006</b> (PI: Werb, Z; UCSF)	07/07/03 – 06/30/08
<b>Source:</b> NIH/NCI	\$1,523,691 directs/yr 6
<b>Title:</b> <i>Proteases in Cancer Biology and Drug Development</i>	\$6,354,685 directs/yr 6-11
Project 3 - <i>Proteases in Models of Tumor Initiation/Progression</i>	\$229,788 directs/yr 6
<b>Role:</b> Co-Investigator, Project 3	\$1,172,879 directs/yr 6-11
The major goal of this project was to study the role of proteases in cancer biology.	
Core C - <i>Transgenic Animal Models</i>	\$151,612 directs/yr 6
<b>Role:</b> Director	\$765,974 directs/yr 6-11
The major goal of this Core was to develop and provide protease null and transgenic mice to program projects.	
<b>R01 CA98075</b> (PI: Coussens, LM; UCSF)	07/01/03-06/30/09
<b>Source:</b> NIH/NCI	\$222,500 directs/yr 1
<b>Title:</b> <i>Microenvironmental Regulation of Tumor Progression</i>	\$1,112,500 directs/yr 1-5
<b>Role:</b> Principal Investigator	
The overall goal of this grant was to determine the role of collagen metabolism on epithelial carcinogenesis.	
<b>P50 CA58207 (van 't Veer; UCSF)</b>	08/01/92–11/30/12
<b>Source:</b> NIH/NCI	
Bay Area Breast Cancer SPORE	
Career Development Research Award Multi Project PI: Weaver, Hwang, Coussens	(5/1/10-04/30/11)
<b>Title:</b> Risk to Malignancy and Immune and Collagen Status	
The goals of this project were to 1) Determine whether immune infiltrate and collagen heterogeneity exist between and within multiple regions of breast tissue, 2) Evaluate whether malignant progression is associated with a distinct immune infiltrate and if that is reflected by physical state of collagen, and 3) Determine relationship between immune infiltrate, collagen, radiographic density and clinical measures of cancer risk.	
<b>Role:</b> Multi P.I.	
<b>P50 CA58207 (van 't Veer; UCSF)</b>	08/01/92–11/30/12
<b>Source:</b> NIH/NCI	\$40,000 (project expenses only)
<b>Title:</b> Bay Area Breast Cancer SPORE	
Career Development and Developmental Research Award, Multi Project PI: Boudreau N; Coussens LM	(5/1/10-04/30/11)
<b>Title:</b> Macrophage-Mediated Delivery of the Breast Tumor Suppressor HoxD10 via Autologous Transfer to Breast Tumors. The aims of this project were to 1) establish function and optimize introduction of the engineered HoxD10 protein into macrophages and/or monocytes; 2) visualization of modified monocyte/macrophage accumulation in mammary tumors in vivo and 3) analysis of the impact of monocyte/macrophage delivered HoxD10 on breast tumor growth, progression and metastasis in MMTV-PyMT mouse model of mammary carcinogenesis.	
<b>Role:</b> Multi P.I.	
<b>BC051640 Era of Hope Scholar Award</b> (PI: Coussens, LM; UCSF)	06/01/06 – 05/31/11
<b>Source:</b> DoD, U.S. Army Medical Research and Materiel Command	\$443,205 directs yr
<b>Title:</b> Microenvironment Regulation of Mammary Carcinogenesis	
The goal of this Scholar Award was to identify leukocytes and their proteases that modify breast carcinogenesis and to develop noninvasive imaging reagents targeting leukocytes to image inflammation.	
<b>Role:</b> P.I.	
<b>W81XWH-08-PRMRP-IIRA</b> (multiPI: Broaddus, C; Coussens, LM)	07/01/09 –06/30/12
<b>Source:</b> DoD, U.S. Army Medical Research and Materiel Command	\$293,637 directs/yr
<b>Title:</b> Role of Macrophage-induced Inflammation in Mesothelioma	
The goals of this project were 1) to determine the functional significance of macrophage phenotype in mesothelioma,	

2) to determine the functional significance of macrophages as regulators of mesothelioma apoptosis in vitro and 3) to define the functional significance of macrophage depletion or repolarization on mesothelioma survival in vivo.

**Role:** multi P.I.

**1S100D010348-01** (PI: Coussens, LM) 06/01/2012 – 05/31/2013  
**Source:** NIH \$403,978 directs/yr

**Title:** Vevo 2100 Ultrasound System

The goal of this shared instrument grant was to purchase a Vevo 2100 Ultrasound System for imaging tumor development in mouse models of cancer for the Mouse Barrier Facility at UCSF.

**Role:** multi P.I.

**RO1 CA132566** (multiPI: Coussens, LM; Jablons DM) 05/01/08-04/30/13  
**Source:** NIH/NCI \$190,000 directs/yr

**Title:** Inflammation and Lung Carcinogenesis

The goal of this study was to determine how inflammation and Wnt signaling regulate stem cell niche autonomy during lung carcinogenesis

**Role:** multi P.I.

**R01CA140943** (multiPI: Coussens, Boudreau, Daldrup-Link) 07/01/09 – 05/31/14  
**Source:** NIH/NCI \$166,000 directs/yr

**Title:** *Improved Imaging and Drug Delivery Using Novel Approaches to Regulate Tissue Perfusion*

The major goals of this project are to: examine how short-term inhibition of ALK5 in vivo alters hemodynamics and tissue perfusion in mouse models of cancer.

**Role:** multi P.I.

**RO1 CA130980** (PI: Coussens, LM) 07/01/08-05/31/14  
**Source:** NIH/NCI \$207,500 directs/yr

**Title:** *Regulation of Inflammation-Associated Epithelial Cancer Development*

The major goals of this project are to: determine regulatory programs activating chronic inflammation during squamous carcinogenesis

**Role:** P.I.

**KG110560** (multiPI: Hwang S; Coussens, LM) 07/1/11 – 06/31/14, no cost extension  
**Source:** Komen Foundation, IDEA Award \$200,000 directs/yr

**Title:** *Immune and Collagen Basis of Breast Cancer Risk*

The major goals of this study are to: establish whether immune and collagen status is correlated with density-associated breast cancer risk.

**Role:** multi P.I.

**1U54CA163123-administrative supplement** (multiPI: Coussens, LM; Nan, X-L) 08/01/14-07/31/15  
**Source:** NIH/NCI \$100,000 directs/yr

**Title:** *Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes*

The major goals of this study are to: utilize advanced high-resolution multi-color fluorescence imaging to reveal the in situ location of distinct immune cell subtypes in breast tumors so as to exploit the information revealed about the immune microenvironment of breast cancer to improve therapeutics and survival.

**Role:** multi P.I.

**1U54CA163123-01** (multiPI: Coussens, LM; Krummel, M) 09/23/11 – 07/31/17  
**Source:** NIH/NCI \$258,900 directs/yr

**Title:** *Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes*

The major goals of this study are to: identify myeloid- and lymphoid-based biomarkers representing either functional mediators of immune cell phenotype or instead reflecting leukocyte composition, and which of these in turn represent predictive variables for predicting breast cancer response to CTX +/- macrophage-depletion therapy

**Role:** multi P.I.

**R01 CA155331** (PI: Coussens, LM) 05/01/11 – 03/31/18  
**Source:** NIH/NCI \$207,500 directs/yr

**Title:** *Regulating the Immune Microenvironment in Breast Cancer*

The major goal of this study is to evaluate the efficacy of T<sub>H</sub>2-blockade as a therapy for reprogramming pro-tumor immune cells in mouse models of mammary carcinogenesis.

**Role:** P.I.

**W81XWH-10-BCRP-EOHS-EXP** (PI: Coussens, LM) 09/30/11 – 01/01/18  
**Era of Hope Scholar Expansion Award**

**Source:** DOD/U.S. Army Medical Research & Materiel Command \$346,174 directs/yr

**Title:** *Modulating Immune Response to Improve Therapy for Breast Cancer*

The major goals of this study are to: test the hypothesis that the immune microenvironment in breast cancer can be effectively manipulated therapeutically to limit breast cancer recurrence and extend overall survival

**Role:** P.I.

<b>SU2C-AACR-DT12-14</b> (PI: Jafee, E; Vonderheide R)	07/01/14-06/31/18
<b>Source:</b> AACR-SU2C	\$506,960 directs/yr
<b>Title:</b> <i>Transforming pancreatic cancer from a death sentence into a treatable disease</i>	
The major goals of this program are to: 1) Develop novel immune strategies that target patient-unique T cell epitopes in pancreatic ductal adenocarcinoma (PDA) identified by tumor exome sequencing; 2) Conduct a series of “shovel ready” combination clinical trials in PDA and establish biomarkers of tumor microenvironment (TME) reprogramming – each trial focusing on a novel immune suppressive pathway within the TME; and, 3) Conduct pre-clinical studies in mouse models of PDA to establish novel combinatorial approaches and develop biomarkers that will drive the next generation of PDA clinical trials	
<b>Role:</b> Dream Team Principal	
<b>KG111084</b> (multiPI: Coussens, LM; Hwang S, Rugo H)	08/08/11 – 08/07/18
<b>Source:</b> Komen Foundation, PROMISE Grant	\$1,137,344 directs/yr
<b>Title:</b> <i>Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages.</i>	
The major goals of this study are to: test the hypothesis that that macrophages in triple negative (TN)/basal-like breast cancer potentiate late-stage disease progression and limit long-term survival, and that by either minimizing tumor associated macrophages (TAM) recruitment or reprogramming TAM bioactivity, outcomes for patients with TN/basal-like breast cancer will significantly improve.	
<b>Role:</b> multi P.I.	
Externally sponsored research (PI: Coussens, LM)	10/03/14 – 10/02/18
<b>Source:</b> Janssen Research & Development LLC	\$182,159 directs/yr
<b>Title:</b> c-FMS inhibitor/JNJ-40646527 and checkpoint blockade in mesothelioma	
The major goals of this study are to: 1) Characterize immune complexity and checkpoint expression in the 40L malignant mesothelioma model in control or $\alpha$ -CSF1R -/+ CTX treated mice. 2) Determine efficacy with checkpoint blockade (single, combinations, bispecifics) alone or together with CSF1R blockade/CTX treatment in the 40L model.	
<b>Role:</b> P.I.	
Externally sponsored research (PI: Coussens, LM)	12/01/14 – 06/30/19
<b>Source:</b> Deciphera Pharmaceuticals	\$159,372 directs/yr
<b>Title:</b> In vivo study of kinase inhibitors in mesothelioma	
The major goals of this study are to: evaluate efficacy of kinase inhibitors and chemotherapy treatment in a murine model of mesothelioma.	
<b>Role:</b> P.I.	
Externally sponsored research (PI: Coussens, LM)	08/14/14 – 08/01/19
<b>Source:</b> Acerta Pharma, LLC	\$146,604 directs/yr
<b>Title:</b> Therapeutic efficacy in SCC	
The major goals of this study are to: Evaluate therapeutic efficacy of a BTK inhibitor plus and minus chemotherapy in a murine model of SCC	
<b>Role:</b> P.I.	
Externally sponsored research (PI: Coussens, LM)	09/01/16 – 09/30/19
<b>Source:</b> Acerta Pharma, LLC	\$149,738 directs/yr
<b>Title:</b> Molecular correlates for NCT02454179	
The major goals of this study are to: Evaluate biomarkers of therapeutic response from NCT02454179.	
<b>Role:</b> P.I.	
<b>A124232 BCRF</b> (PI: Rugo)	10/01/12-09/30/19
<b>Source:</b> The Breast Cancer Research Foundation	\$30,000 directs/yr
<b>Title:</b> <i>Cellular mechanisms of resistance to antiangiogenic and the impact of immune therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer</i>	
The major goals of this study are to: 1) evaluate significance of immune cells in primary mammary carcinomas and lung metastases in the context of response and relapse/resistance to anti-angiogenic and/or immune modulating therapy, 2) Investigate the impact of inhibiting immune cell infiltration alone or in combination with antiangiogenic agents or chemotherapy on the growth of primary tumors and metastases, and 3) characterize the expression of a specific set of genes and gene copy number in circulating tumor cells (CTCs) in patients with ABC, including markers of response and resistance to specific types of therapy.	
<b>Role:</b> subcontract P.I.	
Externally sponsored research (PI: Coussens, LM)	03/01/16 – 02/28/19
<b>Source:</b> Roche Glycart AG	\$82,482 directs/yr
<b>Title:</b> <i>CD20 as a therapeutic target in pancreas cancer</i>	
The major goals of this study are to evaluate therapeutic efficacy and identify select cell populations regulating efficacy.	
<b>Role:</b> P.I.	
No number (PI: Chang/Coussens)	07/01/18 – 06/30/19

<b>Source:</b> Brenden-Colson Center for Pancreatic Health	\$80,000 directs/yr
<b>Title:</b> <i>TiME matters in pancreatic cancer</i>	
The goal of this project is to interpret multi-nodal aspects of immune complexity and functionality in tumor biopsy material elucidated by multiplex immunohistochemistry (mIHC)2 to aid patient stratification and response for precision immune therapy of pancreatic cancer.	
<b>Role:</b> mPI	
<b>No number</b> (PI: Coussens)	12/01/18 – 11/30/19
<b>Source:</b> Parker Institute for Cancer Immunotherapy	\$250,593 total directs
<b>Title:</b> <i>mIHC Analysis of PICI trial; Phase 1b/II Clinical Trial with CD40 with or without PD1</i>	
The goal of this project is to evaluate paired biopsy samples for immune contexture changes from a pancreas cancer clinical trial evaluating efficacy of αCD40 agonist mAb +/- αPD-1 mAb	
<b>Role:</b> PI	
<b>2018-Hillcrest-10</b> (mPI: Coussens; Adey)	01/01/19 – 12/31/19
<b>Source:</b> OHSU Knight Cancer Institute	\$50,000 total directs
<b>Title:</b> <i>Epigenetic TME Reprogramming in TNBC</i>	
The goal of this project is to investigate the impact of a novel combination of immune therapies, along with chemotherapy, to differentially regulate gene expression programs in immune cells present in mammary cancers	
<b>Role:</b> mPI	
<b>Externally Sponsored Research; SRA-18-049</b> (PI: Coussens)	10/12/17 – 10/02/20
<b>Source:</b> Syndax Pharmaceuticals Inc.	\$542,851 total directs
<b>Title:</b> <i>mIHC of Entinostat + pembroluzimab Evaluation</i>	
The Coussens team will perform immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) pre- and post-treatment patient tissues from a clinical trial evaluating Entinostat + pembroluzimab.	
<b>Role:</b> PI	
<b>No Number</b> (PI: Coussens)	01/01/20 – 12/31/20
<b>Source:</b> Oregon Health & Science University (SMMART)	\$188,702 total directs
<b>Title:</b> <i>Multiplex IHC Patient Sample Analysis</i>	
The goals of this project are to facilitate automation and high throughput analysis of a multi-plex IHC platform.	
<b>Role:</b> PI	
<b>No Number</b> (PI: Coussens)	01/01/20 – 12/31/20
<b>Source:</b> Oregon Health & Science University (SMMART)	\$50,000 total directs
<b>Title:</b> <i>Multiplex IHC Patient Sample Analysis</i>	
Utilize multi-plex IHC to evaluate immune contexture of patient tumor samples	
<b>Role:</b> PI	
<b>Externally Sponsored Research; SRA-19-152</b> (PI: Coussens)	12/04/19 – 12/03/21
<b>Source:</b> Innate Pharma S.A.	\$318,471 total directs
<b>Title:</b> <i>Role of C5aR in overcoming chemotherapy resistance in murine orthotopic (OT) models of squamous carcinogenesis</i>	
Consolidate preclinical evidence for targeting the C5aR axis in oncology.	
<b>Role:</b> PI	
<b>No number</b> (PI: Coussens)	10/01/19 – 12/31/21
<b>Source:</b> Johns Hopkins University	\$168,211 total directs
<b>Title:</b> <i>A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced pancreatic cancer</i>	
The goal of this project is to determine if treatment with the histone deacetylase inhibitor (HDACi) entinostat and/ or treatment with immune checkpoint inhibitors (ICIs) has an effect on infiltration and function of lymphoid and myeloid cells into tumors of patients with advanced cancers.	
<b>Role:</b> subcontract PI	
<b>R21 HD099367</b> (PI: Maloyan)	09/01/19 – 08/31/21
<b>Source:</b> NIH/NICHD	\$411,620 (Coussens \$35,335)
<b>Title:</b> <i>Mechanisms of metabolic dysfunction in the offspring of maternal obesity: role of inflammation</i>	
The goal of this project is to identify potential therapeutic targets to alleviate cardiovascular and metabolic diseases in the offspring of pregnancies complicated by maternal obesity.	
<b>Role:</b> co-I	
<b>CRUK6841219</b> (PI: Chang/Zhuang)	10/01/20 – 09/31/22
<b>Source:</b> Cancer Research UK	\$288,496 total directs
<b>Title:</b> <i>Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with multiplex immunostaining and Sparse Subspace Clustering (SCC) approach</i>	
Develop approach for multiplex IHC analytics to study immune complexity in esophageal adenocarcinoma.	
<b>Role:</b> co-I	
<b>K00 CA212132</b> (PI: Berens)	11/16/18 - 06/30/22

<b>Source:</b> NIH/NCI	\$319,846 (Coussens \$0)
<b>Title:</b> <i>Impact of cytoskeletal regulators on cancer cell stromal invasion</i>	
Establish how the activated T cell surface marker known as CD69 and other immune surface genes enhance cancer metastasis; and determine if the acquisition of immune surface markers thwarts immune-mediated destruction of cancer cells in vitro	
<b>Role:</b> Mentor	
<b>No Number</b> (PI: Berens)	12/01/21 – 12/11/22
<b>Source:</b> Collins Medical Trust	\$30,000 total directs
<b>Title:</b> <i>Neoplastic immune surface mimicry as a modulator of the immune response against breast cancer</i>	
Determine whether the acquisition of immune surface receptors by neoplastic breast epithelium confers resistance to cytotoxic activity from the immune system	
<b>Role:</b> Mentor	
<b>R01 HL093056</b> (PI: Habecker)	07/01/19 – 06/30/23
<b>Source:</b> NIH/NHLBI	\$2,463,192 total directs/indirects (Coussens \$65,228 directs)
<b>Title:</b> <i>Neurotrophins and post-infarct plasticity in cardiac sympathetic neurons</i>	
Elucidate structural and functional changes induced in the heart by sympathetic reinnervation after MI, and the role of noradrenergic neurotransmission in restoring electrical stability.	
<b>Role:</b> collaborator	
<b>SRA-21-097B</b> (PI: Kumar)	04/01/22 – 03/21/23
<b>Source:</b> HiberCell, Inc.	\$268,968 Total directs/indirects
<b>Title:</b> <i>Reprogramming tumor microenvironment for cancer therapy by targeting stress signaling pathway</i>	
Establish the molecular link connecting CSF1R activation and PERK activity in macrophages	
<b>No Number</b> (PI: Heiser, Coussens, Schultz)	07/01/22 – 06/30/23
<b>Source:</b> OHSU Center for Women's Health, Circle of Giving	\$125,000 total directs
<b>Title:</b> <i>A comprehensive approach to examine neutrophil elastase in breast cancer</i>	
Develop and deploy novel FRET reporters designed to assess neutrophil elastase activity in the tumor ecosystem and to assess the role of neutrophil elastase activity in mediating disease progression and response to therapy	
<b>Role:</b> multiPI	
<b>No Number</b> (PI: Heiser/Mitri)	01/01/22 – 12/31/24
<b>Source:</b> Wayne D. Kuni & Joan E. Kuni Foundation	\$998,733 total directs/indirects
<b>Title:</b> <i>A preclinical approach to targeting cell state in aggressive metastatic breast cancer</i>	
A comprehensive assessment of therapy-associated cancer cell states in metastatic TNBC	
<b>Role:</b> co-I	
<b>SRA-22-063</b> (PI: Coussens)	02/01/22 – 01/31/25
<b>Source:</b> ZielBio, Inc	\$508,288 total directs/indirects
<b>Title:</b> <i>Immune modulation in response to ZB131 anti-CSP monoclonal antibody treatment for solid tumors</i>	
Clinical study of ZB131-101 before and after treatment with ZB131 for indicators of mechanisms of response and/or resistance to therapy	
<b>Role:</b> PI	
<b>C19767/A27145</b> (PI: Tlsty)	01/02/21 – 12/31/23
<b>Source:</b> Cancer Research UK (CRUK)	
<b>Title:</b> <i>STrOmAl ReprograMing (STORMing) provides new directions to prevent and revert chronic inflammation-associated cancers</i>	
The goal of the study is to gain mechanistic insight into key events that typify progression of chronic inflammation-associated cancers	
<b>Role:</b> co-I	
<b>No Number</b> (PI: Mills)	01/01/21 – 12/31/23
<b>Source:</b> Wayne D. Kuni & Joan E. Kuni Foundation	\$1,500,000 total directs/indirects
<b>Title:</b> <i>Blood Biopsies as a Cost-Effective Approach to Democratize Personalized Therapy for OR &amp; WA Patients</i>	
Development of technologies to measure multiple analytes in patient blood and determine if information can be used in place of tissue biopsies to guide cancer treatments.	
<b>Role:</b> co-I	
<b>R01 CA226909</b> (PI: Varner/Cohen)	07/01/18 – 06/30/23 (NCE)
<b>Source:</b> NIH/NCI	\$1,911,630 total directs/indirects (Coussens \$315,385)
<b>Title:</b> <i>Therapeutic targeting of macrophage PI3Kgamma in HNSCC</i>	

Identify mechanisms by which PI3Kg inhibitors synergize with anti-PD-1 using mouse models of HPV+ and HPV- carcinogen-induced HNSCC and to determine the effect of the PI3Kg inhibitor IPI-549 on tumor immune responses in patients with resectable HNSCC or recurrent/metastatic HNSCC

**Role:** co-I

**U01 CA224012** (mPI: Sears, Coussens, Demir, Brody)

09/12/19 – 08/31/24

**Source:** NIH/NCI

\$2,138,947 total directs/indirects

**Title:** *Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens*

The goal is to conduct comparative analysis of patient-derived models of pancreatic ductal adenocarcinoma from patient specimens to determine biologic differences and responses to perturbagens.

**Role:** multi-PI

**R01 CA 223150** (PI: Jonas)

07/01/18 – 06/30/23 (NCE)

**Source:** NIH/NCI

\$175,574 total directs/indirects (Coussens)

**Title:** *In situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices*

Evaluate immune contexture in response to therapies in mammary tumors implanted with microdevices to examine immune responses to combination therapies

**Role:** co-I

**W81XWH-20-1-0007** (PI: Poissonnier)

01/15/20 -01/14/23 NCE

**Source:** DOD, BCRP

\$461,746 (Coussens \$0)

**Title:** *Relieving immune suppressive pathways in breast cancer to improve outcomes*

Evaluate therapeutic response in mammary tumor bearing mice with CSF1R blocking mAb combined with PTX, αPD1 and entinostat, to reveal efficacy, mechanisms, and response predictors

**Role:** Mentor

**5 U2C CA 233280** (PI: Goecks/Mills/Thomas)

09/01/18 – 08/30/24 (NCE)

**Source:** NIH/NCI

\$8,842,537 total directs/indirects

**Title:** *Omic and multidimensional spatial atlas of metastatic breast and prostate cancers*

Apply state of the art analysis tools to prospective samples and identify changes in components and structures of cancers enabling them to escape therapeutic co.

**Role:** co-I

**R01 CA169175** (PI: Schedin)

04/01/20 – 03/31/25

**Source:** NIH/NCI

\$7,494 (salary only)

**Title:** *NSAIDs During Postpartum Involution for Breast Cancer Chemoprevention*

Pre-clinical investigation of ibuprofen intervention necessary to advance to a clinical chemoprevention trial.

**Role:** co-I

## VIII. PROFESSIONAL, UNIVERSITY AND PUBLIC SERVICE

### Memberships and Service to Professional Societies

#### **American Association for Cancer Research (Member, 1999 - present)**

- 2003 Subsection Co-chair (Tumor Progression, Invasion and Metastasis) Cellular, Molecular and Tumor Biology Subcommittee, AACR Program Committee for *94<sup>th</sup> Annual Meeting*.
- 2003 Chair and organizer, Educational Session (Proteases: Successes and Failures): *94<sup>th</sup> Annual Meeting*, Washington D.C., USA
- 2003 Minisymposium Co-chair (Inflammatory Mediators & Cancer): *94<sup>th</sup> Annual Meeting*, Washington D.C., USA
- 2003 – 2005 Associate Editor, **Cancer Research**
- 2004 - 2006 Member, Grants Committee
- 2004 – 2007 Senior Editor, **Cancer Research (Cell, Tumor and Stem Cell Biology Section)**
- 2005 Minisymposium Co-Chair (Inflammation, Microenvironment and Tumor Progression): *96<sup>th</sup> Annual Meeting*, Anaheim, CA USA
- 2005 Session Chair (Inflammation): *AACR Special Conference: Cancer, Proteases and the Microenvironment*, Bonita Springs, Florida. USA
- 2006 Subsection Co-chair (Tumor Progression, Invasion and Metastasis) of the Tumor Biology

- 2006 Subcommittee, AACR Program Committee for 97<sup>th</sup> Annual meeting  
Minisymposium Co-Chair (Inflammation and Cancer): 97<sup>th</sup> Annual Meeting, Washington DC, USA
- 2006 Co-Chairperson, Program Committee: 6<sup>th</sup> Annual Frontiers in Cancer Prevention Research Conference, December 5-8, 2007, Philadelphia, PA USA.
- 2006 - 2010 Steering Committee Member: AACR Tumor Microenvironment Working Group (TME/AACR).
- 2007 - 2009 Deputy Editor, **Cancer Research**
- 2007 Organizer, Education session (Inflammation and Cancer), 98<sup>th</sup> Annual Meeting, Los Angeles, USA
- 2007 Minisymposium Co-Chair (Tumor Microenvironment): 98<sup>th</sup> Annual Meeting, Los Angeles, CA USA
- 2007 Co-Chairperson, Program Committee: 2008 99<sup>th</sup> Annual Meeting of the AACR. April 12-16, 2008, San Diego, CA. USA
- 2008 Program Committee Member, Tumor Microenvironment Subcommittee for 99<sup>th</sup> Annual Meeting of the AACR. April 12-16, 2008, San Diego, CA. USA
- 2007 - 2010 Member, AACR Special Conferences Committee
- 2008 Co-Organizer AACR Special Conference: *Inflammation and Cancer*, with Drs. Michael Karin and Larry Marnett. Oahu, Hawaii, USA.
- 2008 - 2011 Member, Board of Directors (**elected**)
- 2009 - 2012 Deputy Editor for Breaking Advances, **Cancer Research**
- 2009 Member, 2009 Education Committee, 2009 100<sup>th</sup> AACR Annual Meeting, Denver, CO. USA
- 2009 Organizer and Chair: *Inflammation and Cancer: Novel Mechanisms Regulating Protumor Immunity* Major Symposium, 2009 100<sup>th</sup> AACR Annual Meeting, Denver, CO. USA
- 2009 Organizer and Chair: Education Session, *Aspects of the Tumor Microenvironment that Regulate Solid Tumor Development*, 2009 100<sup>th</sup> AACR Annual Meeting, Denver, CO. USA
- 2010 Co-Chairperson, Program Committee: 2010 101<sup>st</sup> Annual Meeting of the AACR, April 17-21, 2010, Washington, DC USA
- 2009 Member, Scientific Review Committee for *Stand Up to Cancer Innovative Research Grants*
- 2009 - 2010 Member, Selection Committee: 2010 Pezcoller Foundation-AACR International Award for Cancer Research. Dr. Joseph Schlessinger, recipient
- 2010 - 2011 Council Member, *Women in Cancer Research* Council (elected)
- 2010 Co-Chair, Minisymposium 'The Tumor Microenvironment and Therapeutic Strategies' 2010 101<sup>st</sup> Annual Meeting of the AACR, April 17-21, 2010, Washington, DC USA
- 2010 - 2011 Member, Selection Committee: 2010-2011 AACR Award for Lifetime Achievement in Cancer Research. Dr. Susan Horwitz, recipient.
- 2011 Co-Chair, Minisymposium 'Tumor Microenvironments' 2011 102<sup>st</sup> Annual Meeting of the AACR, April 3-6, 2010, Orlando, FL USA
- 2011 Co-Organizer AACR Special Conference: *Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, with Drs. Yves DeClerck (USC, Children's Hospital) and Melody Swartz (EPFL); November 2011, Orlando FL USA
- 2012 Co-Chairperson, Program Committee: 2012 103<sup>rd</sup> Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012-present Senior Editor, **Cancer Immunology Research**
- 2012 Chair, Plenary session: "Tumor Heterogeneity: Challenges and Therapeutic Opportunities" 2012 103<sup>rd</sup> Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Chair, Education session: "Tumor Microenvironment" 2012 103<sup>rd</sup> Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Chair, 2012 Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research Scientific Review Committee, Dr. Judith Varner, recipient.
- 2012 Speaker, 2012 AACR Meet the Research Pioneer, 2012 103<sup>rd</sup> Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Organizing Committee for 9<sup>th</sup> AACR-Japanese Cancer Association International Conference, February 21-25, 2013, Maui, Hawaii.
- 2012 Cancer Immunology (CIMM) Chairperson-elect Nominating Committee 2013-2014.
- 2013 - present Senior Editor, *Cancer Immunology Research*

2013	Member, 2014 AACR Princess Takamatsu Memorial Lectureship Award Committee. <i>Dr. Rakesh Jain, recipient</i>
2013 - 2015	Pancreatic Cancer Action Network-AACR Innovative Grants Scientific Review Committee
2014	Chair, Education session: <i>Phenotyping and Function of Solid Tumor Stroma</i> 2014 105 <sup>th</sup> Annual Meeting of the AACR, April 2014, San Diego, CA USA
2014	Personalized Career Discussions, Associate Member Council, 2014 105 <sup>th</sup> Annual Meeting of the AACR, April 2014, San Diego, CA USA
2015	Program Committee, Second AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy, San Diego, CA USA.
2014	Member Selection Committee, 2014-2015 Pezcoller Foundation-AACR International Award for Cancer Research.
2015	Mentor, WICR Career Mentoring Session, Fourth AACR International Conference on Frontiers in Basic Cancer Research, Philadelphia PA USA
2016	Scientific Program Committee Member, AACR Annual Meeting on April 16 - 20, 2016 in New Orleans, Louisiana USA
2016	Education Committee Member, AACR Annual Meeting on April 16 - 20, 2016 in New Orleans, Louisiana USA
2016	Mentor, AMC/MICR/WICR-sponsored 'Personalized Career Discussions' session, AACR Annual Meeting 2016, New Orleans, LA USA
2016	Member, Steering Committee, AACR Cancer Progress Report, 2016. Chair: Nancy Davidson.
2016 - 2018	Member, Nominating Committee ( <b>elected</b> ).
2016 - 2019	Member, AACR Special Conferences Committee
2016 – 2018	Member, AACR NextGen Grants for Transformative Cancer Research Scientific Review Committee
2017	Search committee member; Editor-in-Chief for <i>Cancer Research</i>
2017-present	Scientific Editor, <b><i>Cancer Discovery</i></b>
2018	Co-organizer 8 <sup>th</sup> AACR Special Conference on <i>Tumor Immunology and Immunotherapy</i> , with Drs. Pardoll, Mellman and Allison (MDACC). Miami, FL, USA
2018	2018 Annual Scientific Program Committee
2019	Co-chair, 2019 Annual Meeting Program Committee
2019	Chair, 2019 Annual Meeting Education Committee
2019	Member, selection committee, NextGenStar applications, 2019 Annual Meeting
2019	Program Committee, AACR Translational Cancer Research for Basic Scientists Workshop
2019	Chair, Education session: "Molecular Regulation of Cancer Inflammation, Progression and Treatment Resistance" 2019 Annual Meeting of the AACR, April 2019, Atlanta GA. USA
2019	Fellow of the AACR Academy (Lifetime)
2020	Co-Chair organizer EACR-AACR-ASPIC Basic and Translational Research Conference, 'Tumor Microenvironment', with Drs. Caldas (EACR) and Costa (ASPIC). Lisbon, PORTUGAL.
2020-present	Course Co-Director, AACR Translational Cancer Research for Basic Scientists Workshop, with Drs. Corcoran, Horwitz, and Oxnard. Virtual in 2020 due to COVID-19
2020	Subcommittee Member, <i>Immunotherapy: Preclinical and Clinical</i> ; Immuno-oncology Section of Immunology Subcommittee of the Program Committee. 2020 Annual Meeting
2020	Chair, AACR NextGen Grants for Transformative Cancer Research Scientific Review Committee.
2021	Member, Education Committee, 2022 Annual meeting
2021	Mentor, Career Breakout Session: Mentoring the Mentor, 2021 AACR Virtual Special Conference: Pancreatic Cancer.
2021-2024	President-elect, President, Past-President (elected) <ul style="list-style-type: none"> <li>• Member, Executive Committee (2021-2024)</li> <li>• Officer, Board of Directors (2021-2024)</li> <li>• Member, Science Policy and Government Affairs Committee (2021-2024)</li> <li>• Member, Finance and Audit Committee (2021-2023)</li> <li>• Trustee, AACR Foundation Board (2021-2024)</li> <li>• Member (2021-2022) and Chair (2022-2023), AACR International-Canada Board of Directors</li> </ul>



2022	Co-organizer AACR Special Conference on ' <i>Carcinoma in situ</i> ', with Drs. Polyak, Esserman, and Reis-Filho).
2022	Chair, Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research selection committee
2022-2024	Member, AACR Trust in Science Task Force; chair, Dr. William S. Dalton

### **American Society for Cell Biology (Member, 2001 – 2008)**

2000	American Society for Cell Biology, photo credits in ' <i>Exploring the Cell</i> ' Ed. W. Wells
2001	Table Leader, Career Discussion Lunch, Women in Cell Biology and Education Committee, 40 <sup>th</sup> Annual Meeting, Washington, DC, USA
2001	Co-chair and Co-organizer, Mini-symposium (Microenvironment/Extracellular Matrix in Development and Disease): 40 <sup>th</sup> Annual Meeting, Washington, DC, USA
2003	Table Leader, Career Discussion Lunch, Women in Cell Biology and Education Committee of the ASCB, 42 <sup>nd</sup> Annual Meeting, San Francisco, CA, USA
2006	Co-Chair Minisymposium (Cancer Mechanisms): 46 <sup>th</sup> Annual Meeting, San Diego CA, USA

### **American Association for Advancement of Science (Member, 2011 – present)**

2014 - 2017	Member, Electorate Nominating Committee (ENC) of the Section on Medical Sciences (elected)
2017 – 2020	Member, Electorate Nominating Committee (ENC) of the Section on Medical Sciences (elected)
2016 – 2019	Board of Reviewing Editors, <i>Science</i>
2018	AAAS Fellow (Lifetime)

### **International Proteolysis Society (Member, 2004 – 2009)**

2007	Member, International Scientific Advisory Committee, 5 <sup>th</sup> General Meeting of the International Proteolysis Society, Rion-Patras, GREECE.
2011	Member, Organizing Committee, 9 <sup>th</sup> General Meeting of the International Proteolysis Society, San Diego CA, USA

### **Society for Immunotherapy of Cancer; (Member, 2016-present)**

2013	SITC Annual Meeting, Session Co-Organizer and Co-Chair (with Georgio Trinchieri, NCI), SITC <i>Tumor Microenvironment and Innate Cell Recognition</i> , Bar Harbor, MA USA
2018 - 2021	SITC Immune Responsiveness Task Force (member)
2022	SITC - Fellow of the Academy of Immuno-Oncology (Lifetime)

### **International Society for Preventive Oncology**

2002	Session Chair (Chemoprevention): 6 <sup>th</sup> Annual Meeting, Pasteur Institute, Paris, France.
2002	Poster Judge (Chemoprevention): 6 <sup>th</sup> Annual Meeting, Pasteur Institute, Paris, France.

### **International Society for Biological Therapy of Cancer (ISBTc)**

2008	Co-Organizer (with Drs. Michael Karin, Steven Dubinett, George Weiner), 2008 Workshop on <i>Inflammation in Cancer Development</i> , San Diego CA, USA
------	--

### **Other Professional Society Memberships**

2000 - 2009	American Society for Matrix Biology
2004 - present	American Society for Investigative Pathology
2014 – present	American Association of Immunology

### **Government Service**

2003 - 2006	National Institutes of Health, Center for Scientific Review	Ad hoc reviewer (10/2003; 02/2005; 10/2005; 06/2006), Tumor Progression & Metastasis (TPM) Study Section, Oncological Sciences Review group
2003	Division of Cancer Biology, National Cancer Institute: <i>Microenvironment Think Tank</i>	Participant and Reporter
2003	Division Cancer Etiology, National Cancer Institute: <i>Validation of A Causal Relationship: Criteria to Establish Etiology Think Tank</i>	Invited speaker and Participant
2004	National Institutes of Health, National Cancer	Subcommittee C (05/2004) – Basic & Preclinical NCI

	Institute	Initial Review Group, NCI-C RPRB (T2) Angiogenesis
2005	National Institutes of Health, National Cancer Institute	Subcommittee D (02/2005) – Clinical Studies NCI Initial Review Group, NCI-D RPRB Tumor Pathology
2005	National Institutes of Health, Center for Scientific Review-Oncology	Special Emphasis Panel (SEP); ZRG1 ONC (03) M, Developmental Therapeutics
2010	National Institutes of Health, Center for Scientific Review-Neuroscience	Special Emphasis Panel (SEP)/Scientific Review Group 2010/05 ZNS1 SRB-R (47)
2010	National Institutes of Health, Center for Scientific Review-Neuroscience	Special Emphasis Panel (SEP)/Scientific Review Group 2011/01 ZRG1 DTCS-A (81)
2010 - 2011	Department of Defense (DOD), Breast Cancer Research Program (BCRP)	6 <sup>th</sup> Era of Hope conference Technical Planning Committee (TPC)
2011	National Institutes of Health, Center for Scientific Review	Ad hoc reviewer (06/2011), Cancer Immunotherapy & Immunology (CII) Study Section, Oncology 2 - Translational Clinical IRG (OTC) Division of Translational and Clinical Sciences
2016 - 2024	National Institutes of Health, National Cancer Institute, Division of Extramural Activities	Scientific Advisory Board. Frederick National Laboratory Advisory Committee (FNLAC)
2019 - 2022	National Cancer Institute (NCI), The Frederick National Laboratory Advisory Committee (FNLAC)	FNLAC <i>ad hoc</i> Working Group on Cancer Models and Therapeutic Development

### **Other Professional Ad hoc Service**

1999	Arkansas Science & Technology Authority	Ad hoc Grant Review
2000	McGraw-Hill, 'Biology' 6 <sup>th</sup> edition, Ed. P.H. Raven and G.B. Johnson	Ad hoc Review, Chapters 17 and 18
2001	Department of Veterans Affairs	Ad hoc Grant Review, Oncology Review Board
2001	Research Grants Council of Hong Kong	Ad hoc Grant Review
2003	Danish Cancer Society, DENMARK	Ad hoc Grant Review
2004	Division of Gastroenterology and Digestive Disease Research Center, Vanderbilt University, Nashville TN, USA	PO1 External Advisory Panel
2004	Cancer Research Ireland, Irish Cancer Society	Ad hoc grant review
2004	Dutch Cancer Society	Ad hoc grant review
2004	Vanderbilt University, Nashville TN, USA; SPORE in GI Cancer	Ad hoc reviewer for SPORE Developmental Research Program
2006	Keystone Symposia Cancer Study Group for 2009 programming	Study group member
2009	GlaxoSmith Kline	Member, Tykerb Post-ASCO KOL Advisory Board
2009 - 2010	Cancer Prevention and Research Institute of Texas (CPRIT)	Member, Scientific Review Committee; Basic Cancer Biology Review Committee
2013	IARC – Italian Association for Cancer Research	Site visit review committee member, Istituto Clinico Humanitas - Centro Congress
2015	Celgene Advisory Board	Member
2015	AstraZeneca Pharmaceuticals LP	Consultant
2015	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Ad hoc P30 review committee for Cancer Immunology Program Review
2015-present	Pharmacyclics, LLC. PCYC-1137-CA Study	Steering Committee Member
2015	AIRC – Italian Association for Cancer Research	"5x mille" Special Program in Molecular Clinical Oncology (MCO), Ad Hoc review, 2-year extension programs
2015-2016	3 <sup>rd</sup> Stand Up to Cancer (SU2C) Innovative Research Grants Committee (IRGC)	Member, IRG committee; AACR
2016-2017	Pancreatic Cancer Action Network (PanCan), Precision Promise Immunotherapy Working Group	Member
2016	2016 Nature Awards for Mentoring in Science (North America, West Coast)	Committee Chair
2017 - present	Dana Farber Cancer Center Breast SPORE	EAB for P50
2017-	Cancer Research United Kingdom (CRUK)	Member: Early Detection (EDx) Research Committee

present		
2019 - present	Lustgarten Foundation	Member: <i>Lustgarten Therapeutics Working Group</i>
2019, 2021	Susan G Komen Foundation	Member, Selection Committee, 2019 and 2021 Brinker Awards for Scientific Distinction
2021	National Foundation for Cancer Research	Member, Selection Committee, Szent-Györgyi Prize for Progress in Cancer Research
2021	Cold Spring Harbor Laboratories	Member, External review committee for 'Animal Facility/Opportunistic Pathogen'
2021	Susan G Komen Foundation	Member, Selection Committee, Metastatic breast cancer, collaborative grants selection committee
2022	Susan G Komen Foundation	Chair, Career Catalyst Research Grants: <i>Beyond T cells: Next generation breast cancer immunotherapy</i> committee
2023	American Cancer Society	Member, Review committee, ACS-Wilmott Family Pancreatic Professorship

### **Ad hoc Peer-Reviewing**

1994	Oncogene;
1995	Am J Pathol; Matrix Biology; J Cell Biology
1999	Am J Pathol; Cancer Letters; Nature Med; Nature; PNAS; Cell Motility & the Cytoskeleton; Can Res;
2000	Am J Pathol; Can Res; Genes & Dev; Int. J Cancer
2001	J Cell Biology; Int. J of Cancer; EMBO; Neoplasia; Can Res
2002	Can Res; Am J Pathol; Int. J Cancer; Biol Chem; Cancer Cell; Cancer Letters
2003	PNAS; Can Res; Int. J of Cancer; J Molecular Medicine; Biol Chem; Science; Cancer Cell; Nature Med; J Leukocyte Biology; Neoplasia; Am J Pathol;
2004	Lancet; Cancer Cell; Can Res; Am J Pathol; J Cell Biology; Nature Reviews Immunology; Nature Reviews Cancer; PNAS; J Biol Chem; Nature; J Exp Med; Int J Cancer
2005	Nature Med, Cancer Cell, Can Res; Am J Pathol; Cell; Nature; Nature Reviews Immunology; Nature Reviews Cancer; Carcinogenesis
2006	Nature Reviews Cancer; Nature; Nature Med; Cell; Can Res; Clinical Can Res; J Exp Med; Cancer Cell; Am J Pathol; J Cell Biology
2007	Cell; Nature; PNAS; J Cell Biology; Can Res; J Exp Med; Breast Cancer Research
2008	Cancer Cell; PNAS; J Immunology; Nature; J Exp Med; Trends in Genetics; Current Opinions in Investigational Drugs
2009	Cancer Cell; Cell; Nature; J Exp Med; J Clin Invest, Can Res; Int J Cancer; Oncogene, J Immunology
2010	Nature; J Exp Med; Nature Med; J Invest Dermatology; Cell; Cancer Cell; J Clinical Onc; PNAS; J Clin Invest; Can Res; Dis Mech Models; Cancer Immuno Immunother;
2011	Nature; Nature Med; Canc Res; Cancer Cell; J Clin Invest; Breast Cancer Research; PlosOne, PNAS; Oncogene; J Exp Med; Oncogene;
2012	PNAS; Can Res; Oncogene; Trends in Immunology; Nature; Clin Can Res; J Exp Med; Cancer Discovery; Immunity; J Cell Physio; JoVE; Immunity; J Clin Invest; BBA - Molecular Basis of Disease; Can Res; EMBO; Genes & Dev; Nature Cell Biol.; TREIMM; Blood; Nature Med; Science Transl Med;
2013	Cancer Discovery; Cell; Genes & Dev; Nature; Can Res, J Translational Medicine; J Exp Res, Nat Med; Frontiers in GI Science; Science Transl Med; Nat Comms; Lung Cancer;
2014	Cancer Cell; Cell; Nature Med; PNAS; J Exp Med; Can Res; Immunity; Can Disc; Br Can Res; Science Transl Med; Pancreas; PNAS;
2015	Science; Nat Rev Clin Onco; Trends in Immunol; Cancer Cell, Can Res; J Clin Invest; J Exp Med; J Natl Can Inst; Science Trans Med; Can Immunol Immunotherapy; Nature Med; Head and Neck; Life Science; JOVE; Cell; PNAS; Genes & Dev
2016	Science; Nature; Nature Cell Biol; Nature Med; J Immunol; Immunity; Genes & Dev; E-Life; Cell Reports; J Clin Invest; J Exp Med; Can Res; Can Immuno Res; Nature Rev Can; Sci Trans Med;
2017	Cell; Cell Reports; Can Immuno Res; Nature Immuno; J Clin Invest; B J Cancer; J Exp Med;
2018	Can Res; J Clin Invest; Nature; Oncolmm; Nat Comm; Immunity; Nat Immuno; Cancer Discovery; Cancer Cell; Cell;
2019	Cancer Cell; Carcinogenesis; Cell; Frontiers; Nat Comm; Sci Transl Med; Clin Can Res; J Exp Med.;

- Histopathology; J Clin Invest.; Meth in Enz; Nature Biomaterials; Sci Data;  
 2020 Cancer Cell; Carcinogenesis; Cell; Life Science; Nat Comm; Lab Invest; J Exp Med; The Oncologist;  
 Cancer Letters; Curr Opin Immuno.; Exp Rev.; Nature Cancer; Nature Genetics; Theranostics;  
 USCAP;  
 2021 Cell; Nat Comm;  
 2022 Nat Comm; Nat Cancer; JITC;

### University Service

#### **Oregon Health & Science University**

- 2012 - present Faculty member, Graduate program in Molecular & Cellular Biosciences  
 2012 - present Faculty member, OHSU Knight Cancer Institute, Program in Cancer Biology  
 2012 - 2013 Chair, Search Committee, Depts of Cell & Developmental Biology, Molecular and Microbial Immunology (Successful co-recruitments of **Evan Lind, Ph.D., Jeffrey Nolze, Ph.D.**)  
 2013 Chair, Search Committee, Depts of Cell & Developmental Biology, Molecular and Microbial Immunology, Biomedical Engineering, Knight Cancer Institute (Successful recruitments of **Amanda Lund, Ph.D.**)  
 2013 Co-Chair (with Chris Amling), Search Committee, Dept. of Cell and Developmental Biology, Dept of Urology and Knight Cancer Institute (Successful recruitment of **Kunyoo Shin, Ph.D.**)  
 2013 Chair, Search Committee, Dept. of Cell and Developmental Biology and Knight Cancer Institute (Successful recruitments of **Sudarshan Anand, Ph.D., Pepper Schedin, Ph.D., and Sara Courtneidge, Ph.D.**)  
 2012 Chair, V Foundation Scholar nomination committee  
 2013 - 2018 Member, Center for Women's Health, Internal Advisory Committee  
 2013 - 2019 Member, OHSU Research Council  
 2013 – present Member, Limited Submissions Grant Review Selection Committee.  
 2013 - 2018 Member, Oregon Clinical and Translational Research Institute (OCTRI) Research review committee  
 2013 - 2015 Member, Search Committee for Chair, Dept. of Medicine. (Successful recruitment of **Sharon Anderson, M.D., Ph.D.**)  
 2014 - 2016 Member, Research Roadmap Task Force 1  
 2014 Table Discussion Leader, 2<sup>nd</sup> Annual BIRCWH Northwest Women's Health Research and Leadership Conference, Portland OR  
 2014 – 2020 Member, Center for Women's Health, *Circle of Giving* grant review committee  
 2015 Co-Chair (with Melissa Wong) School of Medicine Search Committee, Collaborative Recruitment of **Naoki Oshimori, Ph.D.** Depts. of Cell, Developmental & Cancer Biology, Dept of Dermatology, and Dept of Otolaryngology, Head and Neck Surgery.  
 2015 Chair, Search Committee, Dept. of Cell, Developmental & Cancer Biology, and Brenden-Colson Center for Pancreatic Care (BCCPC). (Successful recruitment of **Mara Sherman, Ph.D.**)  
 2015 University Shared Resource working group. Chair: Peter Barr-Gillespie  
 2017 Co-Chair, Search Committee (with Tom Beer), Dept. of Cell, Developmental & Cancer Biology, Dept of Medicine and Div. of Hem/Onc, and Knight Cancer Institute (Successful recruitment of **Amy Moran, Ph.D.**)  
 2017 - 2018 Member, Search Committee, Chief Science Officer for School of Medicine. Disbanded search.  
 2018 Member, Search Committee, Chair, Department of Pathology. Successful recruitment of **Donna Hansel, M.D., Ph.D.**  
 2018 Co-Chair (with Charles Thomas) School of Medicine Search Committee, Collaborative Recruitment of **Joshua Walker, M.D., Ph.D.** Dept. of Radiation Medicine, Dept. of Cell, Developmental & Cancer Biology, and Knight Cancer Institute.  
 2018 Co-Chair (with Paul Flint) School of Medicine Search Committee, Collaborative Recruitment of **Ferdinando Pucci, Ph.D.** by Departments of Otolaryngology, Head & Neck Surgery and Dept. of Cell, Developmental & Cancer Biology.  
 2019 - 2020 Member, OHSU 2025 Research Council  
 2019 - present Melanoma & Skin Cancer Steering Committee, Dept of Dermatology and Knight Cancer Institute  
 2020 University response to COVID-19 (COVID-19 Testing Lab Set-up Task Force; Return to Research Task Force)  
 2020 Co-Chair (with Dr. Kenneth Azarow) Collaborative Recruitment of **Robert Eil, M.D., Ph.D.** Dept. of Surgery, Dept. of Cell, Developmental & Cancer Biology, and Knight Cancer Institute.  
 2020 Chair, Search Committee, Dept. of Cell, Developmental & Cancer Biology, Knight Cancer Institute (Successful recruitment of **Meghan Ruhland, Ph.D.**)  
 2020 - present Member, Steering Committee, *Immune Monitoring and Cancer Omics Services (IMCO)*  
 2020 - present OHSU Knight Cancer Institute Site Co-Leader, AstraZeneca *Partner of Choice Network*

2020 – present	Member, Search Committee: Physician-Scientist Assistant Professor, joint recruitment in Depts. of Radiation Medicine, Biomedical Engineering, and The Cancer Early Detection Advanced Research Center within the Knight Cancer Institute. <i>Ongoing</i>
2020	Member, Search Committee: Associate Dean, Diversity, Equity and Inclusion. School of Medicine.
2020 – present	Member, University Transition Task (UTT) force
2021	Member, Selection Council, Silver Family Foundation Faculty Excellence & Innovation Award
2021 – present	Chair, KCRB Vivarium Oversight Committee
2021 – present	Member, Research Faculty Compensation Task force, subcommittee for Measurement of Research Success Taskforce, Chair, David Ellison, M.D.
2021 – present	Member, Faculty Recognition and Awards Committee
2021	Chair, Search Committee, Dept. of Cell, Developmental & Cancer Biology, and Brenden-Colson Center for Pancreatic Care (BCCPC). (Successful recruitment of <b>Katelyn Byrne, Ph.D.</b> ).
2022	Co-Chair, Search Committee (with Dr. Shivaani Kummar), Dept. of Cell, Developmental & Cancer Biology, and Division of Hematology Oncology. (Successful recruitments of <b>Tanaya Shree, M.D., Ph.D.</b> ; <b>Megan Burgers, Ph.D.</b> ).
2022 – present	Member, The Healthy Oregon Project (HOP) advisory board.
2024	Member, Search Committee (chair, Dr. Greg Cote), Dept. of Cell, Developmental & Cancer Biology, and Division of Gastroenterology (Successful recruitment of <b>Molly Thomas, M.D., Ph.D.</b> ).

### University of California; SYSTEM WIDE

1992 - 1993	Graduate Student Representative, Dept. of Biological Chemistry Faculty Council, UCLA
2004	<i>ad hoc</i> Member External Advisory Panel; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles CA, USA
2009	Member, Site Visit Programmatic Review Group, Department of Pathology & Laboratory Medicine, UCLA School of Medicine. Graduate Council of the UCLA Academic Senate.

### University of California, San Francisco; CAMPUS-WIDE

1997	Presentation, Donor Seminar, UCSF Development Office
1998	Presentation, Donor Seminar, UCSF Development Office
1999 - 2012	Member, Graduate Program in BioMedical Sciences (BMS)
2000 - 2012	Member, Graduate Program in Biological Sciences (PIBS)
2000 - 2004	Member, Steering Committee, Ovarian Cancer Program Project Grant
2000 - 2005	Member, Scholarships and Awards Committee, Academic Senate, School of Medicine
2001 - 2012	Member, BioMedical Sciences Graduate Program (BMS) Executive Committee
2002 - 2004	Member, Medical Scientist Training Program Executive Committee
2004 - 2006	Member, Search Committee, Director of Molecular Imaging, Dept. of Radiology, Committee Chair: Ron Arenson, M.D. no successful recruitment
2004 - 2006	Member, BioMedical Sciences Graduate Program (BMS); Admissions Committee
2004	Organizer, BioMedical Sciences Graduate Program Retreat, Granlibakken, N. Lake Tahoe, CA USA
2004 - 2012	Member, Graduate program in Immunology
2005 - 2006	Member, Tissue Engineering Ladder-rank Faculty Search Committee, Dept. of Surgery. Committee Chair: Nancy Boudreau, Ph.D. Successful recruitment of Valerie Weaver, Ph.D.
2005 - 2009	Member, Ethel and Jane Sokolow Memorial Cancer Endowment Lectureship Committee.
2006	Member, Cancer Faculty Search Committee, Anatomy Dept., Committee Chair: Zena Werb, Ph.D. Successful recruitment of Jeroen Roose, Ph.D.
2006	Member, Faculty Advisory Committee for 2007 Journalist Seminar on <i>Inflammation and Disease</i> . Sponsored by Associate Vice Chancellor Barbara J. French
2007	Member, committee to select recipient of Dean's Postdoctoral Prize Lecture.
2007	Member, Faculty Search Committee for Restorative Neurosurgery and Stem Cell Neurobiology, VA Medical Center/UCSF NeuroSurgery. Committee Chair: Linda Noble, Ph.D.; Status: not filled.
2009	Member, Committee to choose 1 <sup>st</sup> Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology, School of Medicine, UCSF. Recipient: Thierry Jahon, M.D.
2010	Member, 2010 Selection Committee for the Hellman Family Early-Career Faculty Awards.

### University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

1999 - 2012	Member, Helen Diller Family Comprehensive Cancer Center
1999	Member, Cancer Center Research Building Space Review Policy Committee
1999 - 2002	Member, Mt Zion Animal Barrier Facility Committee
1999 - 2005	Member, Cancer Center Friday Seminar Series Committee
2000	Organizer and Chair, MZ Cancer Center Research Building Annual Retreat
2001 - 2012	Co-Director, Mouse Pathology Core



2001	Member, 'Star Performance Award' selection committee
2001	Presentation, Evelyn Herman Reception, UCSF Development Office
2001 - 2002	Member, Cancer Center Research Building, 'Cancer Center Faculty Working Group'
2001 - 2006	Member, Mouse Models of Human Cancer Working Group
2002 - 2003	Member, UCSF Mt Zion campus, Animal Protocol Review Committee
2002	Member, ACS IRG grant review committee
2002 - 2006	Steering Committee Member, Mouse Models of Human Cancer
2003	Member, Review Committee, UCSF Comprehensive Cancer Center Stewart Trust Award
2003 - 2009	Chair, UCSF Mt Zion Campus Animal Protocol Review Committee
2003	Member, Search Committee: Associate Director for Administration, UCSF Comprehensive Cancer Center (Erica Weber, recruited)
2004	Member, Review Committee, UCSF Comprehensive Cancer Center Stewart Trust Award
2006	Co-Organizer, UCSF CCC Annual Symposium, ' <i>Inflammation &amp; Cancer: Bench to Bedside</i> '.
2008	Chair, Committee to nominate Postdoctoral scholar for AACR 2008 Annual Meeting, Inaugural "Future Leaders, New Directions" Special Symposium. Nominee: Laura Soucek, Ph.D. (awarded)
2009 - 2012	Co-Leader, Program in <i>Cancer Immunity and Microenvironment</i>

### University of California, San Francisco, Cancer Research Institute

2001 - 2002	Member, Cancer Research Institute Membership Subcommittee
-------------	---

### University of California, San Francisco, Department of Pathology

2003	Member, Committee to recommend faculty for the <i>Robert E. Smith Endowed Chair in Experimental Pathology</i>
2004	Member, Search Committee, Ladder rank faculty, Physician-Scientist, Anatomic Pathology. Successful recruitment of Jay Debnath, M.D., Ph.D.
2007	Member, Search Committee, Ladder-rank faculty, Physician-Scientist, Pathology and Neuropathology. Committee Chair: Michael D Prados, M.D.; Status: open.
2008	Member, Search Committee, Ladder-rank faculty, Physician-Scientist, Experimental Pathology. Committee Chair: Benedict Yen, M.D.; Status: open
2009 - 2011	Member, Academic Merit and Promotions Committee; Pathology Dept.

### Public Service:

1990	Lecturer, Science Academy of Whittier, Summer Institute. Whittier College, Whittier, CA
1991	Organizer and Lecturer, Science Academy of Whittier, Summer Institute. Whittier College, Whittier, CA.
1993	Lecturer, Joslyn Community Center. Claremont, CA.
1994	Provided elementary educators with science-related supplies (photos, slides, fixed tissue samples).
1995	Co-Coordinator Hormone Research Institute, 'Take Our Daughters To Work Day', Univ. of Calif., San Francisco
1999	Discussant, American Cancer Society <i>14<sup>th</sup> Annual Excalibur Round Table</i> , San Francisco, CA, USA
2000	Speaker, American Cancer Society <i>San Mateo County Annual Volunteer Meeting</i> , San Mateo, CA, USA
2002	Photo credits and interviewed for ' <i>Misdiagnosis: Failure of Promising Cancer Treatment Starts Soul Searching by Researchers &amp; Drug Companies</i> ', in: <i>San Francisco Chronicle</i> , May 12, 2002.
2003	Interviewed for article ' <i>Body's First Defense May Be Root of Diseases</i> ', in: <i>The Washington Post</i> , February 20, 2003
2003	Interviewed for article ' <i>The Body on Fire</i> ', in: U.S. News & World Report, October 20, 2003
2004	Interviewed for comments in: <i>Science News</i> , ' <i>Early Warming: Inflammatory protein tied to colon cancer risk</i> ' February 7, 2004, Vol 165.
2004	Interviewed for article ' <i>The Fires Within</i> ', in: <i>TIME Magazine</i> , February 23, 2004
2004	Interviewed for comments on AACR Annual Meeting in: <i>Oncology Times</i> , ' <i>Exercise Reduces Inflammatory Response, May also Reduce Cancer Risk</i> ', Robert H Carlson, 26(11):33-34, June 10, 2004
2004	Interviewed for article ' <i>Inflammation and Cancer: The Link Grows Stronger</i> ', in: <i>Science</i> , 306, 966-968 (2004)
2005	Interviewed for article ' <i>Quieting a Body's Defenses</i> ', in: <i>Newsweek</i> , Special Edition, Summer 2005
2006	Interviewed for "Expert Commentary" by <i>BreastLink.org</i> , on article "Association Between Circulating White Blood Cell Count and Cancer Mortality." <i>Archives of Internal Medicine</i> , January 23, 2006; 166:188-194. <a href="http://www.breastlink.org/index.php?module=announce&amp;ANN_user_op=view&amp;ANN_id=208">http://www.breastlink.org/index.php?module=announce&amp;ANN_user_op=view&amp;ANN_id=208</a>
2007	UCSF Research Perspectives 2007 – Inflammation as Cause and Consequences of Disease, Media Event for Journalists, September 27, 2007, UCSF Mission Bay Campus
2007	On-Air radio interview by Dave Iversen, KQED <i>FORUM</i> , September 28, 2007 San Francisco CA USA
2012	Delta Kappa Gamma Society International, Winter Keynote Lecture; January 23, 2012, Fairfield, CA USA
2012	Continuing Education Webinar, Project LEAD, Center for NBCC Advocacy Training, National Breast Cancer Coalition
2013	Interview by eCancer: The immune microenvironment as an anti-cancer therapeutic strategy. <a href="https://www.youtube.com/watch?v=2DRkjERKjrE">https://www.youtube.com/watch?v=2DRkjERKjrE</a>

- 2013 Interview by Professor Nicholas Lemoine, on, *Inflammation and Cancer*.  
<https://www.youtube.com/watch?v=TMl8ZbnYLM>
- 2015 Panel discussant for The American Cancer Society, *The Future of Cancer Research*, Portland OR, USA
- 2015 Panel speaker. American Cancer Society, *Making Strides Initiative* Breakfast, Portland OR, USA
- 2016 Expert testimony, Department of Defense, Walter Reed Task Force on Metastatic Research. Bethesda MS. USA
- 2018 Interview, FoxNews.com, by Lindsay Carlton (Senior Producer), on 'Status of Immune Therapy'
- 2019 Susan G. Komen Oregon and SW Washington, **KEYNOTE SPEAKER**, Dinner event, Portland OR, USA

## IX. TEACHING AND MENTORING

### Formal Scheduled Classes for OHSU Students:

Qtr	Academic Yr	Course No. & Title	Teaching Contribution	Units	Class Size
S	2011/2012	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	20
S	2012/2013	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	20
S	2012/2013	CONJ665; <i>Development, Differentiation and Cancer</i>	Course Co-Director, Lecturer	3	10
S	2013/2014	HIP505; Human Investigations Program	Lecture: <i>Team Science: Secrets to success in interdisciplinary research across the lifespan</i>	2	13
S	2013/2014	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	12
S	2013/2014	CONJ665; <i>Development, Differentiation and Cancer</i>	Course Co-Director, Lecturer	3	12
F	2013/2014	CONJ650; The Practice and Ethics of Science	Discussion Leader	1	14
S	2014/2015	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	12
S	2014/2015	CONJ665; <i>Development, Differentiation and Cancer</i>	Lecturer: Cancer Histopathology, immune biology	3	7
F	2018/2019	CONJ650; The Practice and Ethics of Science	Discussion Leader	1	15

### Formal Scheduled Classes for UCSF Students:

Qtr	Academic Yr	Course No. & Title	Teaching Contribution	Units	Class Size
W	1997/98	IDS 100; Histology Laboratory	<i>Neoplastic Skin Histopathology</i> ; Laboratory lecture & instruction	10	150
W	1998/99	IDS 100; Histology Laboratory	<i>Neoplastic Skin Histopathology</i> ; Laboratory lecture & instruction	10	150
W	1999/00	IDS 100; Histology Laboratory	<i>Neoplastic Skin Histopathology</i> ; Laboratory lecture & instruction	10	150
S	1999/00	BMS 297A; Molecular Biology & Pathology of Neoplasia	<i>Animal Models of Cancer Laboratory</i> ; Laboratory lecture & instruction	3	15
S	2000/01	BMS 297A; Molecular Biology & Pathology of Neoplasia	<i>Animal Models of Cancer Laboratory</i> ; Laboratory lecture & instruction	3	15
W	2000/01	BMS 225; Tissue and Organ Biology	Lecture and laboratory instruction	3	15
S	2000/01	BMS 260; Cell Biology	Discussion group leader	1	6
F/W	2001/02	IDS 101; Prologue	Laboratory Instructor	9	30
W	2001/02	BMS 225; Tissue and Organ Biology	Lecture and laboratory instruction	3	15
W	2001/02	IDS 103; Cancer Block	<i>Invasion &amp; Metastasis</i> ; Lecturer	7	150
S	2001/02	BMS 260; Cell Biology	Discussion group leader	1	7
F	2002/03	BMS 260; Cell Biology	Discussion group leader	1	6
W	2002/03	IDS 103; Cancer Block	<i>Invasion &amp; Metastasis</i> ; Lecturer	7	150
F/W	2002/03	IDS 101; Prologue	Laboratory Instructor	9	30

F	2003/04	BMS 260; Cell Biology	Discussion group leader	1	6
S	2003/04	BMS 225B; Tissue and Organ Biology	Lecturer and Laboratory Instructor	1.5 - 5	tbd
W	2003/04	Biochem 297; Molecular Biology & Pathology of Neoplasia	<i>Angiogenesis</i> : Lecturer	3	30
W	2003/04	BMS 297A Molecular Biology & Pathology of Neoplasia Laboratory	Lecturer and Laboratory Instructor, <i>Animal Models of Neoplasia</i>	1	10
S	2003/04	BMS 225B; Tissue & Organ Biology	Lecturer: Cancer I & Cancer II	1.5 - 5	16
F	2004/05	BMS 260; Cell Biology	Discussion group leader	1	6
F	2005/06	BMS 260; Cell Biology	Discussion group leader	1	7
W	2006/07	Biochem 297; Molecular Biology & Pathology of Neoplasia	<i>Inflammation and Cancer</i> : Lecturer	3	30
W	2008/09	BMS230; Cellular & Molecular Biology of Cancer	Course Co-Director	3.5	22
W	2008/09	BMS230; Cellular & Molecular Biology of Cancer	Lecturer: <i>Cancer Microenvironments; Inflammation and Cancer</i>	3.5	22
W	2010/11	BMS230; Cellular & Molecular Biology of Cancer	Course Co-Director	3.5	22
W	2010/11	BMS230; Cellular & Molecular Biology of Cancer	Lecturer: <i>Tumor cell heterogeneity; Cancer Microenvironments; Inflammation and Cancer</i>	3.5	22

**Postgraduate and Other Courses:**

1989	M204, <i>Biochemistry Lab</i> Univ. of Calif., Los Angeles	Student Teaching Assistant for quarter long course (100 medical students)
1989	Biology 250, <i>Human Heredity</i> , Dept. of Biology Whittier College, Whittier CA	Organized and taught entire lecture-based course (30 undergraduate students)
1990	Biology 350 & 350L, <i>Molecular Genetics</i> ; Dept. of Biology, Whittier College, Whittier CA	Organized and taught entire lecture and laboratory course (16 undergraduate students)
1990	M204, <i>Biochemistry Lab</i> Univ. of Calif., Los Angeles	Student Teaching Assistant for quarter long course (100 medical students)
1990	Biology 250, <i>Human Heredity</i> , Dept. of Biology Whittier College, Whittier CA	Organized and taught entire lecture-based course (30 undergraduate students)
1992	Biology 350 & 350L, <i>Molecular Genetics</i> ; Dept. of Biology, Whittier College, Whittier CA	Organized and taught entire lecture and laboratory course (16 undergraduate students)
2002	Graduate <i>Oncology</i> , University of Missouri, Columbia, MS, USA	Invited Guest Lecturer: Lecture syllabus & delivered 2-hr lecture for course (15 students, graduate, medical & postgraduate fellows)
2003	Graduate Program in Cancer Biology, Stanford Univ., Stanford, CA USA	Invited Guest Lecturer: Delivered 1-hr lecture to graduate students in Cancer Biology Graduate program
2004	Graduate Program in Immunology, Stanford Univ., Stanford, CA USA	Invited Guest Lecturer: Delivered 1-hr lecture to graduate students in Immunology Graduate program
2005	UCSF Dermatology residents' Basic Science Seminar Series	Invited Guest Lecturer: Delivered 1-hr lecture to UCSF Dermatology Residents (11 M.D. and M.D., Ph.D. Residents)
2008	ISREC, Lausanne Univ. and Lausanne Ludwig Institute	Guest Instructor: <i>Exploring the Tumor microenvironment</i> , postgraduate course. (20 PhD students, 3 hours of instruction)
2009	OOA Course: Tumor Microenvironment; The Netherlands Cancer Institute	Guest Faculty: (4.5 hours of instruction, 25 PhD students)

2010	25 <sup>th</sup> Annual Harvard Tumor Course: Critical Issues In Tumor Microenvironment, Angiogenesis & Metastasis: <i>From Bench to Bedside &amp; Back</i>	Faculty member: (2 hours of instruction. 100 students)
2010	Eppler Institute for Research in Cancer, Univ. of Nebraska Medical Center. Short Course in Cancer Biology: Metastasis and the Tumor Microenvironment	Faculty member: (3 hours of instruction, 166 students)
2010	San Francisco State University, Dept of Biology Seminar Series	Guest Faculty: (1 1/2 hour of instruction, 75 students)
2010 - present	25 <sup>th</sup> , 26 <sup>th</sup> , 27 <sup>th</sup> , 28 <sup>th</sup> , 30 <sup>th</sup> , 31 <sup>st</sup> , 32 <sup>nd</sup> , 33 <sup>rd</sup> , 34 <sup>th</sup> , 35 <sup>th</sup> , 36 <sup>th</sup> , 37 <sup>th</sup> , 38 <sup>th</sup> , 39 <sup>th</sup> , 40 <sup>th</sup> Annual Harvard Tumor Course: Critical Issues in Tumor Microenvironment, Angiogenesis & Metastasis:	Faculty member: (2 hours of instruction. 50-100 students when in-person; for 35 <sup>th</sup> course in 2020, 123 students virtual due to covid-19; courses in 2021-2024 enrolled 65-100 students for virtual attendance; In person returned in 2025.
2017, 2019-2022	Jackson Laboratory Short Course on Experimental Models of Human Cancer, Bar Harbor, MN	Faculty member (2 hours of instruction. 50 students in 2017 and 2019; 2020-2021 was virtual with ~650 participants); 2022 was hybrid with 350 registrants
2021	Biology of Cancer, Sidney Kimmel Comp. Cancer Center at Johns Hopkins University	Lecturer (2 hours of instruction). 35 students; Virtual.

### High School and Undergraduate Students Supervised or Mentored:

Dates	Name	Program or School	Faculty Role	Current position
1998	Christopher Tinkle	Undergraduate, Univ. of Texas, Austin, TX, USA	Summer Intern Supervisor	Ph.D. awarded 2008; M.D. awarded 2010; Rad/Onc Residency, UCSF Asst Prof, St Judes Childrens Hospital, TENN
2000	Adam Zucker	Undergraduate, Oberlin College, Ohio USA	Summer Intern Supervisor	unknown
2000	Ashkan Hirari	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA, USA	Summer Intern Supervisor	unknown
2001	Jason Reuter	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA	Summer Intern Supervisor	unknown
2002	Destinee Cooper	Undergraduate, Univ. of Calif., Davis USA	Summer Intern Supervisor	unknown
2006	Sunum Mobin	UCSF Science & Health Education Partnership: High School Intern Program	Summer Intern Supervisor	unknown
2008-2009	Julia Lam	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA	Independent study (199), Mentor	B.S. awarded 2009
2010	Scott Keil	Undergraduate, The University of Glasgow, Scotland	Summer Intern Supervisor	B.S. awarded 2012
2010-2011	Heather Chen	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA	Summer Intern Supervisor	unknown
2010	Amy Desalazar	Cupertino High School Cupertino, CA USA	Summer Intern Supervisor	unknown
2010-2011	Nikhil Wadhwani	Undergraduate, Sarah	Summer Intern	B.S. awarded 2012

		Lawrence College, Bronxville, NY USA	Supervisor	
2010	Sharfa Junaid	Undergraduate, Univ. of Calif., San Diego, San Diego CA USA	Summer Intern Supervisor	unknown
2010-2011	Jon Lau	University of Nevada, Reno, Reno, Nevada	Summer Intern Supervisor	unknown
2011	Kara Wang	Undergraduate, Pomona College, Claremont, CA USA	Summer Intern Supervisor	unknown
2011	Graham Litchman	Undergraduate, San Francisco State Univ, San Francisco CA	Summer Intern Supervisor	unknown
2011	Jessica Wignall	Smith College, Northampton, MA USA	Summer Intern Supervisor	unknown
2013	Alexander Rosenbusch	University of Erlangen- Nuremberg, Germany	Mentor	Master's Student, University of Erlangen- Nuremberg, Germany
2013	Alexandra Forsythe	Scripps College, Claremont CA USA	CDCB Summer Intern Program	unknown
2014	Christine Ho	Univ of Calif., Berkeley	CDCB Summer Intern Program	Undergraduate, UC Berkeley
2014	Reid M Goodman	Pomona College, Claremont CA	CDCB Summer Intern Program	Medical School
2015	Chase Smith	Univ of Calif., Berkeley	CDCB Summer Intern Program	Medical School
2015	Amy LI	Portland State University	CDCB Summer Intern Program	unknown
2015	Miriam Marx	State University of New York	CDCB Summer Intern Program	unknown
2015	Ava Young	International School of Beaverton, OR USA	Ted R. Lilley Cancer CURE Program; mentor	unknown
2015-2016	Lia Kim	Asia Pacific International School, Hauula, HI USA	Emperor Science Award Program and CDCB Summer Intern Program	unknown
2016	Lea Garzotto	St. Mary's Academy Portland OR	CDCB Summer Intern Program	unknown
2016	Shiv Shah	Arizona State University	CDCB Summer Intern Program	unknown
2016	Julia Yu	Emory University	CDCB Summer Intern Program	unknown
2016	Catherine Sher	Univ. of New Mexico	CDCB Summer Intern Program; Supervisor	unknown
2016	Kenna Leis	University of Oregon	CDCB Summer Intern Program	unknown
2017	Rowan Talbot- Guerette	University of Rhode Island	CDCB Summer Intern Program	unknown
2017	Daniel Tolstrup	Seattle Pacific University	CDCB Summer Intern Program	unknown
2017	Hannah Zhao	University of Southern California	CDCB Summer Intern Program	unknown
2017	Jane Compton	Northeastern University	CDCB Summer Intern Program	unknown
2017	Jessica Jue	Carnegie Melon University	CDCB Summer Intern Program	unknown
2018	Ward Kirschbaum	Cal Poly San Luis Obispo	CDCB Summer Intern Program	unknown



2018	Ruben Sanchez Flores Jr	University of Oregon	Ted R. Lilley Cancer CURE Program; mentor	unknown
2022	Emma Jenkins	Pacific University, OR	CDCB Summer Intern Program	Undergraduate, Pacific University, OR
2022	Briana Johnson	Middlebury College, VT	Murdock Scholar	Undergraduate, Middlebury College, VT
2022	Bristol Ozturgut	Portland Community College, Portland OR	CDCB Summer Intern Program	Undergraduate, Portland Community College, Portland OR
2022	Nolan Gregg	Indiana University, Bloomington, IN	CDCB Summer Intern Program	Undergraduate, Indiana Univ., Bloomington, IN

**Predoctoral Students Supervised or Mentored:**

Dates	Name	Program or School	Faculty Role	Current position
2000 - 2003	Jin-Sae Rhee	UCSF M.D., Ph.D.,	Ph.D. supervisor	M.D., Ph.D. awarded 2005; Pediatrician (Private Practice) San Jose, CA
2000	Maria Christophorou	UCSF BMS, graduate student	Faculty coach, BMS 297	Ph.D. awarded 2006
2001	Leslie Chu	UCSF BMS, graduate student	Rotation Supervisor	Ph.D. awarded 2005
2001	Rayna Takaki	UCSF BMS, graduate student	Rotation Supervisor	Ph.D. awarded 2006
2001 – 2002	Sophia Bruggerman	University of Nijmegen, The Netherlands	Masters Thesis Supervisor	Ph.D. awarded 2007
2002	Lucy Lebedeva	UCSF PIBS, graduate student	Faculty coach, BMS 297	Ph.D. awarded 2005
2002	Leslie Chu	UCSF BMS, graduate student	Ph.D. Orals committee	Ph.D. awarded 2005
2002	Andre Whitkin	MSTP student, Cornell University USA	Supervised Summer work	unknown
2002	Karin de Visser	The Netherlands Cancer Institute, The Netherlands	Ph.D. Thesis Reading Committee	Ph.D. awarded 2002
2003	Cathy Collins	UCSF MSTP student	MSTP Advisor	PhD awarded 2009 M.D. awarded 2011
2004	Eric Tamm	University of British Columbia, Canada	Doctoral Dissertation External Examiner	Ph.D. awarded 2004
2004	Annie Hsieh	University of Södertörn, Sweden	Masters Thesis Supervisor	Unknown
2005	Geoff Benton	UCSF TETRAD/PIBS, graduate student	Ph.D. Orals committee	Ph.D. awarded 2011
2006	Morgan Truitt	UCSF BMS, graduate student	Rotation Supervisor	PhD awarded 2016
2006	Danielle Shin	UCSF MSTP student	Rotation Supervisor	Ph.D. awarded 2011
2006-2008	Celeste Rivera	SFSU/UCSF NIH Post-baccalaureate Research Experience Program (PREP) student	Masters Thesis Supervisor	M.S. awarded 2010;
2007-2009	Leslie Vasquez	SFSU/UCSF NIH Post-baccalaureate Research Experience Program (PREP) student	Masters Thesis Supervisor	M.S. awarded 2009
2008	Ashley Martin	UCSF BMS, graduate student	Rotation Supervisor	Ph.D. awarded 2012

2009	Kay Wiebrands	Master's Student Utrecht University, the Netherlands	Masters Thesis Supervisor	M.S. awarded 2009
2009-2010	David Tawfik	Medical Student III, UCSF	MSIII break year. Dean's Quarterly Research Fellowship; PACCTR Fall Quarter Fellowship;	M.D., awarded 2011;
2009-2012	Renee Vanderlaan	UCSF BMS, graduate student	Chair: Thesis Committee	Ph.D. awarded 2012
2009-2011	A. Preethi Ganessan, M.D., Ph.D.	Ph.D. Graduate Student Univ of Southampton	Ph.D. supervisor	Ph.D. awarded 2012 Associate Professor, Rady Children's Hospital of San Diego, UC San Diego, CA
2009-2014	Jasmine Lau	UCSF BMS, graduate student	Ph.D. Thesis Committee	Ph.D. awarded 2014
2010 - 2011	Lucia Cottone	Ph.D. graduate student (San Raffaele Institute, Milan Italy)	Ph.D. supervisor and 2 <sup>nd</sup> supervisor del candidato	Ph.D. awarded 2012; Postdoctoral fellow, University College London, GB
2011	Conny Hainer	Master's student, Technical University of Berlin, Berlin, Germany	Masters Thesis Supervisor	M.S. awarded 2012
2011-2012	Melissa Wheeler	PharmD student, UCSF	PharmD research mentor	PharmD awarded 2013
2011-2012	Paul Huynh	PharmD student, UCSF	PharmD research mentor	PharmD awarded 2013
2012	Derek Zachman	OHSU, MD/PhD and PMCB student	Qualifying exam committee	Ph.D. awarded 2018
2012-present	Tim Butler	OHSU, Cancer Biology graduate student, Spellman lab	Thesis committee	Ph.D. awarded 2016
2012	Katelyn Atkins	OHSU, CDB graduate student	Thesis Examiner	Ph.D. awarded 2012
2013, 2014	Xiaoming Ouyang	OHSU PMCB/CanBio graduate student. Kulesz-Martin lab	Rotation supervisor; Qualifying Exam Committee	Ph.D. awarded 2018
2013-2019	Shannon Liudahl	OHSU Can Bio graduate student Coussens lab	Rotation and Thesis supervisor	Ph.D. awarded 2019, Postdoctoral Fellow, Fred Hutchinson Cancer Center, Seattle WA
2013-2016	Charles Ghast	OHSU Can Bio/MSTP graduate student Coussens and Wong lab. Funding: T32 GM071388-10 (2014-15)	Rotation and Thesis supervisor	M.D., PhD. awarded 2018 Private Practise
2013	Tyler Risom	OHSU Can Bio Graduate Program	Qualifying Exam committee	PhD awarded 2018 Staff Scientist, Genentech, Ic
2014	David Messenheimer	OHSU CanBio Graduate program, Fox lab	Thesis committee	PhD awarded 2017
2014-2017	Spencer Watson	OHSU Can Bio Graduate Program; Gray lab	Thesis committee	PhD awarded, 2017 Postdoctoral Fellow, EPFL Switzerland
2014 - 2017	Courtney Betts	OHSU CDB Graduate	Thesis committee	PhD awarded 2017

		program, Schedin lab		Senior Scientist, Akoyo Inc.
2014	Zipei Feng	OHSU MSTP/CanBio Graduate program, Fox lab	Qualifying Exam committee	M.D., Ph.D. awarded 2018
2014 - 2017	Erica Goddard	OHSU CDB Graduate program, Schedin lab	Thesis committee	PhD awarded, 2017.
2016	Ryan Lane	OHSU CDB Graduate program, Lund lab	Qualifying Exam committee	PhD awarded, 2019
2016 - 2019	Kimberline Yang	Johns Hopkins Univ., CMM Graduate Program, Jaffee lab	External member, Thesis committee	PhD awarded, 2019
2018 - 2021	Elliot Gray	OHSU BioMedical Engineering (BME) graduate program	Thesis committee	MS awarded 2021
2019-2020	Femke Ehlers	PhD Graduate program, Univ. of Maastricht, The Netherlands	Research supervisor; 6-mo residency	PhD awarded ,2024
2020 - 2025	Katie Blise	OHSU BioMedical Engineering (BME) graduate program; 2025 New Innovator of the Year award (OHSU); Funding from 2025 OCTRI Biomedical Innovation Program: Device, Diagnostic, and Software	Research Co-mentor	PhD awarded, 2025
2020-2021	Nicky Beleen	PhD Graduate program, Univ. of Maastricht, The Netherlands	Research supervisor; 12-mo residency	Graduate program, Maastricht University

### Postdoctoral Fellows and Residents Directly Supervised or Mentored

Dates	Name	Position & Funding	Faculty Role	Current Position
2000 - 2001	Ernst Lengyel, M.D., Ph.D.	Post-Doc Researcher, Senior Clinical Fellow	Research Supervisor	Professor and Chair, Dept. Gyn. & Oncology, Univ. of Chicago
2000 -2002	Leon Van Kempen, Ph.D.	Post-Doc Researcher, Dutch Cancer Society Postdoctoral Fellowship	Research Supervisor	COO and Scientific Director Molecular Pathology Center at Jewish General Hospital, Dept. of Pathology, McGill University, Canada
2002 – 2005	Robert Diaz, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Senior Scientist, Applied StemCell, Menlo Park, CA
2002 – 2005	Karin de Visser, Ph.D.	Post-Doc Researcher, Dutch Cancer Society Postdoctoral Fellowship	Research Supervisor	Group Leader, The Netherlands Cancer Inst, Amsterdam, The Netherlands
2003 – 2007	Alexandra Eichten, Ph.D.	Post-Doc Researcher, Serono Fndt for the Advancement of Medical Science (2003-2005);	Research Supervisor	Staff Scientist, Regeneron Corp., New York USA
2003 - 2005	Stephen Robinson, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	unknown
2003 - 2004	H. Jennifer Shen, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	NCI-FDA Oncology Product Research/Review Fellowship

2005 -2010	David DeNardo, Ph.D.	Post-Doc Researcher; 1) NGA: 5T32CA09043 PI: BISHOP; <i>Molec. Analysis of Tumor Viruses</i> ; 2) Am Cancer Society Fellowship 2007-2010	Research Supervisor	Professor, Molecular Oncology and Immunology, Washington University, St Louis, St Louis MS USA
2005 –2007	Nor Eddine Sounni, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Principle Investigator, Univ. of Liege, Belgium
2006 –2007	Tingting Tan, M.D., Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Internal medicine, Private practice, San Francisco, CA
2006 -2010	Magnus Johansson, Ph.D., M.B.A.	Post-Doc Researcher; Swedish Cancer Society Fellowship 2006-08	Research Supervisor	Director, Global Product Pipeline Strategy, Medtronic Diabetes, Los Angeles CA
2006- 2012	Nesrine Affara, Ph.D.	Post-Doc Researcher; AACR-Astellas USA Fndt in Basic Cancer Research 2009-2010: T32 Cancer Biology 2010-2011	Research Supervisor	Faculty, Carnegie Mellon University, Doha, Qatar
2007 -2010	Pauline Andreu, Ph.D.	Post-Doc Researcher; Cancer Research Institute (CRI) Irvington Fellowship 2008-2011	Research Supervisor	Director, du Pôle Recherche – Faculty of Science, University of Paris. <b>France</b>
2008- 2015	Brian Ruffell, Ph.D.	Post-Doc Researcher; Dept of Defense Postdoctoral fellowship 2009-2012; K99 CA185325 Pathway to independence	Research Supervisor	Associate Professor, Moffitt Cancer Center, Tampa, FL USA
2009-2011	Stephen Shiao, M.D., Ph.D.	UCSF Radiation Oncology Hollman Fellow	Research Supervisor	Associate Professor, Cedars Sinai Med. Ctr, Los Angeles CA
2010-2012	Collin Blakeley, M.D., Ph.D.	UCSF Hematology-Oncology Fellow; T32 Hem/Onc Training Grant 2011-2013	Research Supervisor	Associate Professor, Div. Hematology & Oncology, UCSF
2010-2013	Anna Wasiuk, Ph.D	Post-Doc Researcher; Coussens grant	Research Supervisor	Senior Scientist, Celldex Therapeutics, NJ
2012 - 2015	Andrew Gunderson, Ph.D.	Post-Doc Researcher; T32, Immunology Training grant 2012-2014	Research Supervisor	Immunology Scientist, Dept. of Surgery, The Ohio State Univ., OH
2012 - 2013	Tina Bose, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	unknown
2012 - 2017	Terry Meddler, Ph.D.	Post-Doc Researcher; T32 Dermatology training grant, 2012-2014; Am. Cancer Society Postdoctoral Fellowship; NCI K22	Research Supervisor	Assistant Member, Earle A Chiles Research Institute, Portland OR
2012 - 2013	Aubie Shaw, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Assistant Professor, Medical School, Duluth, Univ. of Minnesota, MN
2012 - 2024	Sushil Kumar, Ph.D.	Post-Doc Researcher; Coussens grant; Collins Medical Trust	Research Supervisor	Research Asst. Prof, Coussens Lab, OHSU
2013 – 2014	Christopher Chan, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Chief Scientific Officer, Pio Therapeutics Pty Ltd, Australia
2014 - 2019	Dhaarini Murugan, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Scientist, Notch Therapeutics, Seattle WA

2014 - 2017	Takahiro Tsujikawa M.D., Ph.D.	Post-Doc Researcher; OCTRI-Translational Catalyst Grant	Research Supervisor	Assistant Professor, Kyoto Prefectural Univ of Medicine. JAPAN
2015-2017	Tiziana Cotechini, Ph.D.	Post-Doc Researcher; Canadian Institutes of Health Research (CIHR) Fellowship	Research Supervisor	Assistant Professor, Queen's University, Canada
2015-2016	Mahsa Huanhuan He, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Professor, Sun Yat-Sen University (SYSU) in Zhuhai, China
2016 - 2017	Rie Kawashima, DDS, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Private Practice Tokyo, Japan
2016-2017	Casey Means, M.D.	Resident Physician, 6-mo research rotation AHNS Endocrine Surgery Section Eisai Research Award	Research Supervisor	Private Practice
2017 - 2018	Grace Banik, M.D.	Resident Physician, 6-mo research rotation AHNS Endocrine Surgery Section Eisai Research Award	Research Supervisor	Assistant Professor, Oto. Head & Neck Surgery, Univ. of Calif, San Francisco
2017 - present	Amanda Poissonier, Ph.D.	Post-Doc Researcher; CRI Irvington Fellowship, 2019 (declined); BCRP DoD Breast Cancer Postdoctoral Fellowship 2019-2022	Research Supervisor	Research Assistant Professor, Coussens Lab, OHSU
2018 - 2019	Cecil Gomes, Ph.D.	Post-Doc Researcher; T32 Dermatology training grant	Research Supervisor	Scientist, Caris Life Sciences, AZ
2018 - present	Elvind Valen Egeland, Ph.D.	Post-Doc Researcher; FPIPRO Mobility Grant, Norway	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU
2019 - 2020	Jennifer Wherley, M.D., M.S.,	Resident Physician, 6-mo research rotation AHNS Endocrine Surgery Section Stryker Research Award	Research Supervisor	Private practice
2020 - 2022	Christian Huisman, Ph.D.	Post-Doc Researcher; Coussens funding	Research Supervisor	Private sector, unknown
2020 - present	Eric Berens, Ph.D.	Post-Doc Researcher NCI K99/R00	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU
2021-2022	Kristen Kramer, M.D.,	Resident Physician, 6-mo research rotation	Research Supervisor	Resident, Dept. Otolaryngology, Head & Neck Surgery, OHSU
2024 - present	Austin Wright, Ph.D.	Post-Doc Researcher; Coussens funding	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU

**FORMAL INTERNAL FACULTY MENTORING**

Dates	Name	Position while Mentored	Mentoring Role	Current Position
2001 – 2004	Ernst Lengyel, M.D., Ph.D.	Asst. Adjunct Professor, Dept of Hem/Onc, UCSF	Research Mentor	Prof., and Chair, Dept. Gyn. & Oncology, Univ. of Chicago, Chicago, IL
2002 – 2007	Darya Soto, M.D.	Asst. Adjunct Professor, Dept of Medicine, UCSF	K08 Research Mentor	Private Practice, Burlingame, CA
2005 – 2007	Runi Chattopadhyay, M.D.	Clinical Instructor and Clinical Fellow, ept of Medicine, UCSF	Basic Science Mentor, K12	Private Practice, San Francisco, CA
2006 – 2011	Limin Liu, Ph.D.	Assistant Professor,	Member, Mentoring	Dept. of Microbiology &



		Dept of Immunology, UCSF	Committee	Immunology, Sandler Center for Basic Research in Asthma, UCSF
2010 - 2011	Jaynata Debnath, M.D., Ph.D.,	Assistant Professor, Dept of Pathology, UCSF	Faculty Mentor	Professor, Dept. of Pathology, UCSF
2014-2020	Amanda Lund, PhD.	Associate Professor, Dept of Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	Associate Professor, NYU Langone Medical Center
2014-present	Sud Anand, PhD.	Associate Professor, Dept of Cell, Develop, & Cancer Biol, OHSU	Member, Mentoring Committee	same
2014-2016	Kunyoo Shin, PhD.	Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	S. Korea, unknown
2014 - 2018	Xiaolin Nan, PhD	Assistant Professor, Dept. of Biomedical Engineering, OHSU	Member, Mentoring Committee	Associate Professor, CEDAR, OHSU
2015 – 2019	Anupriya Aggarwal, Ph.D.	Associate Professor, Dept. of Medicine, OHSU	Member, Mentoring Committee	same
2016 – present	Laura Heiser, Ph.D.	Associate Professor, Dept. of Biomedical Engineering (BME), OHSU	Member, Mentoring Committee	Vice Chair, BME, OHSU
2016 – 2017	Gulu Gorgun, Ph.D.	Assistant Professor, Dept. of Medicine, Hem/Onc Division, OHSU	Member, Mentoring Committee	unknown
2016-present	Naoki Oshimori, PhD.	Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	same
2016 - 2024	Mara Sherman, Ph.D.	Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	same
2018 - present	Julia Maxon, PhD	Assistant Professor, Dept. of Medicine, Hem/Onc Division, and Dept of Cell, Development & Cancer Biology OHSU	Member, Mentoring Committee	same
2017 - present	Amy Moran, Ph.D.	Assistant Professor, Dept of Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	same
2017 - present	Joshua Walker, M.D, Ph.D.	Assistant Professor, Dept of Radiation Medicine, and Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	same
2019 - 2025	Ferdinando Pucci, Ph.D.	Assistant Professor, Otolaryngology, Head & Neck Surgery, and Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	same

2020 – present	Robert Eil., M.D., Ph.D.	Assistant Professor, Surgery, and Cell, Development & Cancer Biology, OHSU	Member, Mentoring Committee	same
2020 – present	Megan Ruhland, Ph.D.	Assistant Professor, Cell, Development & Cancer Biology, and Dermatology, OHSU	Member, Mentoring Committee	same

**FORMAL EXTERNAL FACULTY MENTORING**

Dates	Name	Position while Mentored	Mentoring Role	Current Position
2001 - 2024	Mikala Egeblad, Ph.D.	Post doctoral Fellow (Werb Lab), UCSF, CA USA; Assistant/Associate/Full Professor, Cold Spring Harbor Laboratory, NY USA	External post-doctoral and faculty mentor	Full Professor, Johns Hopkins University, Baltimore MD
2003-2011	Sheila Stewart, Ph.D.	Assistant Professor of Cell Biology & Physiology, Washington Univ., St Louis, MO, USA	External faculty mentor	Professor of Cell Biology & Physiology, and Medicine, Washington Univ., St Louis, MO, USA
2005-2015	Neta Erez, Ph.D.	Post doc. Fellow, Hanahan Lab, UCSF CA USA Assistant Professor,	External post doctoral (2005-2010)/faculty (2010-2015) mentor	Professor and Vice Dean, Faculty of Medicine, Tel Aviv Univ. Tel Aviv, Israel
2005-2021	Sandra McAllister, Ph.D.	Post doctoral fellow Weinberg lab (2005-2009); Assistant Professor of Medicine, Harvard Medical School (2010-2021)	External faculty mentor	Associate Professor of Medicine, Harvard Medical School; Associate Scientist, Brigham & Women's Hospital, Boston MA USA
2012-2017	Jennifer Guerriero, Ph.D.	Post doctoral fellow (Letai lab), Dana Farber Cancer Inst; A	External post doctoral mentor	Assistant Professor, Brigham and Women's Hospital, Boston MA USA
2012 - present	Michele De Palma, Ph.D.	Assistant Professor, School of Life Sciences Swiss Federal Inst of Technology (EPFL) Lausanne, Switzerland	External faculty mentor	Associate Professor, School of Life Sciences Swiss Federal Inst of Technology (EPFL); Co-director, ISREC, Lausanne, Switzerland
2021 - present	Evanthia Roussos-Torres, M.D., Ph.D.	Assistant Professor of Medicine, Oncology Univ. of Southern Calif. Los Angeles, CA USA	External faculty mentor/Scientific Advisor	Assistant Professor of Medicine, Oncology Univ. of Southern Calif. Los Angeles, CA USA

**Sabbatical Visitors:**

1999 - 2000 Yves DeClerck, M.D. Professor, Univ. of Southern Calif. & Children's Hospital Los Angeles

**X. INVITED LECTURES AND SEMINARS****National and International Symposia and Workshops****1994**

- *Current Transgenic Technology*, B & K Universal, San Mateo, CA, USA

**1996**

- *Human Tumor Heterogeneity II: Cytometric Measurement of Growth Regulation and Genetic*

Alterations: International Society of Analytical Cytometry. Kananaskas, Alberta, Canada.

## 1997

- *GeneMedicine-Boehringer Mannheim Cancer Alliance: Technology Workshop*. Cancún Mexico.
- *Biology of Proteolysis*, Cold Spring Harbor Laboratory, NY, USA
- *Molecular Biology & Pathology of Neoplasia*, AACR, Keystone, CO, USA
- *Matrix Metalloproteinases*, Gordon Research Conference, Proctor Academy, New London, NH, USA

## 1998

- *Proteolysis*, Gordon Research Conference, Colby-Sawyer College, New London, NH, USA
- *Cellular Targets of Viral Carcinogenesis*, AACR Special Conference. Dana Point, CA, USA
- *Mechanisms of Tumor Growth & Invasion Mediated by Proteolysis*, UCSF-Molecular Design Institute. San Francisco, CA, USA
- *Tumor Microenvironment*, Education Session, AACR Annual Meeting. Philadelphia, PA, USA

## 1999

- *Matrix Metalloproteinases*, Gordon Research Conference, Colby-Sawyer New London, NH, USA.

## 2000

- *Epithelial-Stromal Interactions & Tumor Progression Workshop*, National Cancer Inst., Bethesda, MD, USA
- 10<sup>th</sup> National Conference of the Inflammation Research Association, Hot Springs, VA, USA

## 2001

- 'Meet-the-Expert' Sunrise Session, AACR Annual Meeting, New Orleans, LA, USA
- 2<sup>nd</sup> Annual International Protease Society. Freising, Germany.

## 2002

- 6<sup>th</sup> International Symposium on Predictive Oncology & Intervention Strategies, Pasteur Institute, Paris, France
- *Dutch Cancer Society Annual Symposium*, Luntern, The Netherlands
- *Cancer: Genome, Signal & Environment, Takeda Genome Urology International*, Kyoto, Japan
- *Chemotherapy of Experimental & Clinical Cancer*, Gordon Research Conference, Colby Sawyer College, New London, NH, USA
- *Proteolytic Enzymes & their Inhibitors*, Gordon Research Conference, Colby Sawyer, New London, NH, USA
- *From the Cancer Cell to a Tumor - Tumors as Outlaw Organs*, Schilling Research Conference, The American Cancer Society, Aptos CA, USA
- *Cancer Intervention 2002*, Van Andel Research Institute, Grand Rapids, Michigan USA
- *Pathobiochemistry B Study Section Workshop*, Natl. Cancer Institute, Hilton Head, SC, USA
- *Proteases, Extracellular Matrix and Cancer*, AACR Special Conference, Hilton Head Island, SC, USA
- *ECM and Cancer*, Minisymposium, ASCB Annual Meeting, San Francisco, CA, USA

## 2003

- 2<sup>nd</sup> Annual International Symposium on Epithelial Biology, Timberline, Oregon USA
- *Matrix Metalloproteinases*, Gordon Research Conference, Big Sky, Montana, USA
- *Angiogenesis & Microcirculation*, Gordon Research Conference, Salve Regina, Newport R.I., USA
- *Inflammatory Cells and Cancer*, Symposium, American Society of Hematology 2003 Annual Meeting, San Diego, CA, USA
- *Validation of a Causal Relationship: Criteria to Establish Etiology*, National Cancer Institute, Cancer Etiology Branch, Washington, DC, USA.
- *Functional Imaging of Proteolysis*, Special Session, ASCB Annual Meeting, San Francisco, CA, USA

## 2004

- 10<sup>th</sup> International Congress of the *Metastasis Research Society*, 'Progress Against Tumor Progression', Genoa Italy
- Scleroderma Research Foundation Annual Scientific Workshop, San Francisco, CA, USA
- *Systems Biology of Cancer: The Tumor as an Organ*, Symposium, 95<sup>th</sup> AACR Annual Meeting. Orlando, FL, USA
- *Inflammation and Cancer*, Symposium, 95<sup>th</sup> AACR Annual Meeting. Orlando, FL, USA
- *Remarkable Role of the Microenvironment in Development and Disease Pathogenesis*, Symposium;

Experimental Biology 2004, Sponsored by: Assoc. of Anatomy, Cell Biology and Neurobiology, Washington, D.C., USA.

- *Molecular and Cellular Basis of Disease: Structure and Function of the Extracellular Matrix in Disease: Novel Roles and Regulation of MMPs and TIMPs in Disease*, Symposium; Experimental Biology 2004, Sponsored by: the Am. Society of Investigative Pathology, the American Society for Matrix Biology and the North American Vascular Biology organization. Washington, D.C., USA.
- Pacific Coast Protease Workshop, Half Moon Bay, CA, USA.
- 19<sup>th</sup> Aspen Cancer Conference: *Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy*. Aspen, CO, USA.

## 2005

- *International Consortium Meeting of the Children's Tumor Foundation: Molecular Biology of NF1, NF2 and Schwannomatosis*, Aspen, CO, USA
- *International Symposium on Systems Genome Medicine - Bench to Bedside*, Institute of Medical Sciences University of Tokyo, Tokyo, Japan
- *Immunotherapy of Cancer*, XI Annual Symposium of the Danish Cancer Society, Copenhagen, Denmark
- *4<sup>th</sup> General Meeting of the International Proteolysis Society*, Quebec City, Canada
- *Keystone Symposia, The Role of Microenvironment in Tumor Induction and Progression (J5)*, Banff, Alberta CANADA
- *Keystone Symposia, Inflammation and Cancer (B8)*, Breckenridge, CO, USA
- *Symposium on Inflammation, Repair and Carcinogenesis in Liver, Pancreas and Colon*. UCSF Liver Center and the Program in Gastrointestinal Cancer of the UCSF Cancer Center, Rohnert Park, CA, USA
- *In the Forefront of Advances in Cancer Research*, Symposium, 96<sup>th</sup> AACR Annual Meeting. Anaheim, CA, USA
- *Macrophage Symposium*, AMGEN, Seattle, WA, USA
- *Immune Response to Cancer Symposium*, 41<sup>st</sup> Annual Meeting, American Society Clinical Oncology (ASCO), Orlando. FL. USA
- *Phagocyte*, Gordon Research Conference, New London, CT, USA
- *Mouse Models of Human Cancer Consortium*, Annual Steering Committee Meeting, New Brunswick, NJ USA
- *Matrix Metalloproteinases*, Gordon Research Conference, Big Sky, Montana, USA
- *Annual Buffalo Regional Conference on Immunology*, Buffalo, NY, USA
- *Montagna Symposium on 'Tissue repair - molecular mechanisms and clinical challenges'*, Salishan Lodge, OR, USA
- *4<sup>th</sup> Annual AACR Conference on Frontiers in Cancer Prevention Research*, Baltimore MD, USA
- *AACR Special Conference, Cancer, Proteases and the Microenvironment*, Bonita Springs, Florida. USA

## 2006

- *Centro Nacional de Investigaciones Oncológicas (CNIO) Cancer Conference: Inflammation and Cancer*, Madrid SPAIN
- *18<sup>th</sup> Annual Pezcoller Symposium 'Tumor Microenvironment: Heterotypic Interactions'*, Trento ITALY
- *European Association for Cancer Research (EACR) 1<sup>st</sup> Annual Meeting*, Budapest HUNGARY
- *XXXIV<sup>th</sup> Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM: Tumor Biology, Detection and Therapy*, Pasadena, CA, USA
- *37<sup>th</sup> International Symposium of the Princess Takamatsu Cancer Research Fund 'Cancer Cells and Their Microenvironment'*, Tokyo, JAPAN
- *Timberline Annual Symposium on Epithelial Biology, Intrinsic and Microenvironmental Regulation of Epithelial Cancer'*, Timberline Lodge, Oregon, USA
- *Keystone Symposium, Molecular Targets for Cancer Prevention*, Granlibakken Resort, Tahoe City, CA, USA
- *Inflammation and Cancer*, Symposium, 97<sup>th</sup> AACR Annual Meeting. Washington, D.C., USA
- *Lineberger Cancer Center's 30<sup>th</sup> Annual Scientific Symposium*, University of North Carolina, Chapel Hill, North Carolina, USA

- *Vanderbilt-Ingram Cancer Center*, Vanderbilt University, Nashville TN, USA
- *Advances in Neuroblastoma Research 2006*, Los Angeles, CA, USA
- *Genetic, Cellular and Microenvironmental Determinants of Tumor Progression and Metastasis: A 'TPM' Workshop Honoring Martin L Padarathsingh, Ph.D.* TPM Study Section Workshop, Natl. Cancer Institute, Georgetown, VA, USA
- ASCO/Federation of European Societies Symposium: *Inflammation in Cancer Progression*, 2006 ASCO Annual Meeting, Atlanta, GA, USA
- AACR Special Conference, *Mouse Models of Cancer*, Cambridge, MA, USA
- AACR Special Conference, *Tumor Immunology: An Integrated Perspective*. Miami, FL, USA

**2007**

- *4<sup>th</sup> International Conference on Tumor Microenvironment*, Florence, ITALY
- *2<sup>nd</sup> International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy*, San Francisco CA USA
- CNIO – Nature Symposium on “*Oncogenes and Human Cancer*”. The Next 25 Years”, Madrid SPAIN
- *7<sup>th</sup> International Symposium on Hodgkin Lymphoma*, Cologne, GERMANY
- *Inflammation and Cancer: From molecular links to bed side*; Inaugural meeting for the *Istituto Clinico Humanitas*, Milan ITALY
- 7<sup>th</sup> AACR-Japanese Cancer Association Joint Conference: *In the Forefront of Basic and Translational Cancer Research*, Waikoloa, Hawaii, USA
- Keystone Symposium, *'Mouse Models at the Frontiers of Cancer Discovery'*, Whistler, British Columbia, CANADA
- Keystone Symposium *'Inflammation and Cancer'*, Santa Fe, NM, USA
- AAAS Annual Meeting, *Healthy Aging: Inflammation and Chronic Diseases'* Symposium, San Francisco, CA USA
- *Tumor Microenvironment and Tumor-Stromal Interactions* Workshop: Sponsored by Biogen Idec Inc., Oncology Discovery Research, San Diego CA USA
- American Thoracic Society Annual International Conference, *San Francisco Science: Inflammation, Immunity and Signaling*. San Francisco, CA USA
- 22<sup>nd</sup> Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy, Aspen CO, USA
- Gordon Research Conference, *Epithelial Differentiation & Keratinization*, Bryant University, Smithfield, RI, USA
- AACR, *Frontiers in Cancer Prevention Research Conference*, Philadelphia, PA, USA
- National Cancer Institute Workshop, *'Profiling of Immune Response to Guide Cancer Diagnosis, Prognosis and Prediction of Therapy'*, Bethesda, MD, USA

**2008**

- *7<sup>th</sup> Annual International Congress on the Future of Breast Cancer*, Kauai, Hawaii USA
- Cancer Research UK Cambridge Research Institute (CRI) Inaugural Annual Symposium, *'Unanswered Questions in the Tumour Microenvironment'*, Homerton College, Cambridge UK
- 5<sup>th</sup> International Kloster Seeon Meeting, *Angiogenesis: Molecular Mechanisms and Functional Interactions*. Kloster Seeon, GERMANY
- National Cancer Research Institute Annual Conference, Birmingham UNITED KINGDOM
- 47<sup>th</sup> Midwinter Conference of Immunologists, *'Meeting the challenge: Immunobiology in health and disease'*, Asilomar, CA USA
- AACR-TREC-NCI Conference on *Energy Balance and Cancer: Mediators and Mechanisms*, Lansdowne, VA USA
- Keystone Joint Symposium, *'Cell Death in the Immune System / Cell Death and Cellular Senescence'*, Beaver Run Resort in Breckenridge, CO, USA
- Keystone Symposium, *'Inflammation, Microenvironment and Cancer'*, Snowbird Resort in Snowbird, Utah, USA
- *Tumor Microenvironment Symposium*, Stony Brook University, Stony Brook. NY. USA
- Fox Chase Cancer Center 13<sup>th</sup> Annual Postdoctoral Fellow and Graduate Student Symposium, Philadelphia, PA USA



- DOD BCRP Era of Hope Meeting, Symposium Session: *Immune and Inflammatory Contributions to Breast Cancer*, AND *Era of Hope Spotlight Session*, Baltimore MD, USA
- AACR Centennial Conference: *Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine*; Hyatt Regency Monterey in Monterey, CA USA
- University of Michigan Comprehensive Cancer Center 2008 Fall Symposium, Ann Arbor MI, USA
- AACR Special Conference, *Chemical and Biological Aspects of Inflammation and Cancer*, Ko Olina Hawaii, USA
- International Society for Biological Therapy of Cancer (iSBTc), Workshop on Inflammation in Cancer Development, Westin Horton Plaza San Diego, CA USA
- Skirball Symposium, New York University School of Medicine, New York, NY USA
- AACR Special Conference in Cancer Research, *Tumor Immunology: New Perspectives*; Miami FL, USA

**2009**

- 21<sup>ST</sup> Lorne Cancer Conference, Lorne AUSTRALIA
- 6<sup>th</sup> International Symposium on the Intraductal Approach to Breast Cancer, Santa Monica CA USA
- International Cancer Conference, *CANCER 2009*, Dublin IRELAND
- 19<sup>th</sup> Annual BioCity Symposium, *'Tumor Microenvironment in Cancer Progression'*, Tirku FINLAND
- European Association of Cancer Research, Special Conference on *Inflammation and Cancer*, Berlin GERMANY
- 7<sup>th</sup> International Symposium on *Minimal Residual Cancer*, Athens, GREECE
- Tri-Society Annual Conference of the Society for Leukocyte Biology, International Cytokine Society, and the International Society for Interferon and Cytokine Research, Lisbon, Portugal
- 5<sup>th</sup> International Conference on Tumor Microenvironment, Versailles, FRANCE
- Italian Cancer Society Annual Meeting, Milano ITALY
- 1<sup>st</sup> Conference on *Regulatory Myeloid Suppressor Cells*, Clearwater, FL USA
- Keystone Symposium, *'Extrinsic Control of Tumor Genesis*, Vancouver, British Columbia CANADA
- *Inflammation and Cancer: Novel Aspects of Protumor Immunity*, Major Symposium, 100<sup>th</sup> Annual Meeting AACR, Denver CO USA
- 2<sup>nd</sup> Annual Retreat of the CCR-NCI Cancer and Inflammation Program, Gettysburg, PA USA
- 24<sup>th</sup> Annual Aspen Cancer Conference, Aspen, CO, USA
- Geoffrey Beane Cancer Research Symposium: *Inflammation and Cancer*, Memorial-Sloane Kettering Cancer Center, New York NY USA
- AACR Special Conference, *Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications*, San Diego CA USA
- NCI's National Tumor Microenvironment Network, Nashville TN USA

**2010**

- CHUV Research Day, University Hospital (CHUV) and the Faculty of Biology and Medicine, Lausanne, SWITZERLAND.
- NATURE - CNIO Cancer Symposium on *Frontiers in Tumour Progression*, Madrid SPAIN
- Joint Keystone Symposia, *Role of Inflammation in Oncogenesis/Molecular and Cellular Biology of Immune Escape in Cancer*, Keystone CO USA
- 3<sup>rd</sup> Annual Wyeth Discovery *Frontiers in Human Disease Symposium*, New York, NY USA
- Annual Meeting of the American Association for Cancer Research, Washington DC USA
- 10<sup>th</sup> Annual Oncology Research Symposium at MIT's Koch Institute for Integrative Cancer Research. Boston MA USA
- *Metastasis and the Tumor Microenvironment*, Short Course, Eppley Institute for Cancer Research, Univ of Nebraska, Omaha, NB USA
- *Cancer Cell Biology and Signaling Workshop*, ImClone Systems/Eli Lilly, New York NY, USA
- Center for Excellence in Immunology of the National Cancer Institute Symposium, Bethesda MD, USA
- 25<sup>th</sup> Annual Critical Issues in Tumor Microenvironment, *Angiogenesis and Metastasis*, Boston MA, USA
- Metastasis Research Society-AACR Joint Conference on *Metastasis and the Tumor Microenvironment*, Philadelphia, PA USA

- University of Vermont Cancer Center Clinical and Translational Research Symposium, *Inflammation & Cancer*, Burlington VT, USA
- Saban Research Institute *Annual Symposium, Honoring Yves DeClerck*, University of Southern California and Children's Hospital Los Angeles, Los Angeles CA, USA
- American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology, Concurrent Annual Meetings, Baltimore MD, USA

**2011**

- Curie Institute Symposium, *Breast Cancer from Biology to Clinics*, Paris FRANCE
- EPFL Inaugural Symposium, *Hallmarks and Horizons in Cancer*, Lausanne SWITZERLAND
- Joint meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Florence, ITALY
- 41<sup>st</sup> Australian Society for Immunology (ASI), Adelaide, South AUSTRALIA
- 11<sup>th</sup> Annual Meeting of NANT Consortium Investigators. Biology and Therapy of High Risk Neuroblastoma, Redondo Beach CA, USA
- 2<sup>nd</sup> International Conference on *Immunochemotherapy: Correcting Immune Escape in Cancer*, Philadelphia PA USA
- *The Biology of Cancer: Microenvironment, Metastasis & Therapeutics*, Cold Spring Harbor Laboratory Meeting Series. Cold Spring Harbor, NY USA
- 2<sup>nd</sup> NCI Tumor Microenvironment Network Junior Investigator Meeting, Cambridge, MA USA
- AACR Special Conference: *Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, Orlando Florida USA
- San Antonio Breast Cancer Conference, San Antonio, Texas USA

**2012**

- International Symposium of the Collaborative Research Center (ISCR), *Molecular Basis and Modulation of Cellular Interactions in the Tumor Microenvironment*, Cologne, Germany
- Keystone Symposium on *The Role of Inflammation During Carcinogenesis*, Dublin, IRELAND
- Federation of Clinical Immunology Societies (FOCIS) 2012, Improving Human Health Through Immunology, Vancouver, BC, CANADA
- Annual Meeting of the (French) National Institute of Cancer, Plenary session on "*Cancer Immunity and Inflammation*", Paris FRANCE
- 25<sup>th</sup> International IGB Workshop, organized by the Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Capri, ITALY
- 51<sup>st</sup> Midwinter Conference of Immunologists, Asilomar, CA USA
- *Tumor Heterogeneity: Challenges and Therapeutic Opportunities*, 103<sup>rd</sup> Annual Meeting of the AACR, Chicago, IL USA
- 2012 Scientific Colloquium of the Cancer Immunotherapy Consortium. *Immune Signatures in the Tumor and Beyond: Toward Predictive and Prognostic Markers*. Baltimore Maryland, USA
- AACR Special Conference on Pancreatic Cancer, Lake Tahoe NV, USA
- CELL Symposium, *Hallmarks of Cancer*, San Francisco CA USA
- AACR Special Conference, *Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances*, Miami FL, USA
- Karmonas Cancer Institute, Wayne State University School of Medicine, Annual Symposium: Tumor & Microenvironment. Detroit, MI USA.

**2013**

- Cancer Research Center of Lyon (CRCL), First International CRCL Symposium: *A Focus on Tumor Escape*. Lyon FRANCE
- 9<sup>th</sup> AACR-Japanese Cancer Association International Conference; Maui, Hawaii. USA
- 3<sup>rd</sup> Meeting on Immunochemotherapy, Paris FRANCE
- UK National Cancer Research Institute Annual Conference, Liverpool, ENGLAND
- Society of Surgical Oncology Annual Meeting, Washington D.C., USA
- Phagocytes Gordon Research Conference, Waterville Valley, NH, USA
- Salk Institute, Mechanisms and Models of Cancer Annual Symposium, La Jolla CA USA
- Society of Leukocyte Biology, *Regulators of Innate Cell Plasticity Effects in Host Defense* Newport

RI, USA

- 3<sup>rd</sup> Annual Women's Cancer Research Center Retreat, University of Pittsburgh Cancer Institute, Pittsburgh PA USA
- Society for Immunotherapy of Cancer, 28<sup>th</sup> Annual Meeting, National Harbor, MD, USA
- San Antonio Breast Cancer Symposium, Discussant, General Session 1. San Antonio, TX USA

## 2014

- 26<sup>th</sup> Lorne Cancer Conference, Lorne, AUSTRALIA
- 15<sup>th</sup> International Biennial Congress of the Metastasis research Society, Heidelberg, GERMANY
- 3<sup>rd</sup> International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets, Mykonos, GREECE
- Keystone Symposium, *Inflammatory Diseases: Recent Advances in Basic and Translational Research and Therapeutic Treatments*, Vancouver BC CANADA
- Breast Cancer Issues Conference, Portland, OR USA
- AACR Special Conference, *Cellular Heterogeneity in the Tumor Microenvironment*, San Diego, CA USA
- Keystone Symposium, *Immune Evolution in Cancer*, Whistler BC, CANADA
- AACR 105<sup>th</sup> Annual Meeting, Major Symposium: *Translating Preclinical Trials in Genetically Engineered Mouse Models toward Clinical Trials*, San Diego, CA USA
- AACR Annual Meeting, Education Symposium: *Phenotyping Solid Tumor Stroma*, San Diego, CA USA
- PancWest Symposium, Portland, OR USA

## 2015

- Cell Symposia; *Cancer, Inflammation, and Immunity*, Sitges, SPAIN
- 1<sup>st</sup> International Cancer Immunotherapy Conference: "Translating Science into Survival." Sponsored by, Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR). New York NY USA
- AACR International Conference on Frontiers in Basic Cancer Research. Philadelphia PA USA
- National Cancer Institute Intramural Program Retreat, Washington DC, USA
- 17<sup>th</sup> Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer, San Diego, CA USA
- Predictive Preclinical Models in Oncology conference, Molecular Medicine TriConference, San Francisco, CA USA
- Moores Cancer Center 11<sup>th</sup> Industry/Academia Translational Oncology Symposium, La Jolla, CA USA
- Keystone Symposium on *Dendritic Cells and Macrophages Reunited*, Quebec CANADA
- Fundamental Immunology and its Therapeutic Potential, Cold Spring Harbor Laboratory, NY USA
- AACR 106<sup>th</sup> Annual Meeting, "*Oncology Meets Immunology: Not Just Another Hallmark*", Philadelphia, PA USA
- New Horizons in Immunotherapy for Head and Neck Cancer, Newberg, OR USA
- NCI-sponsored workshop on Tumor Heterogeneity, Portland, OR USA
- 6<sup>th</sup> Annual Meeting of the American Pancreatic Association, San Diego CA USA

## 2016

- iMIG 2016, 13<sup>th</sup> International Conference of the International Mesothelioma Interest Group, Birmingham, UK
- Towards Predictive Cancer Models, ICREA and VHIO Symposium, Barcelona SPAIN
- International Association for Breast Cancer Research (IABCR), Portland OR USA
- NATURE – MSKCC conference "Cancer as an evolving and systemic disease". Memorial Sloan Kettering Cancer Center, New York, NY USA
- Keystone Symposia, "Cancer Pathophysiology: Integrating the Host and Tumor Environments", Breckenridge Co, USA
- AACR 107<sup>th</sup> Annual Meeting, Major Symposium "*Inflammation and Cancer: Targeting the Microenvironment*", New Orleans, LA USA
- AAI IMMUNOLOGY 2016, SITC Guest Society Symposium, "Overcoming Failure of Immune

Checkpoint Inhibition in Patients with Cancer”, Seattle WA USA

- National Cancer Institute, Annual Symposium, ‘*From Metchnikov to Systems Biology: The Role of Inflammation and Phagocytic Cells in Cancer*’, Bethesda, MD USA.
- SITC 31<sup>st</sup> Annual Meeting, National Harbor, Maryland, USA

## 2017

- BACR Tumour Microenvironment Meeting, Nottingham UNITED KINGDOM
- EACR-AACR-SIC Special Conference: Challenges of Optimizing Immuno and Targeted Therapies: From Cancer Biology to the Clinic. Florence ITALY
- 1<sup>st</sup> Crick Cancer Meeting, Francis Crick Institute, London UNITED KINGDOM
- Joint Meeting of Bioscience Societies, Buenos Aires, Argentina.
- Immunoterapia: La revolución en el tratamiento del cáncer. Aula Magna-Facultad de Ciencias Exactas y Naturales – University of Buenos Aires, Buenos Aires, ARGENTINA.
- National Cancer Institute, Division of Cancer Biology. Strategy Workshop on ‘Tumor Immune Microenvironment (TIME)’, Rockville, MD USA
- Keystone Symposia, “*Inflammation Driven Cancer: Mechanisms to Therapy/Microbiome in Health and Disease*”, Keystone, Colorado USA
- *Frontiers in Cancer Immunotherapy*, New York Academy of Sciences. New York, NY. USA
- Keystone Symposia, “*Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology*”, Whistler, British Columbia, CANADA.
- Annual Meeting of the American Association for Cancer Research, Education Session & Major Symposium. Washington, DC, USA
- Cell Symposia: Cancer, Inflammation, and Immunity. San Diego CA, USA

## 2018

- Horizons of Cancer Biology and Therapy – 2018, Swiss Cancer Center, Lausanne, SWITZERLAND
- Keystone Symposium, “Cancer Immunotherapy: Combinations”. Montreal, Quebec, CANADA
- 18<sup>th</sup> Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2018). San Francisco, California USA
- Joint Montagna Symposium & Annual PanAmerican Society for Pigment Cell Research Conference, “Melanoma to Vitiligo: The Melanocyte in Biology & Medicine”. Glenenden Beach, Oregon USA
- Forbeck Forum, Colorado Springs, CO USA
- AACR Special Conference: ‘*Tumor Immunology and Immunotherapy*’. Miami, FL. USA.
- San Antonio Breast Cancer Conference, San Antonio, TX USA

## 2019

- TEFAF Oncology Symposia, Maastricht University, Maastricht, The Netherlands
- ‘*Stress and inflammation in Tumor Progression and Metastasis Conference*’, Weizmann Institute of Science, Rehovot, ISRAEL
- 50<sup>th</sup> Princess Takamatsu International Cancer Symposium. Tokyo JAPAN
- Immunology LA Symposium, Los Angeles CA USA
- 2<sup>nd</sup> Triannual Symposium Highlighting Parnassus Campus Cancer Research in the HDFCCC, Univ., of California, San Francisco, CA., USA
- AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care. Boston MA, USA

## 2020

- 32<sup>nd</sup> Lorne Cancer Conference. Lorne AUSTRALIA
- EACR-AACR-ASPIC Basic and Translational Research Conference on *Tumor Microenvironment*. Lisbon, PORTUGAL
- Komen Scholar Annual Meeting, Dallas TX, USA
- 26<sup>th</sup> Congress of the European Association for Cancer Research, *Innovative Cancer Science: Better Outcomes Through Research*. Virtual meeting due to COVID-19.
- Keystone Symposium, *Myeloid Cells and Innate Immunity in Solid Tumors*. Virtual meeting due to COVID-19.
- CRUK Grand Challenge Key Concepts, *STORMing Cancer*. Virtual meeting due to COVID-19.

## 2021

- Tumor Myeloid Microenvironment Directed Therapeutics Summit. Virtual meeting due to COVID-19.
- Breast Cancer Workshop, *Tumor Microenvironment in Breast Cancer Progression*. Experimental Biology 2021. Virtual meeting due to COVID-19.
- **KEYNOTE ADDRESS**, 6<sup>th</sup> Meeting on the Biology of Cancer: Microenvironment & Metastasis, Cold Spring Harbor Laboratory Symposium, New York USA
- **KEYNOTE ADDRESS**, *Moving Breast Cancer Treatments Forward*, Jayne Koskinas Ted Giovanis Foundation for Health and Policy, Bethesda MS USA
- **KEYNOTE ADDRESS**, Society for Immunotherapy of Cancer (SITC) 36<sup>th</sup> Annual Meeting 2021, Washington DC, USA

**2022**

- Stanford Drug Discovery Symposium 2022, Palo Alto CA USA. *Virtual*
- 2022 Annual meeting of the National Foundation for Cancer Research, Washington DC, USA
- USCACA China-US Anti-Cancer Summit, *Virtual*
- HALLMARKS OF CANCER CELL SYMPOSIA, SAN DIEGO CA, USA

**2023**

- **PRESIDENTIAL ADDRESS**, 2023 AACR Annual Meeting, Orlando FL. USA
- JCA-AACR Precision Cancer Medicine International Conference, Kyoto, JAPAN
- CRI-ENCI-AACR Seventh International Cancer Immunotherapy Conference, Translating Science into Survival. Milano, ITALY

**2024**

- 2024 AACR Annual meeting, San Diego, CA USA
- **KEYNOTE ADDRESS**, Aspen Cancer Ideas Lecture, 2024 Aspen Cancer Conference, Aspen CO USA
- **RESEARCH BRIEFING**, National Academy of Sciences. Washington DC, USA
- AACR Special Conference in Cancer Research: Tumor-Body Interactions. The Roles of Micro- and Macroenvironment in Cancer. Boston, MA. USA

**2025**

- 2025 AACR Annual meeting, Chicago, IL USA
- New Horizons in Immunotherapy for Cancer, Portland OR USA
- CRUK-ACS The Cancer Prevention Research Conference, London UK

**Academic, Biotechnology and Pharmaceutical: Invited Presentations****1997**

- Biologic Therapy Research Conference. Univ. of Pittsburgh Medical Center, Pittsburgh, PA, USA
- Immunology Seminar Series. Univ. of Pittsburgh Medical Center, Pittsburgh, PA, USA

**1999**

- Axys Pharmaceuticals, South San Francisco, CA, USA
- Berlex Pharmaceuticals, Emeryville, CA, USA
- Axys Pharmaceuticals, La Jolla, CA, USA
- 14<sup>th</sup> Annual Excalibur Round Table, American Cancer Society, San Francisco, CA, USA
- Colloquium in Microbiology, Cell and Molecular Biology. San Francisco State Univ., San Francisco, CA, USA

**2000**

- Medical Genome Center, Division of Molecular Medicine, Australian National University, Canberra, A.C.T. AUSTRALIA.
- Chiron Corporation, Emeryville, CA, USA
- Oral and Pharyngeal Cancer Branch/NIDCR, National Institutes of Health, Bethesda, MD, USA
- Fibrogen, Inc., South San Francisco, CA, USA
- Scios Inc., Sunnyvale, CA, USA
- Molecular Biology Department, University of Southern California, Los Angeles, CA, USA

**2001**

- German Cancer Center, Heidelberg, GERMANY.
- MERCK Pharmaceutical, Darmstadt GERMANY.

- Dept. of Pediatric Hematology and Oncology, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA
  - Jonnson Comprehensive Cancer Center, Univ. of Calif., Los Angeles, Los Angeles, CA, USA
- 2002**
- Institute for Engineering and Medicine, Univ. of Pennsylvania, Philadelphia, PA, USA
  - Oncology Grand Rounds, Univ. of Missouri, Columbia, MO.
  - Cancer Center, Univ. of California, Davis, Davis CA, USA
  - AstraZeneca, Waltham, MA USA
  - Pharmacology Seminar Series, Dept. of Pharmacology, Wayne State Univ., Detroit, MI, USA
- 2003**
- University of Toronto, Ontario Cancer Institute & Princess Margaret Hospital, Toronto, Ontario, CANADA
  - Dept. of Biology, Univ. of Calif., San Diego, San Diego, CA USA
  - Tularik, Inc., South San Francisco, CA USA
  - Dept. of Cancer Biology's Cancer Metastasis Research Program Seminar Series, M.D. Anderson Cancer Center, Univ. of Texas, Houston, TX, USA
  - Dept. of Cancer Biology, Stanford University, Stanford, CA, USA
- 2004**
- Cancer Research UK, Barts & The London Queen Mary's School of Medicine & Dentistry, John Vane Science Center, Charterhouse Square, London, UNITED KINGDOM
  - Cancer Research UK, London Research Institute, Lincoln's Inn Fields Laboratories, London, UNITED KINGDOM
  - Burnham Cancer Institute, San Diego, CA, USA
  - The Wistar Cancer Institute, Philadelphia, PA, USA
  - Regeneron Pharmaceuticals, Inc. Tarrytown, New York, USA
  - Dana Farber Cancer Center, Harvard Medical School, Boston MA, USA
  - Indiana University, Herman B. Wells Center for Pediatric Research and Clinical Cancer Center, Indianapolis IN, USA
  - Immunology Graduate Program Seminar, Stanford University, Stanford, CA, USA
  - University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, British Columbia, CANADA
- 2005**
- Dept. of Nutritional Sciences & Toxicology, Univ. of Calif., Berkeley, Berkeley, CA USA
  - Rigel, Inc., South San Francisco, CA USA
  - Dept of Pathology & Lab Medicine, Univ. of California, Los Angeles, Los Angeles, CA USA
- 2006**
- Division of Cancer Biology and Angiogenesis in the Department of Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA USA
  - Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA
- 2007**
- Angiogenesis and Tumor Targeting Research Unit & Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, ITALY
  - *Lymphoma and Myeloma Conference*, M.D. Anderson Cancer Center, Houston, TX, USA
  - University of Minnesota, Dept. of Lab Medicine and Pathology, Minneapolis, MN, USA
  - Memorial-Sloan Kettering Cancer Center, Program in Cancer Biology and Aging, New York NY, USA
  - Abramson Family Cancer Research Institute and Univ. of Pennsylvania, Division of Hematology-Oncology, Philadelphia, PA USA
  - Albert Einstein College of Medicine, New York NY, USA
  - Oncology Division Research, Biogen Idec Inc., San Diego, CA USA
  - Genentech, Inc. Immunology Program. South San Francisco, CA USA
  - University of Iowa Carver College of Medicine, Dept of Pathology, *Pathology Grand Rounds*, Iowa City, Iowa, USA



- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
- University of Michigan, Program in Immunology and Cancer Research Series, Ann Arbor, MI USA

**2008**

- Institute of Cell Biology, ETH Zurich Switzerland
- Institute of Cancer and the CR-UK Clinical Centre, Barts & The London School of Medicine and Dentistry, London UNITED KINGDOM
- Department of Pathology/UCLA School of Medicine Seminar, Los Angeles CA USA
- University of Virginia, Charlottesville VA, USA
- Department of Cancer Biology, Meharry Medical College, Nashville, TN USA
- University of California, Davis Cancer Center, Sacramento, CA USA
- Department of Immunology, University of Pittsburgh School of Medicine. Pittsburgh, PA, USA
- Cancer Biology Series, Ben May Cancer Center, University of Chicago, Chicago, IL, USA
- National Cancer Institute Center for Cancer Research Grand Rounds Series in Clinical and Molecular Oncology. Bethesda MD, USA

**2009**

- University of South Hampton, UNITED KINGDOM
- The Netherlands Cancer Institute, Amsterdam, THE NETHERLANDS
- University of Michigan, Oral Health Sciences Program and Biomedical Engineering Seminar Series, Ann Arbor, MI USA
- Department of Pharmacology, Wayne State University, Detroit, MI USA
- Molecular Biology Seminar Series, Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Aurora, CO USA
- National Institutes of Health/National Cancer Institute, Vascular Biology Seminar Series, Bethesda MD, USA
- Genentech, Inc., Molecular Oncology Program. South San Francisco, CA USA
- Breast Cancer Network of Strength, California Breast Cancer Organizations, Northern California Affiliate, David CA USA
- Fred Hutchinson Cancer Center, Seattle WA USA

**2010**

- Institute of Cancer, Barts & London School of Medicine. London UNITED KINGDOM
- Cold Spring Harbor Laboratory, CSH NY USA
- Albert Einstein College of Medicine, New York, NY USA
- Department of Cell Biology & Physiology Washington University, St Louis, MO USA
- Cancer Center Seminar Series at Burnham Institute for Medical Research, San Diego CA, USA
- Oncology Seminar Series, MedImmune, Gaithersburg, MD, USA
- Immunology Institute Seminar Series, Mt Sinai School of Medicine, NY, NY USA
- San Francisco State University, Fall Seminar Series, San Francisco CA USA

**2011**

- McArdle Seminar in Cancer Biology series, Univ of Wisconsin-Madison, USA
- Duke University Medical Center, Durham, North Carolina USA
- Immunology and Infectious Disease Program, Dept of Veterinary and Biomedical Sciences, Pennsylvania State Univ. University Park, PA USA
- The Huck Institute, University Park, Pennsylvania State Univ. University Park, PA USA
- Weill Cornell Medical College of Cornell University, Center for Vascular Biology, NY USA
- Dana-Farber Cancer Institute and the Dana-Farber Cancer Institute, Boston MA, USA
- Tulane Cancer Center, Hematology & Medical Oncology, Tulane Univ. School of Medicine, New Orleans, LA USA
- Northwestern University Breast Cancer Research Program and Breast Cancer Research Seminar Series, Northwestern University, Chisago IL, USA
- Novartis Institutes for Biomedical Research, Emeryville CA USA
- FivePrime Therapeutics, South San Francisco, CA USA
- Abbott Biotherapeutics, Redwood City CA USA

**2012**

- Excellence in Genetics and Immunology Lecture Series, Complex Traits Group at McGill University, Montreal, Qc, CANADA
- German Cancer Aid, and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, GERMANY
- Cambridge Research Institute Distinguished Lecture, Cambridge UK.
- Brown Foundation Institute of Medicine, Univ. of Texas, Health Science Center at Houston, Houston TX USA
- Baylor College of Medicine, Houston TX USA
- Harvard Medical School's (HMS) Committee on Immunology Seminar Series
- Massachusetts General Hospital's (MGH) Seminar Series
- University of Rochester, Department of Microbiology and Immunology, Rochester, NY, USA
- Becton, Dickinson and Company, San Jose CA, USA
- Eisai, Inc. Andover MA, USA

**2013**

- University of Colorado, Denver-Anschutz Medical Campus, Cancer Biology Graduate Program Seminar. Denver, CO USA
- Earle A Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center, Portland OR. USA
- University of Wisconsin, Milwaukee, WI USA

**2014**

- University of Western Australia, Harry Perkins Institute for Medical Research, Seminar Series. Perth, AUSTRALIA
- Netherlands Cancer Institute, Amsterdam, The NETHERLANDS
- Institute Suisse de Recherche Experimentale sur le Cancer (ISREC), Lausanne SWITZERLAND
- Center for Cancer Research, National Cancer Institute, Eminent Lecture Series, Bethesda MD USA
- Huntsman Cancer Center, Salt Lake City UT, USA
- Halozyme Inc., San Diego Ca, USA
- Moffit Cancer Center, Tampa FL, USA
- Stanford University, Departments of Cancer Biology and Immunology, Palo Alto, CA USA
- Infinity Pharmaceuticals, Cambridge MA, USA
- Koch Institute Cancer Center, Massachusetts Institute of Technology, Boston MA, USA

**2015**

- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, N. Ireland
- Dept of Pharmacology, Univ. of Calif., San Diego, La Jolla CA, USA
- The Salk Institute, La Jolla, CA USA
- Helen Diller Family Comprehensive Cancer Center, Univ. of Calif., San Francisco. San Francisco, CA USA
- Fox Chase Cancer Center, Philadelphia PA, USA.
- Frontiers in Oncology series of University of Maryland Greenebaum Cancer Center, UM School of Medicine at Baltimore, Baltimore MD, USA
- Genentech, Inc., S. San Francisco, CA USA

**2016**

- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas, Madrid SPAIN
- Columbia University Medical Center, Hematology/Oncology Division Grand Rounds. New York, NY USA

**2017**

- Barts Cancer Institute, London UK.
- Aduro Biotech, Berkeley, CA, USA
- Harvard Medical School Immunology Seminar Series. Harvard Medical School, Boston MA USA
- Massachusetts General Hospital, Immunology and Imaging Programs, Boston MA USA
- Cell Signaling Technology, Danvers MA USA
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH USA
- The Salk Institute, La Jolla CA, USA.

**2018**

- European Academy of Tumor Immunology (EATI), Centre de Recherche de Cordeliers, Paris, FRANCE.
- Div. of Hematology and Oncology Seminar, Weill Cornell Medicine Medical College, New York NY USA

**2019**

- Kyoto Prefectural University of Medicine, Kyoto, JAPAN
- Simmons Cancer Center Distinguished Lecture Series, UT Southwestern, Dallas TX USA
- Seattle Genetics, Seattle WA USA
- Roswell Park Cancer Center, Buffalo NY. USA
- Cell Signaling Technologies, Danvers, MA USA
- Department of Cancer Research, Ben May Cancer Center, University of Chicago, Chicago IL. USA
- Perlmutter Cancer Center Research Seminar Series, NYU Langone Health NYU, NY USA

**2020**

- Department of Medical Biology, Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne. Melbourne AUSTRALIA
- AbbVie Oncology Discovery Group, Chicago IL USA. *virtual*
- Breast Disease Research Seminar Series, Baylor College of Medicine, TX USA. *virtual*

**2021**

- Biology of Cancer series, Johns Hopkins University, Baltimore MD USA. *Virtual*
- Breast Disease Research Seminar, Baylor College of Medicine, Houston TX USA *Virtual*

**2022**

- Cell Signaling Technologies, Immunology series. Danvers, MA USA. *Virtual*
- CRUK Manchester Cancer Institute, Manchester UK. *Virtual*
- 31<sup>st</sup> Annual Short Course on Experimental Models of Cancer, JAX, CT. *Virtual*
- 37<sup>th</sup> Annual Critical Issues in Tumor Microenvironment, Harvard University. *Virtual*

**2023**

- **MARGARET L KRIPKE LEGEND AWARD LECTURE**, MD Anderson Cancer Center, Houston TX, USA
- **KEYNOTE ADDRESS**, 2023 Internal Medicine Research Retreat, University of Texas, MD Anderson Comprehensive Cancer Center. *Virtual*
- **ZENA WERB INAUGURAL LECTURE IN CANCER BIOLOGY**, Univ. of Calif., San Francisco, CA, USA
- **KEYNOTE ADDRESS**, Dept of Molecular and Medical Pharmacology Graduate Retreat, Huntington Beach, CA USA. October 2023

**2024**

- **DIRECTORS VISITING PROFESSOR (2023-2024)**: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University. USA
- **KEYNOTE LECTURE**, *Tumor Microenvironment & Therapy*, Rogel Cancer Center Retreat, University of Michigan Medical School, Ann Arbor, MI USA
- Mark Foundation, Tumor Microenvironment as a Drug Target, Workshop, Charleston, SC. USA
- **KEYNOTE ADDRESS**, Einstein College of Medicine, Jeffrey Pollard Inaugural Lecture, Queens, NY, USA

**2025**

- **DISTINGUISHED LECTURE IN CANCER RESEARCH**. Abramson Family Cancer Research Institute. University of Pennsylvania Perelman School of Medicine, Philadelphia PA. USA
- **HILLDALE LECTURESHIP**. University of Wisconsin, McArdle Laboratory for Cancer Research and Dept. of Oncology. Madison WI. USA
- Komen Investigator Speaker Series, Virtual.

**Invited Lectures/Seminars: OHSU****2012**

- OHSU Knight Cancer Biology Research Group Meeting, OHSU
- OHSU School of Medicine, TEDMED 2012 Live Simulcast
- **KEYNOTE**: OHSU PMCB Annual Retreat
- OHSU MD/PhD Annual Retreat, McMenemy's Edgefield, Troutdale, OR.

- OHSU, Medical & Molecular Genetics Weekly Seminar Series; OHSU, Portland, OR, USA.
- 2013**
  - OCSSB and Dept. of Biomedical Engineering Weekly Seminar Series
  - OHSU Knight Cancer Institute, Annual Retreat; OHSU, Portland, OR, USA.
- 2014**
  - Marquam Hill Lecture; OHSU, Portland, OR, USA.
  - Department of Dermatology Grand Rounds, OHSU, Portland, OR, USA.
- 2015**
  - Department of Surgery Grand Rounds, OHSU, Portland OR USA
- 2016**
  - OHSU Knight Cancer Institute and Dept. of Surgical Oncology: *Metastatic Colorectal Cancer: Early Detection and Prediction of Recurrence. A State of the Science Symposium.*
  - Knight Cancer Institute and Cancer Research UK: Sondland-Durant Early Detection of Cancer Conference, Portland, OR USA
  - Mouse Models of Human Disease Research in Progress Forum. OHSU, Portland, OR, USA.
- 2017**
  - SMMART Retreat, OHSU, Portland, OR, USA.
  - Knight Cancer Institute, Cancer Biology and Translational Oncology Program Retreat. OHSU, Portland, OR, USA.
- 2018**
  - Pancreas Research Meeting group; Brenden-Colson Center for Pancreatic Care. OHSU, Portland, OR, USA.
- 2019**
  - Pancreas Research Meeting group; Brenden-Colson Center for Pancreatic Care. OHSU, Portland, OR, USA.
- 2020**
  - Basic & Translational Sciences Seminar Series, OHSU Dept of CDCB and Knight Cancer Institute
- 2022**
  - Hematology & Oncology Grand Rounds, OHSU School of Medicine and Knight Cancer Institute
- 2023**
  - Hematology & Oncology Research Fellows, OHSU School of Medicine and Knight Cancer Institute
- 2025**
  - Hematology & Oncology Research Fellows, OHSU School of Medicine and Knight Cancer Institute

### **Invited Lectures/Seminars: UCSF**

- 1997**
  - Breast Cancer SPORE Seminar. UCSF
- 1999**
  - Cancer Research Institute Retreat, Tomales Bay, CA
- 2000**
  - Chemistry and Cancer: How Chemistry-Based Tools Are Helping Solve Today's Serious Health Problems, Dev. & Alumni Relations, UCSF
  - Oncology Grand Rounds, Department of Hematology and Oncology, UCSF
  - PIBS-Cell Biology Seminar Series, UCSF
  - Pathology and Lab Medicine Grand Rounds, UCSF
  - BMS Student Pizza Talk, UCSF
  - Cell Cycle & Dysregulation Club, Comprehensive Cancer Center, UCSF
  - Comprehensive Cancer Center Retreat, Granlibakken, Tahoe City, CA
- 2001**
  - BMS Student Pizza Talk, UCSF
  - Pathology and Lab Medicine Grand Rounds, Departments of Medicine and Pathology, UCSF

- UCSF, Cell Biology Retreat, Wilbur Hot Springs, CA, USA
- UCSF TETRAD Retreat, Granlibakken, Lake Tahoe, CA, USA
- UCSF Cancer Research Institute/BMS Retreat, Granlibakken, Lake Tahoe, CA. USA
- 2002**
  - Current Topics in Medical Science, UCSF Medical Scientist Training Program (M170.09)
  - Mouse Models of Human Cancer Program, Comprehensive Cancer Center, UCSF
  - Cancer Research Institute Retreat, Santa Cruz, CA
- 2003**
  - PIBS Student Pizza Talk, UCSF
  - Breast Oncology Program, Comprehensive Cancer Center, UCSF
  - Comprehensive Cancer Center Faculty Retreat: *Identification and Functional Assessment of Cancer Effectors*, Golden Gate Club, San Francisco CA
- 2004**
  - BMS Graduate Program Retreat, Granlibakken Tahoe City, CA
- 2005**
  - BMS Student Pizza Talk, UCSF
- 2006**
  - *Introduction to Research*, Department of Pathology, UCSF
- 2008**
  - Division of Experimental Medicine, Divisional Seminar Series, UCSF
- 2009**
  - Immunology Program, UCSF
  - Helen Diller Family Comprehensive Cancer Center *Research Symposium*; UCSF
- 2010**
  - Bay Area Workshop on Lung Development, Physiology and Cancer, San Francisco CA USA
  - UCSF-GIVI Center for AIDS Research (CFAR) Scientific Symposium for 2010: *HIV Infection, Inflammation, and Premature Aging*, San Francisco, CA USA
  - Breast Oncology Program Seminar, Helen Diller Family Comprehensive Cancer Center, UCSF
- 2011**
  - Breast Oncology Program Annual Retreat, Helen Diller Family Comprehensive Cancer Center, UCSF
- 2012**
  - Breast Oncology Program Annual Retreat, Helen Diller Family Comprehensive Cancer Center, UCSF